In O
the O
present O
study O
, O
we O
found O
that O
Ni B
( I
2 I
+ I
) I
exposure O
led O
to O
a O
time O
- O
and O
dose O
- O
dependent O
proliferation O
arrest O
and O
death O
in O
human O
leukemia O
HL O
- O
60 O
cells O
. O

In O
the O
presence O
of O
1 O
mM O
Ni B
( I
2 I
+ I
) I
, O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
( O
indicated O
by O
the O
level O
of O
malondialdehyde B
) O
increased O
to O
323 O
% O
and O
histone O
acetylation O
decreased O
to O
32 O
% O
. O

Interestingly O
, O
quercetin B
( O
QU O
) O
dose O
dependently O
prevented O
Ni B
( I
2 I
+ I
) I
- O
induced O
cell O
proliferation O
arrest O
and O
death O
from O
0 O
to O
80 O
mu O
M O
but O
showed O
similar O
activity O
of O
scavenging O
ROS O
at O
the O
concentrations O
of O
20 O
, O
40 O
and O
80 O
micro O
M O
. O

When O
the O
effect O
of O
QU O
on O
histone O
acetylation O
was O
studied O
, O
QU O
significantly O
prevented O
Ni B
( I
2 I
+ I
) I
- O
induced O
histone O
hypoacetylation O
at O
40 O
or O
80 O
micro O
M O
. O

Thus O
, O
our O
results O
further O
confirmed O
the O
critical O
role O
of O
ROS O
and O
histone O
hypoacetylation O
in O
the O
cytotoxicity O
of O
Ni B
( I
2 I
+ I
) I
exposure O
and O
proved O
that O
QU O
is O
a O
potentially O
useful O
native O
dietary O
compound O
to O
efficiently O
prevent O
Ni B
( I
2 I
+ I
) I
- O
caused O
cytotoxicity O
through O
both O
diminishing O
ROS O
generation O
and O
increasing O
histone O
acetylation O
. O

Thus O
, O
our O
results O
further O
confirmed O
the O
critical O
role O
of O
ROS O
and O
histone O
hypoacetylation O
in O
the O
cytotoxicity O
of O
Ni B
( I
2 I
+ I
) I
exposure O
and O
proved O
that O
QU O
is O
a O
potentially O
useful O
native O
dietary O
compound O
to O
efficiently O
prevent O
Ni B
( I
2 I
+ I
) I
- O
caused O
cytotoxicity O
through O
both O
diminishing O
ROS O
generation O
and O
increasing O
histone O
acetylation O
. O

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

gugglsterol B
I I
, O
( B
E I
) I
- I
guggulsterone I
and O
( B
Z I
) I
- I
guggulsterone I
. O

gugglsterol B
I I
, O
( B
E I
) I
- I
guggulsterone I
and O
( B
Z I
) I
- I
guggulsterone I
. O

The O
IC O
( O
50 O
) O
values O
of O
epi B
- I
mukulin I
and O
( B
Z I
) I
- I
guggulsterone I
were O
found O
to O
be O
159 O
. O
33 O
and O
132 O
. O
14 O
micro O
M O
, O
respectively O
. O

A O
90 O
- O
day O
oral O
( O
dietary O
) O
toxicity O
study O
of O
arruva B
, O
an O
R B
, I
R I
- I
monatin I
salt O
isomer O
, O
in O
Crl O
: O
CD O
- O
1 O
( O
ICR O
) O
mice O
. O

R B
, I
R I
- I
Monatin I
[ O
2R B
, I
4R I
- I
isomer I
of I
2 I
- I
hydroxy I
- I
2 I
- I
( I
indol I
- I
3 I
- I
ylmethyl I
) I
- I
4 I
- I
aminoglutaric I
acid I
] O
is O
one O
of O
four O
natural O
constituent O
isomers O
in O
the O
root O
bark O
of O
Sclerochitin O
ilicifolius O
; O
and O
" O
arruva B
" O
is O
the O
common O
/ O
usual O
name O
that O
is O
proposed O
to O
represent O
R B
, I
R I
- I
monatin I
salt O
forms O
, O
which O
have O
potential O
use O
as O
high O
potency O
sweetener O
food O
ingredients O
. O

R B
, I
R I
- I
Monatin I
[ O
2R B
, I
4R I
- I
isomer I
of I
2 I
- I
hydroxy I
- I
2 I
- I
( I
indol I
- I
3 I
- I
ylmethyl I
) I
- I
4 I
- I
aminoglutaric I
acid I
] O
is O
one O
of O
four O
natural O
constituent O
isomers O
in O
the O
root O
bark O
of O
Sclerochitin O
ilicifolius O
; O
and O
" O
arruva B
" O
is O
the O
common O
/ O
usual O
name O
that O
is O
proposed O
to O
represent O
R B
, I
R I
- I
monatin I
salt O
forms O
, O
which O
have O
potential O
use O
as O
high O
potency O
sweetener O
food O
ingredients O
. O

A O
series O
of O
F O
( O
D O
) O
LF O
( O
D O
) O
LF O
analogs O
has O
been O
synthesized O
, O
including O
either O
N B
- I
t I
- I
Boc I
or O
different O
N B
- I
ureido I
substituents O
. O

Furthermore O
, O
CA O
- O
induced O
vasorelaxation O
was O
inhibited O
by O
the O
PKG O
inhibitor O
KT5823 B
( O
0 O
. O
3 O
mu O
M O
) O
and O
the O
Ca B
( I
2 I
+ I
) I
- O
activated O
K B
( I
+ I
) I
channel O
inhibitor O
tetraethylammonium B
( O
10 O
( O
- O
3 O
) O
M O
) O
. O

The O
methanol B
extract O
of O
the O
tubers O
of O
Polygonum O
perfoliatum O
L O
. O
afforded O
a O
new O
lignan B
: O
8 B
- I
oxo I
- I
pinoresinol I
( O
1 O
) O
, O
and O
five O
known O
compounds O
3 B
' I
, I
5 I
- I
dihydroxy I
- I
3 I
, I
4 I
' I
, I
5 I
' I
, I
7 I
- I
tetramethoxy I
- I
flavone I
( O
2 O
) O
, O
catechin B
( O
3 O
) O
, O
quercetin B
( O
4 O
) O
, O
quercetin B
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
glucuronide I
( O
5 O
) O
and O
rutin B
( O
6 O
) O
. O

The O
effects O
of O
temperature O
and O
salinity O
on O
17 B
- I
alpha I
- I
ethynylestradiol I
uptake O
and O
its O
relationship O
to O
oxygen B
consumption O
in O
the O
model O
euryhaline O
teleost O
( O
Fundulus O
heteroclitus O
) O
. O

The O
synthetic O
estrogen B
17 B
- I
alpha I
- I
ethynylestradiol I
( O
EE2 B
) O
, O
a O
component O
of O
birth O
control O
and O
hormone O
replacement O
therapy O
, O
is O
discharged O
into O
the O
environment O
via O
wastewater O
treatment O
plant O
( O
WWTP O
) O
effluents O
. O

Other O
agents O
such O
as O
prostaglandin B
E I
( I
2 I
) I
and O
phosphodiesterase O
inhibitors O
that O
also O
increase O
intracellular O
cAMP B
levels O
in O
ASM O
, O
can O
also O
antagonize O
ASM O
contraction O
, O
and O
inhibit O
other O
ASM O
functions O
including O
proliferation O
and O
migration O
. O

We O
have O
utilised O
dissociated O
primary O
cortical O
neuronal O
cultures O
, O
which O
after O
7 O
days O
in O
vitro O
have O
formed O
functional O
synaptic O
connections O
and O
display O
periodic O
and O
spontaneous O
synchronised O
calcium B
( O
Ca B
( I
2 I
+ I
) I
) O
oscillations O
in O
response O
to O
intrinsic O
action O
potential O
bursts O
. O

We O
herein O
demonstrate O
that O
in O
addition O
to O
non O
- O
selective O
group O
II O
mGlu O
receptor O
agonists O
, O
( B
2R I
, I
4R I
) I
- I
APDC I
, O
LY379268 B
and O
DCG B
- I
IV I
, O
a O
selective O
mGlu2 O
agonist O
, O
LY541850 B
, O
and O
mGlu2 O
positive O
allosteric O
modulators O
, O
BINA O
and O
CBiPES O
, O
inhibit O
the O
frequency O
of O
synchronised O
Ca B
( I
2 I
+ I
) I
oscillations O
in O
primary O
cultures O
of O
rat O
and O
mouse O
cortical O
neurons O
. O

Dihydroxy B
- I
Isosteviol I
Methyl I
Ester I
from O
Pulsatilla O
nigricans O
Induces O
Apoptosis O
in O
HeLa O
Cells O
: O
Its O
Cytoxicity O
and O
Interaction O
with O
Calf O
Thymus O
DNA O
. O

Dihydroxy B
- I
isosteviol I
methyl I
ester I
( O
DIME B
) O
, O
the O
principal O
biological O
compound O
isolated O
from O
the O
medicinal O
plant O
Pulsatilla O
nigricans O
( O
Fam O
: O
Ranunculaceae O
) O
having O
the O
molecular O
formula O
of O
C21 B
H34 I
O3 I
( O
molecular O
weight O
334 O
. O
25 O
) O
, O
was O
administered O
to O
cervical O
cancer O
cells O
( O
HeLa O
) O
in O
vitro O
to O
evaluate O
its O
possible O
apoptotic O
( O
anti O
- O
cancer O
) O
potentials O
. O

Disorders O
of O
coenzyme B
Q I
( I
10 I
) I
( O
CoQ B
( I
10 I
) I
) O
biosynthesis O
represent O
the O
most O
treatable O
subgroup O
of O
mitochondrial O
diseases O
. O

Rectifying O
behavior O
of O
charge O
transfer O
complexes O
of O
tetrakis B
( I
dimethylamino I
) I
ethene I
with O
acceptor O
molecules O
: O
a O
theoretical O
study O
. O

The O
effect O
of O
electric O
field O
induced O
electron O
transfer O
on O
the O
rectification O
properties O
of O
molecular O
rectifiers O
based O
on O
charge O
transfer O
complexes O
of O
tetrakis B
( I
dimethylamino I
) I
ethane I
( O
TDAE B
) O
with O
acceptor O
molecules O
was O
explored O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

A O
crown B
- I
ether I
dithiol I
quaterthiophene I
is O
synthesized O
and O
immobilized O
on O
gold O
surface O
by O
double O
covalent O
fixation O
. O

UV O
- O
vis O
spectroscopy O
and O
cyclic O
voltammetry O
show O
that O
the O
corresponding O
dithioester B
precursor O
can O
complex O
Pb B
( I
2 I
+ I
) I
in O
solution O
and O
that O
this O
property O
is O
maintained O
for O
monolayers O
of O
the O
dithiol B
on O
gold O
. O

Current O
- O
voltage O
measurements O
by O
eutectic O
GaIn B
drop O
contact O
on O
the O
monolayer O
show O
a O
significant O
increase O
( O
up O
to O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
times O
) O
of O
the O
current O
at O
low O
bias O
after O
Pb B
( I
2 I
+ I
) I
complexation O
. O

Coordination O
and O
bond O
activation O
in O
complexes O
of O
regioisomeric O
phenylpyridines B
with O
the O
nickel B
( I
II I
) I
chloride I
cation O
in O
the O
gas O
phase O
. O

Electrospray O
ionization O
of O
dilute O
solutions O
of O
phenylpyridines B
( O
phpy B
) O
in O
the O
presence O
of O
nickel B
( I
II I
) I
chloride I
leads O
to O
gaseous O
ions O
of O
the O
type O
[ B
Ni I
( I
phpy I
) I
( I
m I
) I
] I
( I
2 I
+ I
) I
with O
m O
= O
3 O
- O
5 O
and O
[ B
NiCl I
( I
phpy I
) I
( I
n I
) I
] I
( I
+ I
) I
with O
n O
= O
1 O
- O
3 O
, O
which O
are O
characterized O
by O
various O
gas O
- O
phase O
experiments O
in O
combination O
with O
calculations O
using O
density O
functional O
theory O
. O

Manganese B
( O
Mn B
) O
is O
recognized O
an O
essential O
nutrient O
, O
permanganate B
( O
MnO4 B
( I
- I
) I
) O
and O
manganous B
( O
Mn B
( I
+ I
2 I
) I
) O
ions O
are O
caustic O
, O
and O
the O
acute O
toxicity O
of O
KMnO B
( I
4 I
) I
is O
defined O
by O
its O
oxidant O
/ O
irritant O
properties O
and O
by O
the O
toxicity O
of O
Mn B
. O

In O
this O
study O
, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb B
( I
2 I
+ I
) I
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
) O
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine B
choline I
; O
understanding O
these O
effects O
would O
help O
explain O
the O
lead O
- O
induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O
relief O
strategies O
. O

In O
this O
study O
, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb B
( I
2 I
+ I
) I
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
) O
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine B
choline I
; O
understanding O
these O
effects O
would O
help O
explain O
the O
lead O
- O
induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O
relief O
strategies O
. O

In O
this O
study O
, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb B
( I
2 I
+ I
) I
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
) O
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine B
choline I
; O
understanding O
these O
effects O
would O
help O
explain O
the O
lead O
- O
induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O
relief O
strategies O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

The O
addition O
of O
10 O
, O
20 O
, O
or O
40 O
mmol O
/ O
L O
methionine B
choline I
simultaneously O
with O
addition O
of O
10 O
mu O
mol O
/ O
L O
Pb B
( I
2 I
+ I
) I
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
culture O
medium O
by O
39 O
. O
0 O
% O
, O
66 O
. O
0 O
% O
, O
and O
61 O
. O
6 O
% O
, O
respectively O
, O
in O
a O
concentration O
- O
dependant O
manner O
in O
a O
certain O
dose O
range O
. O

The O
addition O
of O
10 O
, O
20 O
, O
or O
40 O
mmol O
/ O
L O
methionine B
choline I
simultaneously O
with O
addition O
of O
10 O
mu O
mol O
/ O
L O
Pb B
( I
2 I
+ I
) I
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
culture O
medium O
by O
39 O
. O
0 O
% O
, O
66 O
. O
0 O
% O
, O
and O
61 O
. O
6 O
% O
, O
respectively O
, O
in O
a O
concentration O
- O
dependant O
manner O
in O
a O
certain O
dose O
range O
. O

The O
addition O
of O
10 O
, O
20 O
, O
or O
40 O
mmol O
/ O
L O
methionine B
choline I
simultaneously O
with O
addition O
of O
10 O
mu O
mol O
/ O
L O
Pb B
( I
2 I
+ I
) I
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
culture O
medium O
by O
39 O
. O
0 O
% O
, O
66 O
. O
0 O
% O
, O
and O
61 O
. O
6 O
% O
, O
respectively O
, O
in O
a O
concentration O
- O
dependant O
manner O
in O
a O
certain O
dose O
range O
. O

Our O
results O
suggest O
that O
Pb B
( I
2 I
+ I
) I
induces O
ER O
calcium B
release O
to O
increase O
the O
resting O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
; O
and O
methionine B
choline I
inhibit O
this O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

Our O
results O
suggest O
that O
Pb B
( I
2 I
+ I
) I
induces O
ER O
calcium B
release O
to O
increase O
the O
resting O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
; O
and O
methionine B
choline I
inhibit O
this O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

Our O
results O
suggest O
that O
Pb B
( I
2 I
+ I
) I
induces O
ER O
calcium B
release O
to O
increase O
the O
resting O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
; O
and O
methionine B
choline I
inhibit O
this O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

High O
intensity O
ultrasonic O
( O
HUS O
, O
20 O
kHz O
, O
400 O
W O
) O
pre O
- O
treatments O
of O
soybean O
protein O
isolate O
( O
SPI O
) O
improved O
the O
water O
holding O
capacity O
( O
WHC O
) O
, O
gel O
strength O
and O
gel O
firmness O
( O
final O
elastic O
moduli O
) O
of O
glucono B
- I
delta I
- I
lactone I
induced O
SPI O
gels O
( O
GISG O
) O
. O

A O
recombined O
coarse O
milk O
emulsion O
with O
fat O
globules O
stained O
with O
oil B
- I
red I
- I
O I
dye O
was O
selected O
for O
the O
separation O
trials O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
chemical O
and O
genetic O
loss O
- O
of O
- O
function O
of O
antiapoptotic O
Bcl O
- O
2 O
and O
Bcl O
- O
x O
( O
L O
) O
significantly O
augments O
glucose B
- O
dependent O
metabolic O
and O
Ca B
( I
2 I
+ I
) I
signals O
in O
primary O
pancreatic O
beta O
- O
cells O
. O

Antagonism O
of O
Bcl O
- O
2 O
/ O
Bcl O
- O
x O
( O
L O
) O
by O
two O
distinct O
small O
- O
molecule O
compounds O
rapidly O
hyperpolarized O
beta O
- O
cell O
mitochondria O
, O
increased O
cytosolic O
Ca B
( I
2 I
+ I
) I
, O
and O
stimulated O
insulin O
release O
via O
the O
ATP B
- O
dependent O
pathway O
in O
beta O
- O
cell O
under O
substimulatory O
glucose B
conditions O
. O

Pancreatic O
beta O
- O
cells O
from O
Bcl O
- O
2 O
( O
- O
/ O
- O
) O
mice O
responded O
to O
glucose B
with O
significantly O
increased O
NAD B
( I
P I
) I
H I
levels O
and O
cytosolic O
Ca B
( I
2 I
+ I
) I
signals O
, O
as O
well O
as O
significantly O
augmented O
insulin O
secretion O
. O

Pancreatic O
beta O
- O
cells O
from O
Bcl O
- O
2 O
( O
- O
/ O
- O
) O
mice O
responded O
to O
glucose B
with O
significantly O
increased O
NAD B
( I
P I
) I
H I
levels O
and O
cytosolic O
Ca B
( I
2 I
+ I
) I
signals O
, O
as O
well O
as O
significantly O
augmented O
insulin O
secretion O
. O

Inducible O
deletion O
of O
Bcl O
- O
x O
( O
L O
) O
in O
adult O
mouse O
beta O
- O
cells O
also O
increased O
glucose B
- O
stimulated O
NAD B
( I
P I
) I
H I
and O
Ca B
( I
2 I
+ I
) I
responses O
and O
resulted O
in O
an O
improvement O
of O
in O
vivo O
glucose B
tolerance O
in O
the O
conditional O
Bcl O
- O
x O
( O
L O
) O
knockout O
animals O
. O

Inducible O
deletion O
of O
Bcl O
- O
x O
( O
L O
) O
in O
adult O
mouse O
beta O
- O
cells O
also O
increased O
glucose B
- O
stimulated O
NAD B
( I
P I
) I
H I
and O
Ca B
( I
2 I
+ I
) I
responses O
and O
resulted O
in O
an O
improvement O
of O
in O
vivo O
glucose B
tolerance O
in O
the O
conditional O
Bcl O
- O
x O
( O
L O
) O
knockout O
animals O
. O

Pretreatment O
of O
the O
A549 O
cells O
with O
N B
- I
acetyl I
- I
cysteine I
( O
NAC B
) O
, O
an O
antioxidant O
, O
decreased O
the O
effects O
of O
AgNPs O
on O
the O
reduced O
cell O
viability O
, O
change O
in O
the O
MMP O
and O
proportion O
of O
cells O
in O
the O
sub O
- O
G1population O
, O
but O
had O
no O
effect O
on O
the O
AgNP O
- O
mediated O
S O
phase O
arrest O
or O
down O
- O
regulation O
of O
PCNA O
. O

Electron O
paramagnetic O
resonance O
( O
EPR O
) O
spectroscopy O
of O
the O
spin O
label O
5 B
- I
doxyl I
stearic I
acid I
( O
5 B
- I
DSA I
) O
was O
used O
to O
monitor O
the O
effect O
of O
sesquiterpene B
nerolidol B
and O
various O
monoterpenes B
on O
membrane O
fluidity O
in O
erythrocyte O
and O
fibroblast O
cells O
. O

The O
IC O
( O
50 O
) O
values O
for O
the O
terpenes B
in O
the O
cytotoxicity O
assay O
indicated O
that O
1 B
, I
8 I
- I
cineole I
showed O
lower O
cytotoxicity O
and O
alpha B
- I
terpineol I
and O
nerolidol B
showed O
higher O
cytotoxicity O
. O

The O
correlation O
between O
the O
hemolytic O
effect O
and O
the O
IC O
( O
50 O
) O
values O
for O
fibroblast O
viability O
was O
low O
( O
R O
= O
0 O
. O
61 O
) O
; O
however O
, O
in O
both O
tests O
, O
nerolidol B
was O
among O
the O
most O
aggressive O
of O
terpenes B
and O
1 B
, I
8 I
- I
cineole I
was O
among O
the O
least O
aggressive O
. O

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid B
, O
3 B
' I
- I
hydroxy I
- I
isoscutellarein I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
; O
three O
iridoid B
glucosides I
: O
harpagide B
, O
acetyl B
harpagide I
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 B
- I
epi I
- I
loganin I
; O
two O
known O
acetylated B
flavonoid I
glycosides I
: O
3 B
' I
- I
hydroxy I
- I
4 I

Identification O
of O
various O
antioxidant O
agents O
, O
such O
as O
thiol B
molecules O
( O
glutathione B
and O
mucolytic O
drugs O
, O
such O
as O
N B
- I
acetyl I
- I
Lcysteine I
, O
N B
- I
acystelyn I
, O
erdosteine B
, O
fudosteine B
, O
ergothioneine B
, O
and O
carbocysteine B
lysine I
salt O
) O
, O
dietary O
natural O
productderived O
polyphenols B
and O
other O
compounds O
( O
curcumin B
, O
resveratrol B
, O
green O
tea O
catechins B
, O
quercetin B
sulforaphane I
, O
lycopene B
, O

mediators O
/ O
inflammatory O
resolving O
lipid O
mediators O
, O
omega B
- I
3 I
fatty I
acids I
, O
vitamin B
D I
, O
and O
hydrogen B
sulfide I
. O

The O
recreational O
and O
illicit O
use O
of O
amphetaminic O
designer O
compounds O
, O
specially O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
; O
Ecstasy B
) O
, O
is O
of O
concern O
worldwide O
. O

We O
examined O
in O
cats O
the O
1 O
) O
ulcerogenic O
effects O
of O
selective O
COX O
- O
1 O
( O
SC B
- I
560 I
, O
ketorolac B
) O
and O
COX O
- O
2 O
( O
celecoxib B
, O
meloxicam B
) O
inhibitors O
on O
the O
gastrointestinal O
mucosa O
, O
2 O
) O
effect O
of O
feeding O
and O
cimetidine B
on O
the O
expression O
of O
COX O
isoforms O
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
level O
in O
the O
duodenum O
, O
and O
3 O
) O
localization O
of O
COX O
isoforms O
in O
the O
duodenum O
. O

pH O
- O
and O
thermo O
- O
sensitive O
pluronic B
/ O
poly B
( I
acrylic I
acid I
) I
in O
situ O
hydrogels O
for O
sustained O
release O
of O
an O
anticancer O
drug O
. O

Major O
changes O
were O
also O
observed O
for O
carotenoids O
, O
except O
for O
the O
5 B
- I
cis I
- I
lycopene I
isomer O
, O
which O
remain O
unchanged O
after O
24h O
of O
MIPEF O
treatments O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr B
( I
2 I
+ I
) I
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr B
( I
2 I
+ I
) I
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr B
( I
2 I
+ I
) I
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr B
( I
2 I
+ I
) I
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr B
( I
2 I
+ I
) I
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr B
( I
2 I
+ I
) I
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H B
( I
2 I
) I
O I
, O
the O
sequence O
Ba B
( I
2 I
+ I
) I
> O
= O
Ca B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
was O
found O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H B
( I
2 I
) I
O I
, O
the O
sequence O
Ba B
( I
2 I
+ I
) I
> O
= O
Ca B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
was O
found O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H B
( I
2 I
) I
O I
, O
the O
sequence O
Ba B
( I
2 I
+ I
) I
> O
= O
Ca B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
was O
found O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H B
( I
2 I
) I
O I
, O
the O
sequence O
Ba B
( I
2 I
+ I
) I
> O
= O
Ca B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
was O
found O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H B
( I
2 I
) I
O I
, O
the O
sequence O
Ba B
( I
2 I
+ I
) I
> O
= O
Ca B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
was O
found O
. O

In O
D B
( I
2 I
) I
O I
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba B
( I
2 I
+ I
) I
> O
Ca B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
. O

In O
D B
( I
2 I
) I
O I
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba B
( I
2 I
+ I
) I
> O
Ca B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
. O

In O
D B
( I
2 I
) I
O I
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba B
( I
2 I
+ I
) I
> O
Ca B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
. O

In O
D B
( I
2 I
) I
O I
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba B
( I
2 I
+ I
) I
> O
Ca B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
. O

In O
D B
( I
2 I
) I
O I
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba B
( I
2 I
+ I
) I
> O
Ca B
( I
2 I
+ I
) I
> O
Sr B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
. O

The O
different O
hydrophobicity O
between O
D B
( I
2 I
) I
O I
and O
H B
( I
2 I
) I
O I
was O
shown O
to O
affect O
significantly O
the O
T O
( O
Ps O
) O
of O
caseinate O
in O
the O
presence O
of O
calcium B
, O
strontium B
and O
barium B
. O

The O
different O
hydrophobicity O
between O
D B
( I
2 I
) I
O I
and O
H B
( I
2 I
) I
O I
was O
shown O
to O
affect O
significantly O
the O
T O
( O
Ps O
) O
of O
caseinate O
in O
the O
presence O
of O
calcium B
, O
strontium B
and O
barium B
. O

Vitamin B
D I
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 B
- I
hydroxyvitamin I
D I
3 I
( O
25 B
( I
OH I
) I
D I
3 I
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
( O
1 B
, I
25 I
( I
OH I
) I
2 I
D I
3 I
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium B
absorption O
from O
the O
gut O
. O

Electrical O
detection O
of O
spin O
precession O
in O
freely O
suspended O
graphene B
spin O
valves O
on O
cross O
- O
linked O
poly B
( I
methyl I
methacrylate I
) I
. O

The O
devices O
are O
fabricated O
with O
a O
single O
electron O
- O
beam O
- O
resist O
poly B
( I
methyl I
methacrylate I
) I
process O
that O
minimizes O
both O
the O
fabrication O
steps O
and O
the O
number O
of O
( O
aggressive O
) O
chemicals O
used O
, O
greatly O
reducing O
contamination O
and O
increasing O
the O
yield O
of O
high O
- O
quality O
, O
mechanically O
stable O
devices O
. O

A O
broad O
variety O
of O
ligands O
was O
employed O
, O
affording O
novel O
and O
previously O
inaccessible O
cycloheptatrienyl B
( O
sandwich O
) O
complexes O
of O
the O
type O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
Zr I
( I
Y I
) I
] O
; O
Y O
comprises O
pentadienyl B
, O
cyclopentadienyl B
, O
allyl B
, O
phospholyl B
, O
boratabenzene B
, O
imidazolin B
- I
2 I
- I
iminato I
and O
amido B
systems O
. O

The O
cycloheptatrienyl B
ring O
in O
these O
systems O
usually O
acts O
as O
an O
" O
innocent O
spectator O
ligand O
" O
, O
but O
reactivity O
can O
arise O
from O
the O
second O
ligand O
Y O
or O
the O
Lewis O
acidity O
of O
the O
, O
formally O
, O
Zr B
( I
+ I
iv I
) I
center O
, O
which O
was O
probed O
in O
selected O
examples O
and O
put O
in O
perspective O
to O
related O
studies O
. O

Benzo B
[ I
a I
] I
pyrene I
- O
induced O
transcriptomic O
responses O
in O
primary O
hepatocytes O
and O
in O
vivo O
liver O
: O
toxicokinetics O
is O
essential O
for O
in O
vivo O
- O
in O
vitro O
comparisons O
. O

Recently O
, O
the O
differential O
gene O
expression O
response O
in O
wild O
- O
type O
and O
cancer O
- O
prone O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
primary O
mouse O
hepatocytes O
after O
exposure O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
) O
revealed O
downregulation O
of O
cancer O
- O
related O
pathways O
in O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
hepatocytes O
only O
. O

Recently O
, O
the O
differential O
gene O
expression O
response O
in O
wild O
- O
type O
and O
cancer O
- O
prone O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
primary O
mouse O
hepatocytes O
after O
exposure O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
) O
revealed O
downregulation O
of O
cancer O
- O
related O
pathways O
in O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
hepatocytes O
only O
. O

Here O
, O
we O
investigated O
pathway O
regulation O
upon O
in O
vivo O
B B
[ I
a I
] I
P I
exposure O
of O
wild O
- O
type O
and O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
mice O
. O

In O
order O
to O
be O
able O
to O
make O
a O
meaningful O
in O
vivo O
- O
in O
vitro O
comparison O
we O
estimated O
internal O
in O
vivo O
B B
[ I
a I
] I
P I
concentrations O
using O
DNA O
adduct O
levels O
and O
physiologically O
based O
kinetic O
modeling O
. O

However O
, O
we O
were O
unable O
to O
detect O
cancer O
- O
related O
pathways O
in O
either O
wild O
- O
type O
or O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
exposed O
livers O
, O
which O
were O
previously O
found O
to O
be O
induced O
by O
B B
[ I
a I
] I
P I
in O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
primary O
hepatocytes O
. O

In O
conclusion O
, O
we O
showed O
parallels O
in O
gene O
expression O
responses O
between O
livers O
and O
primary O
hepatocytes O
upon O
exposure O
to O
equivalent O
concentrations O
of O
B B
[ I
a I
] I
P I
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
whether O
low O
serum O
25 B
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
levels O
were O
associated O
with O
vertebral O
fractures O
in O
patients O
with O
type O
2 O
diabetes O
. O

Serum O
concentrations O
of O
25 B
( I
OH I
) I
D I
were O
measured O
and O
the O
presence O
of O
vertebral O
fracture O
was O
assessed O
using O
lateral O
plain O
radiographs O
of O
the O
thoracolumbar O
spine O
. O

Women O
had O
lower O
25 B
( I
OH I
) I
D I
levels O
than O
men O
( O
31 O
. O
3 O
+ O
/ O
- O
17 O
. O
7 O
vs O
. O
41 O
. O
3 O
+ O
/ O
- O
26 O
. O
5 O
ng O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
. O

Men O
with O
a O
serum O
25 B
( I
OH I
) I
D I
concentration O
greater O
than O
30 O
ng O
/ O
mL O
showed O
a O
lower O
prevalence O
of O
vertebral O
fractures O
compared O
to O
those O
with O
20 O
- O
29 O
. O
9 O
ng O
/ O
mL O
or O
those O
with O
less O
than O
20 O
ng O
/ O
mL O
( O
9 O
. O
4 O
% O
vs O
. O
17 O
. O
9 O
% O
vs O
. O
21 O
. O
7 O
% O
, O
p O
for O
trend O
= O
0 O
. O
036 O
) O
. O

After O
adjusting O
for O
multiple O
confounding O
factors O
, O
men O
with O
a O
serum O
25 B
( I
OH I
) I
D I
concentration O
of O
less O
than O
20 O
ng O
/ O
mL O
were O
associated O
with O
an O
increased O
risk O
of O
vertebral O
fractures O
( O
OR O
7 O
. O
87 O
; O
95 O
% O
CI O
1 O
. O
69 O
- O
36 O
. O
71 O
) O
, O
but O
not O
women O
. O

In O
conclusion O
, O
serum O
25 B
( I
OH I
) I
D I
levels O
below O
20 O
ng O
/ O
mL O
were O
associated O
with O
an O
increased O
vertebral O
fracture O
risk O
in O
men O
with O
type O
2 O
diabetes O
. O

NMDA B
receptors O
regulate O
channels O
that O
are O
highly O
permeable O
to O
calcium B
, O
and O
calcium B
imaging O
data O
demonstrated O
that O
neurons O
exposed O
to O
ketamine B
had O
a O
significantly O
elevated O
amplitude O
of O
calcium B
influx O
and O
higher O
intracellular O
free O
calcium B
concentrations O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
evoked O
by O
NMDA B
( O
50 O
micro O
M O
) O
, O
compared O
with O
control O
neurons O
. O

The O
present O
study O
compared O
( B
- I
) I
- I
coniine I
, O
( B
+ I
) I
- I
coniine I
, O
and O
nicotine B
for O
the O
ability O
to O
inhibit O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
and O
in O
TE O
- O
671 O
cells O
that O
express O
fetal O
muscle O
- O
type O
nAChR O
. O

The O
present O
study O
compared O
( B
- I
) I
- I
coniine I
, O
( B
+ I
) I
- I
coniine I
, O
and O
nicotine B
for O
the O
ability O
to O
inhibit O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
and O
in O
TE O
- O
671 O
cells O
that O
express O
fetal O
muscle O
- O
type O
nAChR O
. O

( B
- I
) I
- I
Coniine I
was O
more O
effective O
at O
eliciting O
electrical O
changes O
in O
TE O
- O
671 O
cells O
and O
inhibiting O
fetal O
movement O
than O
was O
( B
+ I
) I
- I
coniine I
, O
suggesting O
stereoselectivity O
by O
the O
receptor O
. O

( B
- I
) I
- I
Coniine I
was O
more O
effective O
at O
eliciting O
electrical O
changes O
in O
TE O
- O
671 O
cells O
and O
inhibiting O
fetal O
movement O
than O
was O
( B
+ I
) I
- I
coniine I
, O
suggesting O
stereoselectivity O
by O
the O
receptor O
. O

Unlike O
the O
majority O
of O
G O
protein O
- O
coupled O
receptors O
, O
the O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
E B
- I
prostanoid I
3 O
( O
EP3 O
) O
receptor O
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine B
5 I
[ I
prime I
] I
- I
O I
- I
( I
3 I
- I
thio I
) I
triphosphate I
( O
GTP B
gamma I
S I
) O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
fundamentals O
, O
applications O
, O
and O
recent O
advances O
of O
injectable O
thermosensitive O
hydrogel O
as O
DDSs O
, O
including O
chitosan O
and O
related O
derivatives O
, O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
based O
( O
PNIPAAM B
) O
copolymers O
, O
poly B
( I
ethylene I
oxide I
) I
/ O
poly B
( I
propylene I
oxide I
) I
( O
PEO B
/ O
PPO B
) O
copolymers O
and O
its O
derivatives O
, O
and O
poly B
( I
ethylene I
glycol I
) I
/ O
biodegradable O
polyester B
copolymers O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
fundamentals O
, O
applications O
, O
and O
recent O
advances O
of O
injectable O
thermosensitive O
hydrogel O
as O
DDSs O
, O
including O
chitosan O
and O
related O
derivatives O
, O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
based O
( O
PNIPAAM B
) O
copolymers O
, O
poly B
( I
ethylene I
oxide I
) I
/ O
poly B
( I
propylene I
oxide I
) I
( O
PEO B
/ O
PPO B
) O
copolymers O
and O
its O
derivatives O
, O
and O
poly B
( I
ethylene I
glycol I
) I
/ O
biodegradable O
polyester B
copolymers O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
fundamentals O
, O
applications O
, O
and O
recent O
advances O
of O
injectable O
thermosensitive O
hydrogel O
as O
DDSs O
, O
including O
chitosan O
and O
related O
derivatives O
, O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
based O
( O
PNIPAAM B
) O
copolymers O
, O
poly B
( I
ethylene I
oxide I
) I
/ O
poly B
( I
propylene I
oxide I
) I
( O
PEO B
/ O
PPO B
) O
copolymers O
and O
its O
derivatives O
, O
and O
poly B
( I
ethylene I
glycol I
) I
/ O
biodegradable O
polyester B
copolymers O
. O

Preorganization O
of O
polypyridyl B
ligands O
ranging O
from O
bidentate O
to O
tetradentate O
by O
bridging O
benzo B
groups O
, O
as O
are O
present O
in O
1 B
, I
10 I
- I
phenanthroline I
( O
phen B
) O
compared O
to O
2 B
, I
2 I
' I
- I
bipyridyl I
( O
bpy B
) O
, O
is O
discussed O
. O

The O
altered O
activities O
of O
key O
enzymes O
such O
as O
glucose B
- O
6 O
- O
phosphatase O
and O
fructose B
- O
1 O
, O
6 O
- O
bisphosphatase O
of O
carbohydrate B
metabolism O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
whereas O
hexokinase O
, O
pyruvate B
kinase O
, O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
and O
glycogen O
content O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
in O
the O
liver O
of O
diabetic O
rats O
and O
also O
increased O
activities O
of O
aspartate B
transaminase O
( O
AST O
) O
, O
alanine B
transaminase O
( O
ALT O
) O
and O
alkaline O

Active O
self O
- O
healing O
encapsulation O
of O
two O
antigens O
, O
ovalbumin O
and O
tetanus O
toxoid O
( O
TT O
) O
, O
in O
PLGA B
microspheres O
was O
adjusted O
by O
preparing O
blank O
microspheres O
containing O
different O
vaccine O
adjuvants O
( O
aluminum B
hydroxide I
( O
Al B
( I
OH I
) I
3 I
) O
or O
calcium B
phosphate I
) O
. O

Active O
loading O
of O
vaccine O
antigen O
in O
Al B
( I
OH I
) I
3 I
- O
PLGA B
microspheres O
was O
found O
to O
: O
a O
) O
increase O
with O
an O
increasing O
loading O
of O
Al B
( I
OH I
) I
3 I
( O
0 O
. O
88 O
- O
3 O
wt O
. O
% O
) O
and O
addition O
of O
porosigen O
, O
b O
) O
decrease O
when O
the O
inner O
Al B
( I
OH I
) I
3 I
/ O
trehalose B
phase O
to O
1 O
mL O
outer O
oil O
phase O
and O
size O
of O
microspheres O
was O
respectively O
> O
0 O
. O
2 O
mL O
and O
63 O
mu O
m O
, O
and O
c O
) O
change O
negligibly O
by O
PLGA B
concentration O
and O
initial O
incubation O
( O
loading O
) O
temperature O
. O

Active O
loading O
of O
vaccine O
antigen O
in O
Al B
( I
OH I
) I
3 I
- O
PLGA B
microspheres O
was O
found O
to O
: O
a O
) O
increase O
with O
an O
increasing O
loading O
of O
Al B
( I
OH I
) I
3 I
( O
0 O
. O
88 O
- O
3 O
wt O
. O
% O
) O
and O
addition O
of O
porosigen O
, O
b O
) O
decrease O
when O
the O
inner O
Al B
( I
OH I
) I
3 I
/ O
trehalose B
phase O
to O
1 O
mL O
outer O
oil O
phase O
and O
size O
of O
microspheres O
was O
respectively O
> O
0 O
. O
2 O
mL O
and O
63 O
mu O
m O
, O
and O
c O
) O
change O
negligibly O
by O
PLGA B
concentration O
and O
initial O
incubation O
( O
loading O
) O
temperature O
. O

Active O
loading O
of O
vaccine O
antigen O
in O
Al B
( I
OH I
) I
3 I
- O
PLGA B
microspheres O
was O
found O
to O
: O
a O
) O
increase O
with O
an O
increasing O
loading O
of O
Al B
( I
OH I
) I
3 I
( O
0 O
. O
88 O
- O
3 O
wt O
. O
% O
) O
and O
addition O
of O
porosigen O
, O
b O
) O
decrease O
when O
the O
inner O
Al B
( I
OH I
) I
3 I
/ O
trehalose B
phase O
to O
1 O
mL O
outer O
oil O
phase O
and O
size O
of O
microspheres O
was O
respectively O
> O
0 O
. O
2 O
mL O
and O
63 O
mu O
m O
, O
and O
c O
) O
change O
negligibly O
by O
PLGA B
concentration O
and O
initial O
incubation O
( O
loading O
) O
temperature O
. O

Encapsulation O
of O
protein O
sorbing O
Al B
( I
OH I
) I
3 I
in O
PLGA B
microspheres O
resulted O
in O
suppression O
of O
self O
- O
healing O
of O
PLGA B
pores O
, O
which O
was O
then O
overcome O
by O
improving O
polymer O
chain O
mobility O
, O
which O
in O
turn O
was O
accomplished O
by O
coincorporating O
hydrophobic O
plasticizers O
in O
PLGA B
. O

This O
calcification O
increase O
was O
also O
observed O
in O
the O
aortas O
of O
a O
vascular O
calcification O
model O
: O
5 O
/ O
6 O
nephrectomized O
rats O
fed O
with O
a O
high O
Pi O
diet O
and O
treated O
with O
vitamin B
D I
( I
3 I
) I
. O

We O
studied O
the O
viability O
and O
antiproliferative O
effects O
of O
griseofulvin B
on O
cultured O
NCI O
- O
H295R O
adrenocortical O
carcinoma O
cells O
using O
Wst B
- I
1 I
- O
, O
BrdUrd B
- O
, O
and O
[ B
3H I
] I
- I
thymidine I
assays O
. O

A O
cyclometallated B
iridium I
( I
III I
) I
complex O
as O
a O
c O
- O
myc O
G O
- O
quadruplex O
stabilizer O
and O
down O
- O
regulator O
of O
c O
- O
myc O
oncogene O
expression O
. O

A O
new O
cyclometallated B
iridium I
( I
III I
) I
complex O
with O
the O
2 B
, I
2 I
' I
- I
biquinoline I
N B
- O
donor O
ligand O
has O
been O
synthesized O
and O
characterized O
. O

Working O
at O
a O
concentration O
level O
of O
I O
( O
Na B
) O
enhancement O
, O
ECG B
has O
no O
notable O
effect O
on O
voltage O
- O
gated O
K B
( I
+ I
) I
currents O
and O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
currents O
. O

On O
the O
basis O
of O
RRLC O
retention O
times O
, O
cochromatography O
with O
available O
authentic O
standards O
, O
mass O
spectral O
fragmentation O
patterns O
and O
literature O
information O
, O
a O
total O
of O
41 O
chemical O
compounds O
, O
including O
4 O
flavone B
- I
C I
- I
glycosides I
, O
7 O
flavonoid B
- I
O I
- I
glycosides I
and O
19 O
polymethoxyflavones B
were O
unambiguously O
identified O
or O
tentatively O
characterised O
in O
CRP O
. O

On O
the O
basis O
of O
RRLC O
retention O
times O
, O
cochromatography O
with O
available O
authentic O
standards O
, O
mass O
spectral O
fragmentation O
patterns O
and O
literature O
information O
, O
a O
total O
of O
41 O
chemical O
compounds O
, O
including O
4 O
flavone B
- I
C I
- I
glycosides I
, O
7 O
flavonoid B
- I
O I
- I
glycosides I
and O
19 O
polymethoxyflavones B
were O
unambiguously O
identified O
or O
tentatively O
characterised O
in O
CRP O
. O

The O
occurrence O
of O
1 O
flavone B
- I
C I
- I
glycoside I
and O
3 O
cyclic O
peptides O
in O
particular O
has O
not O
yet O
been O
described O
. O

Besides O
enniatins B
A I
, I
A1 I
, I
B I
and I
B1 I
, O
also O
deoxynivalenol B
and O
its O
conjugated O
form O
( O
deoxynivalenol B
- I
3 I
- I
glucoside I
) O
were O
determined O
in O
almost O
all O
tested O
cereal O
- O
based O
samples O
. O

The O
general O
formula O
of O
the O
OPCs O
was O
( B
RO I
) I
2P I
( I
O I
) I
X I
, O
where O
R O
= O
alkyl B
, O
X O
= O
- O
SCH B
( I
Hal I
) I
COOEt I
( O
Hal B
= O
Cl B
, O
Br B
) O
, O
- O
SCHCl2 B
, O
- O
SCH2Br B
, O
- O
OCH B
( I
CF3 I
) I
R I
( I
1 I
) I
( O
R O
( O
1 O
) O
= O
C6H5 B
, O
CF3 B
, O
COOEt B
, O
COOMe B
) O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
synthesize O
Pluronic B
F127 I
- I
polyethylenimine I
- I
folate I
( O
PF127 B
- I
PEI I
- I
FA I
) O
copolymer O
, O
construct O
a O
mixed O
micelle O
system O
with O
PF127 B
- I
PEI I
- I
FA I
copolymer O
and O
Pluronic B
P123 I
( O
PP123 B
) O
and O
to O
evaluate O
the O
potential O
of O
these O
mixed O
micelles O
as O
an O
oral O
drug O
delivery O
system O
for O
paclitaxel B
( O
PTX B
) O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
synthesize O
Pluronic B
F127 I
- I
polyethylenimine I
- I
folate I
( O
PF127 B
- I
PEI I
- I
FA I
) O
copolymer O
, O
construct O
a O
mixed O
micelle O
system O
with O
PF127 B
- I
PEI I
- I
FA I
copolymer O
and O
Pluronic B
P123 I
( O
PP123 B
) O
and O
to O
evaluate O
the O
potential O
of O
these O
mixed O
micelles O
as O
an O
oral O
drug O
delivery O
system O
for O
paclitaxel B
( O
PTX B
) O
. O

The O
results O
of O
intestinal O
absorption O
revealed O
that O
the O
PTX B
- O
loaded O
micelles O
displayed O
superior O
permeability O
across O
intestinal O
barrier O
than O
free O
drug O
and O
PF127 B
- I
PEI I
- I
FA I
/ O
PP123 B
mixed O
micelles O
exhibited O
the O
strongest O
permeability O
across O
intestinal O
barrier O
. O

In O
general O
PF127 B
- I
PEI I
- I
FA I
/ O
PP123 B
mixed O
micelles O
were O
proved O
to O
be O
potential O
oral O
drug O
delivery O
system O
for O
PTX B
. O

The O
structural O
analysis O
showed O
that O
lipids O
bind O
dendrimers O
through O
both O
hydrophilic O
and O
hydrophobic O
contacts O
with O
overall O
binding O
constants O
of O
K O
( O
chol B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
2 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
0 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
G3 I

The O
structural O
analysis O
showed O
that O
lipids O
bind O
dendrimers O
through O
both O
hydrophilic O
and O
hydrophobic O
contacts O
with O
overall O
binding O
constants O
of O
K O
( O
chol B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
2 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
0 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
G3 I

) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
3 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
9 O
x O
10 O
( O

) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
3 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
9 O
x O
10 O
( O

2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
PAMAM I
- I
G4 I
) O
= O
7 O
. O
0 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
9 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
and O
K O
( O
DOTAP B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
7 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
. O

2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
PAMAM I
- I
G4 I
) O
= O
7 O
. O
0 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
9 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
and O
K O
( O
DOTAP B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
7 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
. O

2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
PAMAM I
- I
G4 I
) O
= O
7 O
. O
0 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
9 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
and O
K O
( O
DOTAP B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
7 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
. O

The O
free O
binding O
energies O
from O
docking O
were O
- O
5 O
. O
15 O
( O
cholesterol B
) O
, O
- O
5 O
. O
79 O
( O
DDAB B
) O
, O
and O
- O
5 O
. O
36 O
kcal O
/ O
mol O
( O
DOTAP B
) O
with O
the O
order O
of O
stability O
DDAB B
- I
PAMAM I
- I
G I
- I
4 I
> O
DOTAP B
- I
PAMAM I
- I
G4 I
> O
cholesterol B
- O
PAMAM B
- I
G4 I
, O
consistent O
with O
the O
spectroscopic O
results O
. O

Glycogen O
synthase O
, O
a O
key O
enzyme O
in O
muscle O
glycogen O
synthesis O
, O
is O
extensively O
regulated O
, O
both O
allosterically O
( O
by O
glucose B
- I
6 I
- I
phosphate I
, O
ATP B
, O
and O
others O
) O
and O
covalently O
( O
by O
phosphorylation O
) O
. O

Copper B
toxicity O
and O
accumulation O
in O
plants O
are O
affected O
by O
physicochemical O
characteristics O
of O
soil O
solutions O
such O
as O
the O
concentrations O
of O
coexistent O
cations O
( O
e O
. O
g O
. O
, O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
K B
( I
+ I
) I
, O
Na B
( I
+ I
) I
, O
and O
H B
( I
+ I
) I
) O
. O

Copper B
toxicity O
and O
accumulation O
in O
plants O
are O
affected O
by O
physicochemical O
characteristics O
of O
soil O
solutions O
such O
as O
the O
concentrations O
of O
coexistent O
cations O
( O
e O
. O
g O
. O
, O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
K B
( I
+ I
) I
, O
Na B
( I
+ I
) I
, O
and O
H B
( I
+ I
) I
) O
. O

The O
BLM O
approach O
, O
which O
incorporated O
competition O
of O
Mg B
( I
2 I
+ I
) I
with O
Cu B
( I
2 I
+ I
) I
to O
occupy O
the O
biotic O
ligands O
on O
root O
surfaces O
, O
was O
developed O
to O
predict O
Cu B
rhizotoxicity O
and O
accumulation O
by O
grapevine O
roots O
. O

The O
BLM O
approach O
, O
which O
incorporated O
competition O
of O
Mg B
( I
2 I
+ I
) I
with O
Cu B
( I
2 I
+ I
) I
to O
occupy O
the O
biotic O
ligands O
on O
root O
surfaces O
, O
was O
developed O
to O
predict O
Cu B
rhizotoxicity O
and O
accumulation O
by O
grapevine O
roots O
. O

In O
the O
results O
, O
the O
effective O
activity O
of O
Cu B
, O
{ O
Cu B
( I
2 I
+ I
) I
} O
, O
resulting O
in O
a O
50 O
% O
reduction O
of O
root O
elongation O
( O
EA O
( O
50 O
) O
) O
, O
linearly O
increased O
with O
increments O
of O
Mg B
activity O
, O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

In O
the O
results O
, O
the O
effective O
activity O
of O
Cu B
, O
{ O
Cu B
( I
2 I
+ I
) I
} O
, O
resulting O
in O
a O
50 O
% O
reduction O
of O
root O
elongation O
( O
EA O
( O
50 O
) O
) O
, O
linearly O
increased O
with O
increments O
of O
Mg B
activity O
, O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

In O
addition O
, O
the O
Cu B
concentration O
in O
root O
, O
Cu B
( O
root O
) O
, O
was O
retarded O
by O
an O
increase O
of O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

The O
linear O
model O
was O
significantly O
fitted O
to O
the O
relationship O
between O
{ O
Cu B
( I
2 I
+ I
) I
} O
/ O
Cu B
( O
root O
) O
and O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

The O
linear O
model O
was O
significantly O
fitted O
to O
the O
relationship O
between O
{ O
Cu B
( I
2 I
+ I
) I
} O
/ O
Cu B
( O
root O
) O
and O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

According O
to O
the O
concept O
of O
BLM O
, O
the O
present O
results O
revealed O
that O
the O
amelioration O
effects O
of O
Mg B
on O
Cu B
toxicity O
and O
accumulation O
in O
roots O
could O
arise O
from O
competition O
between O
Mg B
( I
2 I
+ I
) I
and O
Cu B
( I
2 I
+ I
) I
on O
the O
binding O
sites O
( O
i O
. O
e O
. O
, O
the O
biotic O
ligands O
) O
. O

According O
to O
the O
concept O
of O
BLM O
, O
the O
present O
results O
revealed O
that O
the O
amelioration O
effects O
of O
Mg B
on O
Cu B
toxicity O
and O
accumulation O
in O
roots O
could O
arise O
from O
competition O
between O
Mg B
( I
2 I
+ I
) I
and O
Cu B
( I
2 I
+ I
) I
on O
the O
binding O
sites O
( O
i O
. O
e O
. O
, O
the O
biotic O
ligands O
) O
. O

Then O
, O
the O
developed O
Cu B
- O
BLMs O
incorporating O
the O
Mg B
( I
2 I
+ I
) I
competition O
effectiveness O
were O
validated O
provide O
accurate O
predictions O
of O
Cu B
toxicity O
and O
accumulation O
in O
grapevine O
roots O
. O

Furthermore O
, O
the O
potential O
of O
this O
platform O
is O
demonstrated O
for O
( O
i O
) O
the O
in O
- O
depth O
characterization O
of O
BLMs O
comprising O
both O
synthetic O
and O
natural O
lipids O
( O
1 B
, I
2 I
- I
diphytanoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DPhPC B
) O
and O
L B
- I
alpha I
- I
phosphatidylcholine I
( O
L B
- I
alpha I
- I
PC I
) O
/ O
cholesterol B
, O
respectively O
) O
in O
terms O
of O
seal O
resistance O
, O
capacitance O
, O
surface O
area O
, O
specific O
capacitance O
, O
and O
membrane O
hydrophobic O
thickness O
; O
( O
ii O
) O
confocal O
microscopy O
imaging O

Furthermore O
, O
the O
potential O
of O
this O
platform O
is O
demonstrated O
for O
( O
i O
) O
the O
in O
- O
depth O
characterization O
of O
BLMs O
comprising O
both O
synthetic O
and O
natural O
lipids O
( O
1 B
, I
2 I
- I
diphytanoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DPhPC B
) O
and O
L B
- I
alpha I
- I
phosphatidylcholine I
( O
L B
- I
alpha I
- I
PC I
) O
/ O
cholesterol B
, O
respectively O
) O
in O
terms O
of O
seal O
resistance O
, O
capacitance O
, O
surface O
area O
, O
specific O
capacitance O
, O
and O
membrane O
hydrophobic O
thickness O
; O
( O
ii O
) O
confocal O
microscopy O
imaging O

of O
phase O
separation O
in O
sphingomyelin B
/ O
L B
- I
alpha I
- I
PC I
/ O
cholesterol B
ternary O
membranes O
; O
( O
iii O
) O
electrical O
measurements O
of O
individual O
nanopores O
( O
alpha O
- O
hemolysin O
, O
gramicidin B
) O
; O
and O
( O
iv O
) O
indirect O
assessment O
of O
the O
alteration O
of O
membrane O
properties O
upon O
exposure O
to O
chemical O
stimuli O
using O
the O
natural O
nanopore O
gramicidin B
as O
a O
sensor O
. O

The O
most O
oxidizable O
base O
in O
DNA O
is O
2 B
- I
deoxyguanosine I
( O
dG O
) O
, O
and O
the O
primary O
oxidation O
products O
are O
8 B
- I
oxodG I
and O
2 B
- I
amino I
- I
imidazolone I
. O

The O
toxicity O
of O
ABA B
was O
assessed O
by O
monitoring O
oxygen B
consumption O
and O
mitochondrial O
membrane O
potential O
, O
intracellular O
ATP B
concentration O
, O
cell O
viability O
, O
intracellular O
Ca B
( I
2 I
+ I
) I
homeostasis O
, O
release O
of O
cytochrome O
c O
, O
caspase O
3 O
activity O
and O
necrotic O
cell O
death O
. O

The O
hepatocytes O
that O
were O
previously O
incubated O
with O
proadifen B
, O
a O
cytochrome O
P450 O
inhibitor O
, O
are O
more O
sensitive O
to O
the O
compound O
as O
observed O
by O
a O
rapid O
decrease O
in O
the O
mitochondrial O
membrane O
potential O
accompanied O
by O
reductions O
in O
ATP B
concentration O
and O
cell O
viability O
and O
a O
disruption O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
homeostasis O
followed O
by O
necrosis O
. O

In O
the O
present O
study O
, O
to O
investigate O
whether O
characteristic O
expression O
profiles O
of O
PAHs B
exist O
in O
rat O
liver O
and O
whether O
a O
characteristic O
molecular O
signature O
can O
discriminate O
and O
predict O
among O
different O
PAHs B
at O
an O
early O
exposure O
time O
, O
we O
analyzed O
the O
genome O
- O
wide O
expression O
profiles O
of O
rat O
livers O
exposed O
to O
PAHs B
[ O
benzo B
[ I
a I
] I
anthracene I
( O
BA O
) O
, O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
, O
phenanthrene B
( O
PA O
) O
and O
naphthalene B
( O
NT O
) O
] O
. O

In O
the O
present O
study O
, O
to O
investigate O
whether O
characteristic O
expression O
profiles O
of O
PAHs B
exist O
in O
rat O
liver O
and O
whether O
a O
characteristic O
molecular O
signature O
can O
discriminate O
and O
predict O
among O
different O
PAHs B
at O
an O
early O
exposure O
time O
, O
we O
analyzed O
the O
genome O
- O
wide O
expression O
profiles O
of O
rat O
livers O
exposed O
to O
PAHs B
[ O
benzo B
[ I
a I
] I
anthracene I
( O
BA O
) O
, O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
, O
phenanthrene B
( O
PA O
) O
and O
naphthalene B
( O
NT O
) O
] O
. O

Data O
are O
presented O
showing O
the O
spontaneous O
formation O
of O
electric O
fields O
within O
solid O
films O
of O
the O
chlorofluorocarbons B
( O
CFCs B
) O
CF B
( I
3 I
) I
Cl I
, O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
and O
CFCl B
( I
3 I
) I
as O
a O
function O
of O
film O
deposition O
temperature O
from O
40 O
K O
and O
above O
. O

Maximum O
deposition O
temperatures O
for O
display O
of O
an O
electric O
field O
lie O
at O
~ O
50 O
K O
, O
~ O
65 O
K O
and O
~ O
52 O
K O
for O
CF B
( I
3 I
) I
Cl I
, O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
and O
CFCl B
( I
3 I
) I
respectively O
. O

CF B
( I
3 I
) I
Cl I
and O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
demonstrate O
temperatures O
of O
~ O
65 O
K O
and O
~ O
80 O
K O
at O
which O
the O
electric O
field O
in O
the O
film O
is O
removed O
by O
heating O
, O
so O
- O
called O
Curie O
points O
, O
with O
decay O
of O
the O
field O
spread O
over O
more O
than O
10 O
K O
. O

Hydrogen B
sulfide I
( O
H B
( I
2 I
) I
S I
) O
was O
recently O
discovered O
to O
be O
synthesized O
in O
mammalian O
tissues O
by O
several O
different O
enzymes O
. O

Numerous O
studies O
have O
shown O
that O
H B
( I
2 I
) I
S I
has O
vasodilator O
and O
antihypertensive O
effects O
in O
the O
cardiovascular O
system O
. O

However O
, O
intracellular O
mechanisms O
of O
the O
H B
( I
2 I
) I
S I
- O
induced O
vasodilation O
and O
its O
interactions O
with O
other O
endothelium O
- O
derived O
relaxing O
factors O
, O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
remain O
unclear O
. O

We O
investigated O
whether O
H B
( I
2 I
) I
S I
directly O
regulates O
endothelial O
NO B
synthase O
( O
eNOS O
) O
activity O
and O
NO B
production O
in O
endothelial O
cells O
. O

NaHS B
, O
a O
H B
( I
2 I
) I
S I
donor O
, O
dose O
- O
dependently O
increased O
NO B
production O
in O
cultured O
endothelial O
cells O
. O

The O
data O
of O
this O
study O
suggest O
that O
H B
( I
2 I
) I
S I
directly O
acts O
on O
endothelial O
cells O
to O
induce O
eNOS O
activation O
and O
NO B
production O
by O
releasing O
calcium B
from O
the O
intracellular O
store O
in O
endoplasmic O
reticulum O
, O
which O
may O
explain O
one O
of O
mechanisms O
of O
its O
vasodilator O
function O
. O

This O
is O
because O
methoxylated B
phenolic I
antioxidants O
like O
sinapic B
acid I
, O
ferulic B
acid I
; O
2 B
, I
6 I
- I
dimethoxyphenol I
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH B
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O B
( I
2 I
) I
( I
. I
- I
) I
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO B
and O
OH B
radicals O
as O
demonstrated O
during O
this O
study O
. O

While O
reduced O
glutathione B
, O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
( O
G6PD O
) O
and O
catalase O
activities O
were O
reduced O
, O
glutathione B
peroxidase O
and O
glutathione B
- O
s O
- O
transferase O
activities O
increased O
in O
all O
the O
treated O
groups O
compared O
to O
the O
control O
group O
. O

Gamma B
- I
aminobutyric I
- I
acid I
- O
receptors O
and O
glutamtergic O
N B
- I
Methyl I
- I
D I
- I
aspartic I
- I
acid I
- O
receptors O
are O
most O
likely O
to O
be O
involved O
in O
this O
complex O
interplay O
, O
which O
may O
reflect O
a O
disturbed O
signal O
- O
to O
- O
noise O
ratio O
in O
schizophrenia O
patients O
. O

Density O
functional O
theory O
calculations O
were O
performed O
to O
examine O
the O
effect O
of O
a O
C B
vacancy O
on O
the O
physisorption O
of O
H B
( I
2 I
) I
onto O
Ti B
- O
functionalized O
C B
( I
60 I
) I
fullerene I
when O
H B
( I
2 I
) I
is O
oriented O
along O
the O
x O
- O
, O
y O
- O
, O
and O
z O
- O
axes O
of O
the O
fullerene B
. O

A O
significant O
reduction O
in O
the O
energy O
gap O
of O
the O
pristine O
C B
( I
60 I
) I
fullerene I
is O
observed O
when O
TiH B
( I
2 I
) I
is O
adsorbed O
by O
it O
. O

While O
the O
C B
( I
n I
) I
fullerene I
readily O
participates O
in O
nucleophilic O
processes O
, O
the O
adjacent O
TiH B
( I
2 I
) I
fragment O
is O
available O
for O
electrophilic O
processes O
. O

In O
most O
catchments O
, O
HCO B
3 I
( I
- I
) I
and O
SO B
4 I
( I
2 I
- I
) I
concentrations O
were O
greater O
than O
Cl B
( I
- I
) I
concentration O
. O

Podophyllum O
species O
are O
sources O
of O
( B
- I
) I
- I
podophyllotoxin I
, O
an O
aryltetralin B
lignan I
used O
for O
semi O
- O
synthesis O
of O
various O
powerful O
and O
extensively O
employed O
cancer O
- O
treating O
drugs O
. O

Its O
biosynthetic O
pathway O
, O
however O
, O
remains O
largely O
unknown O
, O
with O
the O
last O
unequivocally O
demonstrated O
intermediate O
being O
( B
- I
) I
- I
matairesinol I
. O

Both O
enzymes O
were O
capable O
of O
converting O
( B
- I
) I
- I
matairesinol I
into O
( B
- I
) I
- I
pluviatolide I
by O
catalyzing O
methylenedioxy B
bridge O
formation O
and O
did O
not O
act O
on O
other O
possible O
substrates O
tested O
. O

Both O
enzymes O
were O
capable O
of O
converting O
( B
- I
) I
- I
matairesinol I
into O
( B
- I
) I
- I
pluviatolide I
by O
catalyzing O
methylenedioxy B
bridge O
formation O
and O
did O
not O
act O
on O
other O
possible O
substrates O
tested O
. O

This O
overall O
strategy O
has O
thus O
enabled O
facile O
further O
identification O
of O
enzymes O
putatively O
involved O
in O
( B
- I
) I
- I
podophyllotoxin I
biosynthesis O
and O
underscores O
the O
deductive O
power O
of O
next O
generation O
sequencing O
and O
bioinformatics O
to O
probe O
and O
deduce O
medicinal O
plant O
biosynthetic O
pathways O
. O

A O
VUV O
photoionization O
study O
of O
the O
multichannel O
reaction O
of O
phenyl B
radicals O
with O
1 B
, I
3 I
- I
butadiene I
under O
combustion O
relevant O
conditions O
. O

We O
studied O
the O
reaction O
of O
phenyl B
radicals O
( O
C B
( I
6 I
) I
H I
( I
5 I
) I
) O
with O
1 B
, I
3 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCHCHCH I
( I
2 I
) I
) O
exploiting O
a O
high O
temperature O
chemical O
reactor O
under O
combustion O
- O
like O
conditions O
( O
300 O
Torr O
, O
873 O
K O
) O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

A O
comparison O
with O
results O
from O
recent O
crossed O
molecular O
beam O
studies O
of O
the O
1 B
, I
3 I
- I
butadiene I
- I
phenyl I
radical O
reaction O
and O
electronic O
structure O
calculations O
suggests O
that O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
( O
130 O
amu O
) O
, O
1 B
, I
4 I
- I
dihydronaphthalene I
( O
130 O
amu O
) O
, O
and O
styrene B
( O
104 O
amu O
) O
are O
reaction O
products O
formed O
as O
a O
consequence O
of O
a O
bimolecular O
reaction O
between O
the O
phenyl B
radical O
and O
1 B
, I
3 I
- I
butadiene I
. O

A O
comparison O
with O
results O
from O
recent O
crossed O
molecular O
beam O
studies O
of O
the O
1 B
, I
3 I
- I
butadiene I
- I
phenyl I
radical O
reaction O
and O
electronic O
structure O
calculations O
suggests O
that O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
( O
130 O
amu O
) O
, O
1 B
, I
4 I
- I
dihydronaphthalene I
( O
130 O
amu O
) O
, O
and O
styrene B
( O
104 O
amu O
) O
are O
reaction O
products O
formed O
as O
a O
consequence O
of O
a O
bimolecular O
reaction O
between O
the O
phenyl B
radical O
and O
1 B
, I
3 I
- I
butadiene I
. O

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

3 I
) I
) O
; O
these O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
can O
be O
formed O
from O
1 B
, I
3 I
- I
butadiene I
via O
hydrogen B
atom O
assisted O
isomerization O
reactions O
or O
via O
thermal O
rearrangements O
of O
1 B
, I
3 I
- I
butadiene I
involving O
hydrogen B
shifts O
in O
the O
high O
temperature O
chemical O
reactor O
. O

3 I
) I
) O
; O
these O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
can O
be O
formed O
from O
1 B
, I
3 I
- I
butadiene I
via O
hydrogen B
atom O
assisted O
isomerization O
reactions O
or O
via O
thermal O
rearrangements O
of O
1 B
, I
3 I
- I
butadiene I
involving O
hydrogen B
shifts O
in O
the O
high O
temperature O
chemical O
reactor O
. O

The O
proton O
NMR O
spectra O
of O
several O
1 B
, I
2 I
- I
diols I
in O
benzene B
have O
been O
analysed O
so O
as O
to O
associate O
each O
magnetically O
nonequivalent O
proton O
with O
its O
chemical O
shift O
. O

The O
conformer O
distribution O
and O
the O
proton O
NMR O
shifts O
of O
these O
1 B
, I
2 I
- I
diols I
in O
benzene B
have O
been O
computed O
on O
the O
basis O
of O
density O
functional O
theory O
. O

The O
latter O
gamma B
- I
diketo I
CoA I
ester I
undergoes O
two O
parallel O
cyclization O
processes O
. O

Lastly O
, O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
, O
like O
2 B
, I
5 I
- I
diketohexane I
, O
pyrrolates B
free O
lysine B
and O
, O
presumably O
, O
lysine B
residues O
from O
proteins O
. O

In O
the O
current O
study O
, O
derivatives O
of O
25 B
- I
hydroxyprotopanaxadi I
( O
25 B
- I
OH I
- I
PPD I
) O
were O
prepared O
and O
their O
in O
vitro O
anti O
- O
tumor O
activities O
were O
tested O
on O
six O
different O
human O
tumor O
cell O
lines O
by O
standard O
MTT B
assay O
. O

Compounds O
2c O
, O
3c O
, O
4c O
, O
5c O
, O
6c O
and O
8b O
showed O
better O
anti O
- O
tumor O
activities O
compared O
to O
the O
parent O
compound O
25 B
- I
OH I
- I
PPD I
. O

Chronic O
boldine B
treatment O
normalized O
ROS O
over O
- O
production O
in O
the O
diabetic O
group O
and O
this O
correlated O
with O
reduction O
of O
NAD B
( I
P I
) I
H I
oxidase O
subunits O
, O
NOX2 O
and O
p47 O
( O
phox O
) O
. O

N B
, I
N I
- I
dihydroxypyromelliti I
( O
NDHPI B
) O
and O
N B
, I
N I
' I
, I
N I
' I
' I
- I
trihydroxyisocyanuri I
acid I
( O
THICA B
) O
have O
been O
recently O
demonstrated O
to O
act O
as O
better O
carbon B
- O
radical O
- O
producing O
catalysts O
than O
the O
popular O
N B
- I
hydroxyphthalimide I
( O
NHPI B
) O
. O

Six O
individual O
phenolics B
( O
gallic B
acid I
, O
chlorogenic B
acid I
, O
( B
+ I
) I
- I
catechin I
, O
caffeic B
acid I
, O
( B
- I
) I
- I
epicatechin I
, O
and O
rutin B
) O
were O
detected O
in O
litchi O
pulp O
by O
HPLC O
. O

Six O
individual O
phenolics B
( O
gallic B
acid I
, O
chlorogenic B
acid I
, O
( B
+ I
) I
- I
catechin I
, O
caffeic B
acid I
, O
( B
- I
) I
- I
epicatechin I
, O
and O
rutin B
) O
were O
detected O
in O
litchi O
pulp O
by O
HPLC O
. O

1 B
, I
3 I
, I
6 I
, I
6 I
' I
- I
tetra I
- I
feruloyl I
sucrose I
named O
taroside O
was O
a O
new O
phenlypropanoid B
glycoside I
, O
together O
with O
3 B
, I
6 I
- I
di I
- I
p I
- I
coumaroyl I
- I
1 I
, I
6 I
' I
- I
di I
- I
feruloyl I
sucrose I
, O
1 B
, I
6 I
, I
6 I
' I
- I
tri I
- I
feruloyl I
- I
3 I
- I
p I
- I
coumaroyl I
sucrose I
, O
N B
- I
trans I
- I
feruloyltyramine I
and O
quercetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
D I
- I
xyloxyl I
- I

TNF O
- O
alpha O
) O
, O
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
. O

Bisphenol B
A I
inhibits O
voltage O
- O
activated O
Ca B
( I
2 I
+ I
) I
channels O
in O
vitro O
: O
mechanisms O
and O
structural O
requirements O
. O

In O
this O
study O
we O
show O
that O
BPA B
acts O
as O
a O
potent O
blocker O
of O
voltage O
- O
activated O
Ca B
( I
2 I
+ I
) I
channels O
. O

Macroscopic O
Ba B
( I
2 I
+ I
) I
/ O
Ca B
( I
2 I
+ I
) I
currents O
through O
native O
L O
- O
, O
N O
- O
, O
P O
/ O
Q O
- O
, O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
rat O
endocrine O
GH O
( O
3 O
) O
cells O
, O
mouse O
dorsal O
root O
ganglion O
neurons O
or O
cardiac O
myocytes O
, O
and O
recombinant O
human O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
expressed O
in O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
were O
rapidly O
and O
reversibly O
inhibited O
by O
BPA B
with O
similar O
potency O
( O
EC O
( O
50 O
) O
values O
: O
26 O
- O
35 O
mu O
M O
) O
. O

Macroscopic O
Ba B
( I
2 I
+ I
) I
/ O
Ca B
( I
2 I
+ I
) I
currents O
through O
native O
L O
- O
, O
N O
- O
, O
P O
/ O
Q O
- O
, O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
rat O
endocrine O
GH O
( O
3 O
) O
cells O
, O
mouse O
dorsal O
root O
ganglion O
neurons O
or O
cardiac O
myocytes O
, O
and O
recombinant O
human O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
expressed O
in O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
were O
rapidly O
and O
reversibly O
inhibited O
by O
BPA B
with O
similar O
potency O
( O
EC O
( O
50 O
) O
values O
: O
26 O
- O
35 O
mu O
M O
) O
. O

Macroscopic O
Ba B
( I
2 I
+ I
) I
/ O
Ca B
( I
2 I
+ I
) I
currents O
through O
native O
L O
- O
, O
N O
- O
, O
P O
/ O
Q O
- O
, O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
rat O
endocrine O
GH O
( O
3 O
) O
cells O
, O
mouse O
dorsal O
root O
ganglion O
neurons O
or O
cardiac O
myocytes O
, O
and O
recombinant O
human O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
expressed O
in O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
were O
rapidly O
and O
reversibly O
inhibited O
by O
BPA B
with O
similar O
potency O
( O
EC O
( O
50 O
) O
values O
: O
26 O
- O
35 O
mu O
M O
) O
. O

Macroscopic O
Ba B
( I
2 I
+ I
) I
/ O
Ca B
( I
2 I
+ I
) I
currents O
through O
native O
L O
- O
, O
N O
- O
, O
P O
/ O
Q O
- O
, O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
rat O
endocrine O
GH O
( O
3 O
) O
cells O
, O
mouse O
dorsal O
root O
ganglion O
neurons O
or O
cardiac O
myocytes O
, O
and O
recombinant O
human O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
expressed O
in O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
were O
rapidly O
and O
reversibly O
inhibited O
by O
BPA B
with O
similar O
potency O
( O
EC O
( O
50 O
) O
values O
: O
26 O
- O
35 O
mu O
M O
) O
. O

Pharmacological O
and O
biophysical O
analysis O
of O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
revealed O
that O
BPA B
interacts O
with O
the O
extracellular O
part O
of O
the O
channel O
protein O
. O

Immortalized O
human O
bronchial O
epithelial O
cells O
( O
16HBE14o O
- O
) O
were O
exposed O
to O
0 O
, O
130 O
, O
or O
330nM O
arsenic B
( O
as O
Na B
- I
arsenite I
) O
for O
4 O
- O
5 O
weeks O
and O
examined O
for O
wound O
repair O
efficiency O
and O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
. O

We O
found O
that O
chronic O
arsenic B
exposure O
at O
these O
low O
doses O
slows O
wound O
repair O
and O
reduces O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
. O

We O
further O
show O
that O
arsenic B
compromises O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
by O
altering O
both O
Ca B
( I
2 I
+ I
) I
release O
from O
intracellular O
stores O
( O
via O
metabotropic O
P2Y O
receptors O
) O
and O
Ca B
( I
2 I
+ I
) I
influx O
mechanisms O
( O
via O
ionotropic O
P2X O
receptors O
) O
. O

We O
further O
show O
that O
arsenic B
compromises O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
by O
altering O
both O
Ca B
( I
2 I
+ I
) I
release O
from O
intracellular O
stores O
( O
via O
metabotropic O
P2Y O
receptors O
) O
and O
Ca B
( I
2 I
+ I
) I
influx O
mechanisms O
( O
via O
ionotropic O
P2X O
receptors O
) O
. O

We O
further O
show O
that O
arsenic B
compromises O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
by O
altering O
both O
Ca B
( I
2 I
+ I
) I
release O
from O
intracellular O
stores O
( O
via O
metabotropic O
P2Y O
receptors O
) O
and O
Ca B
( I
2 I
+ I
) I
influx O
mechanisms O
( O
via O
ionotropic O
P2X O
receptors O
) O
. O

To O
better O
model O
the O
effects O
of O
arsenic B
on O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
under O
conditions O
of O
natural O
exposure O
, O
we O
cultured O
tracheal O
epithelial O
cells O
obtained O
from O
mice O
exposed O
to O
control O
or O
50 O
ppb O
Na B
- I
arsenite I
supplemented O
drinking O
water O
for O
4 O
weeks O
. O

Tracheal O
epithelial O
cells O
from O
arsenic B
- O
exposed O
mice O
displayed O
reduced O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
dynamics O
similar O
to O
our O
in O
vitro O
chronic O
exposure O
. O

The O
cytotoxic O
activity O
of O
these O
phenylpropanoids B
against O
HeLa O
cells O
is O
in O
the O
order O
of O
eugenol B
> O
ferulic B
> O
cinnamic B
> O
caffeic B
> O
chlorogenic B
> O
p B
- I
coumaric I
> O
3 B
, I
4 I
- I
dimethoxycinnamic I
> O
2 B
, I
4 I
, I
5 I
- I
trimethoxycinnamic I
acids I
. O

For O
this O
purpose O
, O
the O
combined O
effect O
of O
23 B
- I
methyl I
- I
6 I
- I
O I
- I
desmethylauricepyron I
( O
1 O
) O
, O
quercetin B
( O
2 O
) O
and O
3 B
- I
O I
- I
methylquercetin I
( O
3 O
) O
, O
obtained O
through O
bioguided O
fractionation O
from O
A O
. O
satureioides O
ethanol B
extract O
, O
was O
evaluated O
against O
Staphylococcus O
aureus O
and O
Escherichia O
coli O
. O

pH O
- O
responsive O
composite O
microspheres O
, O
consisting O
of O
a O
core O
of O
Fe3O4 B
nanoparticle O
, O
a O
sandwiched O
layer O
of O
mesoporous O
silica B
and O
a O
shell O
of O
crosslinked O
poly B
( I
methacrylic I
acid I
) I
( O
PMAA B
) O
, O
were O
successfully O
synthesized O
via O
distillation O
precipitation O
polymerization O
. O

In O
this O
work O
, O
bioconjugation O
techniques O
are O
developed O
to O
achieve O
peptide O
functionalization O
of O
poly B
( I
vinyl I
alcohol I
) I
, O
PVA B
, O
as O
both O
a O
polymer O
in O
solution O
and O
within O
microstructured O
physical O
hydrogels O
, O
in O
both O
cases O
under O
physiological O
conditions O
. O

Bioresorbable O
surface O
- O
adhered O
enzymatic O
microreactors O
based O
on O
physical O
hydrogels O
of O
poly B
( I
vinyl I
alcohol I
) I
. O

Hydrogel O
biomaterials O
based O
on O
poly B
( I
vinyl I
alcohol I
) I
, O
PVA B
, O
have O
an O
extensive O
history O
of O
biomedical O
applications O
, O
yet O
in O
their O
current O
form O
suffer O
from O
significant O
shortcomings O
, O
such O
as O
a O
lack O
of O
mechanism O
of O
biodegradation O
and O
poor O
opportunities O
in O
controlled O
drug O
release O
. O

Bifunctional O
CA O
- O
PEG B
( O
catechol B
- O
poly B
( I
ethylene I
glycol I
) I
) O
and O
multifunctional O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
( O
poly B
( I
glycidyl I
amine I
) I
/ O
poly B
( I
ethylene I
glycol I
vinyl I
glycidyl I
ether I
) I
) O
ligands O
for O
the O
functionalization O
and O
solubilization O
of O
nanoparticles O
are O
introduced O
. O

Bifunctional O
CA O
- O
PEG B
( O
catechol B
- O
poly B
( I
ethylene I
glycol I
) I
) O
and O
multifunctional O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
( O
poly B
( I
glycidyl I
amine I
) I
/ O
poly B
( I
ethylene I
glycol I
vinyl I
glycidyl I
ether I
) I
) O
ligands O
for O
the O
functionalization O
and O
solubilization O
of O
nanoparticles O
are O
introduced O
. O

CA O
- O
OH B
was O
used O
both O
for O
homopolymerization O
of O
ethylene B
oxide I
( O
EO O
) O
as O
well O
as O
copolymerization O
with O
functional O
epoxides B
N B
, I
N I
- I
diallyl I
glycidyl I
amine I
( O
DAGA B
) O
, O
releasing O
primary B
amino I
groups O
and O
ethylene B
glycol I
vinyl I
glycidyl I
ether I
( O
EVGE B
) O
, O
exhibiting O
a O
double O
bond O
for O
click O
- O
type O
reactions O
, O
to O
generate O
CA O
- O
PEG B
and O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
. O

In O
contrast O
, O
inhibitors O
of O
AC O
, O
ATP B
- O
sensitive O
K B
( I
+ I
) I
channels O
, O
or O
high O
- O
conductance O
Ca B
( I
2 I
+ I
) I
- O
activated O
K B
( I
+ I
) I
channels O
did O
not O
change O
the O
effects O
of O
NCA B
. O

NCA B
significantly O
reduced O
contractile O
response O
and O
platelet O
aggregation O
mediated O
by O
the O
thromboxane B
A I
( I
2 I
) I
mimetic O
9 B
, I
11 I
- I
dideoxy I
- I
11 I
alpha I
, I
9 I
alpha I
- I
epoxymethanoprostagl I
F I
( I
2 I
) I
( I
alpha I
) I
in O
a O
cGMP B
- O
dependent O
manner O
. O

After O
acclimation O
, O
groups O
were O
exposed O
to O
equivalent O
free O
- O
ion O
Cd B
concentration O
( O
4 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
mg O
/ O
L O
, O
Cd B
( I
2 I
+ I
) I
) O
in O
their O
respective O
acclimated O
salinity O
to O
compare O
survival O
among O
salinity O
treatments O
. O

Results O
of O
Kaplan O
- O
Meier O
survival O
analysis O
indicated O
that O
3 O
. O
0 O
ppt O
- O
- O
> O
3 O
. O
0 O
ppt O
shrimp O
were O
more O
sensitive O
to O
Cd B
( I
2 I
+ I
) I
than O
any O
other O
group O
( O
p O
< O
0 O
. O
0001 O
) O
. O

Additionally O
, O
3 O
. O
0 O
ppt O
- O
- O
> O
13 O
. O
5 O
ppt O
shrimp O
were O
less O
sensitive O
to O
Cd B
( I
2 I
+ I
) I
than O
were O
24 O
. O
0 O
ppt O
- O
- O
> O
13 O
. O
5 O
ppt O
shrimp O
( O
p O
= O
0 O
. O
0013 O
) O
. O

This O
was O
done O
by O
introduction O
of O
a O
heteroatom O
( O
N B
or O
O B
) O
in O
alpha O
- O
position O
to O
the O
phosphonate B
and O
using O
the O
resultant O
OH B
and O
NH B
2 I
groups O
as O
a O
handle O
for O
appending O
a O
variety O
of O
substituents O
by O
means O
of O
several O
functional O
groups O
such O
as O
ether B
, O
amide B
, O
urea B
, O
and O
1 B
, I
4 I
- I
triazole I
. O

The O
5 B
, I
7 I
- I
OH I
group O
of O
A O
ring O
and O
one O
4 B
' I
- I
OH I
group O
of O
the O
B O
ring O
in O
apigenin B
and O
naringenin B
are O
important O
for O
synergistic O
activity O
. O

In O
our O
study O
, O
the O
percutaneous O
penetration O
of O
the O
occupationally O
relevant O
chemicals O
anisole B
, O
cyclohexanone B
and O
1 B
, I
4 I
- I
dioxane I
was O
investigated O
for O
freshly O
excised O
as O
well O
as O
for O
4 O
and O
30 O
days O
at O
- O
20 O
degrees O
C O
stored O
human O
skin O
using O
the O
diffusion O
cell O
technique O
. O

Considering O
the O
percutaneously O
penetrated O
amounts O
, O
the O
following O
ranking O
was O
determined O
: O
1 B
, I
4 I
- I
dioxane I
> O
anisole B
> O
cyclohexanone B
( O
decline O
to O
a O
factor O
of O
5 O
. O
9 O
) O
. O

Hexylsubstituted B
poly I
( I
lactic I
acid I
) I
( O
hexPLA B
) O
is O
a O
viscous O
polymer O
, O
which O
degrades O
in O
the O
presence O
of O
water O
similar O
to O
the O
structure O
related O
poly B
( I
lactic I
acid I
) I
. O

It O
depends O
on O
the O
adsorption O
mode O
and O
the O
presence O
of O
H B
( I
2 I
) I
O I
but O
is O
almost O
the O
same O
for O
300 O
and O
350 O
K O
. O

The O
elongated O
structures O
of O
polyamine B
inverse O
agonists O
such O
as O
1 B
, I
12 I
- I
diaminododecane I
( O
N12N B
) O
and O
5 B
- I
( I
4 I
- I
aminobutyl I
) I
- I
2 I
- I
thiopheneoctanamine I
( O
N4T8N B
) O
lend O
themselves O
to O
a O
combinatorial O
chemistry O
approach O
to O
explore O
a O
potential O
polyamine B
pharmacophore O
at O
the O
NMDA B
receptor O
. O

With O
the O
optimal O
film O
thickness O
, O
the O
adsorptions O
from O
bovine O
serum O
albumin O
, O
human O
serum O
, O
and O
human O
plasma O
onto O
the O
pSerMA B
- O
grafted O
surfaces O
, O
as O
evaluated O
by O
a O
surface O
plasmon O
resonance O
( O
SPR O
) O
biosensor O
, O
were O
1 O
. O
8 O
, O
9 O
. O
2 O
, O
and O
12 O
. O
9 O
ng O
/ O
cm O
( O
2 O
) O
, O
respectively O
, O
comparable O
to O
the O
traditional O
antifouling O
material O
such O
as O
poly B
( I
ethylene I
glycol I
) I
. O

The O
microcapsules O
were O
subsequently O
placed O
within O
a O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
- O
coated O
poly B
( I
epsilon I
- I
caprolactone I
) I
( O
PCL B
) O
chamber O
covered O
with O
a O
PEG B
- I
grafted I
PCL I
nanoporous O
membrane O
formed O
by O
phase O
inversion O
. O

Pin1 O
was O
adducted O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
treated O
with O
8 B
- I
alkynyl I
- I
HNE I
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin B
followed O
by O
streptavidin O
- O
based O
pulldown O
and O
Western O
blotting O
with O
anti O
- O
Pin1 O
antibody O
. O

Analysis O
of O
both O
primary O
and O
secondary O
water O
molecule O
losses O
from O
each O
sized O
complex O
provides O
thermochemistry O
for O
the O
sequential O
hydration O
energies O
of O
Mg B
( I
2 I
+ I
) I
for O
x O
= O
2 O
- O
10 O
and O
the O
first O
experimental O
values O
for O
x O
= O
2 O
- O
4 O
. O

In O
this O
study O
, O
well O
- O
defined O
poly B
( I
glycidyl I
methacrylate I
) I
( O
P B
( I
GMA I
) I
) O
homopolymers O
were O
synthesized O
using O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
followed O
by O
decoration O
using O
three O
different O
types O
of O
oligoamines B
, O
i O
. O
e O
. O
, O
tetraethylenepentami B
( O
TEPA B
) O
, O
pentaethylenehexamin B
( O
PEHA B
) O
, O
and O
tris B
( I
2 I
- I
aminoethyl I
) I
amine I
( O
TREN B
) O
, O
respectively O
, O
to O
generate O
various O
P B
( I
GMA I
- I
oligoamine I
) I

Acid O
- O
degradable O
cationic O
poly B
( I
ketal I
amidoamine I
) I
for O
enhanced O
RNA O
interference O
in O
vitro O
and O
in O
vivo O
. O

In O
the O
present O
study O
, O
we O
report O
a O
new O
acid O
- O
degradable O
poly B
( I
ketal I
amidoamine I
) I
( O
PKAA B
) O
as O
a O
siRNA O
carrier O
, O
which O
has O
high O
delivery O
efficiency O
and O
low O
cytotoxicity O
. O

5 B
- I
Benzylglycinyl I
- I
amiloride I
kills O
proliferating O
and O
nonproliferating O
malignant O
glioma O
cells O
through O
caspase O
- O
independent O
necroptosis O
mediated O
by O
apoptosis O
- O
inducing O
factor O
. O

Poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
epsilon I
- I
caprolactone I
) I
( O
PEG B
- I
b I
- I
PCL I
) O
micelles O
were O
loaded O
with O
paclitaxel B
( O
cytotoxic O
agent O
) O
, O
cyclopamine B
( O
hedgehog O
inhibitor O
) O
, O
and O
gossypol B
( O
Bcl O
- O
2 O
inhibitor O
) O
. O

After O
physicochemical O
studies O
focusing O
on O
combination O
drug O
solubilization O
, O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
were O
evaluated O
in O
vitro O
in O
2 O
- O
D O
and O
3 O
- O
D O
cell O
culture O
and O
in O
vivo O
in O
xenograft O
models O
of O
ovarian O
cancer O
, O
tracking O
bioluminescence O
signals O
from O
ES O
- O
2 O
and O
SKOV3 O
human O
ovarian O
cancer O
cell O
lines O
after O
IP O
injection O
. O

3 O
- O
Drug O
PEG B
- I
b I
- I
PCL I
micelles O
were O
not O
significantly O
more O
potent O
in O
2 O
- O
D O
cell O
culture O
in O
comparison O
to O
paclitaxel B
; O
however O
, O
they O
disaggregated O
ES O
- O
2 O
tumor O
spheroids O
, O
whereas O
single O
drugs O
or O
2 O
- O
drug O
combinations O
only O
slowed O
growth O
of O
ES O
- O
2 O
tumor O
spheroids O
or O
had O
no O
noticeable O
effects O
. O

In O
ES O
- O
2 O
and O
SKOV3 O
xenograft O
models O
, O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
had O
significantly O
less O
tumor O
burden O
than O
paclitaxel B
based O
on O
bioluminescence O
imaging O
, O
3 B
' I
- I
deoxy I
- I
3 I
' I
- I
( I
18 I
) I
F I
- I
fluorothymidine I
( O
( B
18 I
) I
F I
- I
FLT I
) O
PET O
imaging O
, O
and O
overall O
survival O
. O

( B
18 I
) I
F I
- I
FLT I
- O
PET O
images O
clearly O
showed O
that O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
dramatically O
reduce O
tumor O
volumes O
over O
paclitaxel B
and O
vehicle O
controls O
. O

In O
summary O
, O
PEG B
- I
b I
- I
PCL I
micelles O
enable O
the O
IP O
combination O
drug O
delivery O
of O
paclitaxel B
, O
cyclopamine B
and O
gossypol B
, O
resulting O
in O
tumor O
growth O
inhibition O
and O
prolonged O
survival O
over O
paclitaxel B
alone O
. O

These O
results O
validate O
a O
novel O
treatment O
strategy O
for O
ovarian O
cancer O
based O
on O
drug O
combinations O
of O
cytotoxic O
agents O
and O
molecular O
targeted O
agents O
, O
delivered O
concurrently O
by O
a O
nanoscale O
drug O
delivery O
system O
, O
e O
. O
g O
. O
PEG B
- I
b I
- I
PCL I
micelles O
. O

Here O
, O
we O
show O
that O
halogen B
bonding O
between O
a O
pyridyl B
substituent O
in O
a O
bis B
( I
pyridyl I
urea I
) I
and O
1 B
, I
4 I
- I
diiodotetrafluoroben I
brings O
about O
gelation O
, O
even O
in O
polar O
media O
such O
as O
aqueous O
methanol B
and O
aqueous O
dimethylsulfoxide B
. O

Here O
, O
we O
show O
that O
halogen B
bonding O
between O
a O
pyridyl B
substituent O
in O
a O
bis B
( I
pyridyl I
urea I
) I
and O
1 B
, I
4 I
- I
diiodotetrafluoroben I
brings O
about O
gelation O
, O
even O
in O
polar O
media O
such O
as O
aqueous O
methanol B
and O
aqueous O
dimethylsulfoxide B
. O

For O
two O
derivatives O
the O
X O
- O
ray O
wave O
function O
refinement O
was O
performed O
to O
evaluate O
the O
character O
of O
bonds O
in O
the O
NBF B
( I
2 I
) I
O I
moiety O
by O
topological O
and O
integrated O
bond O
descriptors O
. O

When O
ether B
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solution O
of O
an O
enantiomer O
of O
a O
hexa B
- I
peri I
- I
hexabenzocoronene I
( O
HBC B
) O
derivative O
carrying O
a O
chiral O
( B
BINAP I
) I
Pt I
( I
II I
) I
- O
appended O
coordination O
metallacycle O
( O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) O
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

In O
the O
present O
study O
, O
we O
expressed O
bovine O
Oatp1a2 O
in O
human O
embryonic O
kidney O
293 O
cells O
and O
found O
that O
, O
unlike O
human O
OATP1A2 O
, O
the O
transport O
of O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
exhibited O
biphasic O
saturation O
kinetics O
. O

In O
the O
present O
study O
, O
we O
expressed O
bovine O
Oatp1a2 O
in O
human O
embryonic O
kidney O
293 O
cells O
and O
found O
that O
, O
unlike O
human O
OATP1A2 O
, O
the O
transport O
of O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
exhibited O
biphasic O
saturation O
kinetics O
. O

Further O
study O
on O
other O
Oatp1a2 O
substrates O
showed O
that O
the O
high O
affinity O
component O
for O
E B
- I
3 I
- I
S I
is O
responsible O
for O
the O
interaction O
with O
taurocholate B
, O
bromsulphthalein B
, O
and O
rifampicin B
and O
is O
sensitive O
to O
proton O
concentration O
change O
, O
whereas O
the O
low O
affinity O
binding O
site O
is O
only O
involved O
in O
the O
binding O
of O
the O
antitumor O
drug O
methotrexate B
and O
had O
no O
response O
to O
change O
of O
pH O
. O

The O
activated O
carbon B
( O
AC O
) O
nanoparticles O
in O
suspension O
during O
electrophoresis O
play O
an O
important O
role O
in O
supporting O
the O
GNs O
perpendicular O
to O
the O
FTO B
( O
fluorine B
- I
doped I
tin I
oxide I
) O
glass O
. O

We O
find O
that O
: O
( O
i O
) O
Ti B
and O
Cu B
in O
( B
TiO I
( I
2 I
) I
) I
( I
x I
) I
( I
Cu I
( I
2 I
) I
O I
) I
( I
y I
) I
alloys O
have O
similar O
local O
environments O
as O
in O
bulk O
TiO B
( I
2 I
) I
and O
Cu B
( I
2 I
) I
O I
except O
for O
( O
TiO B
( I
2 I
) I
) O
( O
Cu B
( I
2 I
) I
O I
) O
which O
has O
some O
trigonal O
- O
planar O
Cu B
ions O
. O

We O
find O
that O
: O
( O
i O
) O
Ti B
and O
Cu B
in O
( B
TiO I
( I
2 I
) I
) I
( I
x I
) I
( I
Cu I
( I
2 I
) I
O I
) I
( I
y I
) I
alloys O
have O
similar O
local O
environments O
as O
in O
bulk O
TiO B
( I
2 I
) I
and O
Cu B
( I
2 I
) I
O I
except O
for O
( O
TiO B
( I
2 I
) I
) O
( O
Cu B
( I
2 I
) I
O I
) O
which O
has O
some O
trigonal O
- O
planar O
Cu B
ions O
. O

Tailorable O
cell O
culture O
platforms O
from O
enzymatically O
cross O
- O
linked O
multifunctional O
poly B
( I
ethylene I
glycol I
) I
- O
based O
hydrogels O
. O

Herein O
we O
describe O
a O
process O
for O
making O
hydrogels O
composed O
of O
hydroxyphenyl B
propionic I
acid I
( O
HPA B
) O
conjugated O
, O
branched O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
via O
an O
enzyme O
mediated O
, O
oxidative O
cross O
- O
linking O
method O
. O

The O
comparison O
of O
CBCP B
- I
one I
reduction O
with O
NADPH B
to O
reductions O
of O
physiological O
substrates O
revealed O
in O
general O
higher O
efficiencies O
, O
except O
for O
reduction O
of O
9 B
- I
cis I
- I
retinaldehyde I
by O
AKR1C3 O
. O

Anti O
- O
tumor O
efficacy O
of O
chitosan O
- O
g O
- O
poly B
( I
ethylene I
glycol I
) I
nanocapsules O
containing O
docetaxel B
: O
anti O
- O
TMEFF O
- O
2 O
functionalized O
nanocapsules O
vs O
. O
non O
- O
functionalized O
nanocapsules O
. O

When O
OATP2B1 O
- O
expressing O
Xenopus O
oocytes O
were O
preincubated O
with O
GFJ O
, O
orange O
juice O
( O
OJ O
) O
, O
or O
apple O
juice O
( O
AJ O
) O
, O
AJ O
induced O
a O
remarkable O
decrease O
in O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
in O
a O
concentration O
- O
dependent O
manner O
( O
IC O
( O
50 O
) O
= O
1 O
. O
5 O
% O
) O
. O

Kinetic O
analysis O
revealed O
that O
coincubation O
and O
preincubation O
with O
AJ O
reduced O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
via O
competitive O
and O
noncompetitive O
mechanisms O
, O
respectively O
. O

Selenium B
chloride I
oxide I
( O
SeCl B
( I
2 I
) I
O I
) O
was O
added O
to O
the O
EPS O
to O
synthesize O
selenium B
- O
exopolysaccharide O
( O
Se B
- O
EPS O
) O
. O

In O
general O
, O
the O
highest O
concentration O
of O
total O
phenolics B
was O
found O
in O
the O
mash O
- O
heated O
wines O
, O
whereas O
the O
total O
flavan B
- I
3 I
- I
ol I
and O
total O
anthocyanin B
contents O
in O
all O
of O
the O
wines O
, O
decreased O
notably O
during O
the O
winemaking O
and O
ageing O
processes O
. O

The O
wines O
treated O
by O
the O
pectolytic O
enzyme O
addition O
had O
a O
lower O
monomeric O
flavan B
- I
3 I
- I
ol I
content O
than O
had O
the O
other O
wines O
, O
and O
the O
amount O
of O
monomeric O
anthocyanins B
extracted O
did O
not O
increase O
with O
the O
addition O
of O
enzymes O
. O

The O
results O
indicate O
that O
the O
binding O
of O
VO B
( I
2 I
+ I
) I
to O
asparagine B
and O
the O
decrease O
in O
the O
pH O
of O
the O
potato O
samples O
resulted O
in O
a O
significant O
reduction O
of O
acrylamide B
formation O
in O
fried O
potato O
products O
. O

Described O
is O
the O
synthesis O
of O
5 B
- I
hydroxytryptamine I
- I
tetramethylrhodamine I
( O
5HT B
* O
) O
; O
an O
indole B
nitrogen I
linked O
fluorescent O
conjugate O
of O
serotonin B
. O

Modified O
H B
- I
phosphonates I
containing O
3 B
' I
- I
phenyl I
selenides I
as O
well O
as O
saturated B
and I
unsaturated I
sugars I
were O
obtained O
and O
incorporated O
in O
ODNs B
. O

Furthermore O
, O
ganodermanondiol B
exposure O
enhanced O
the O
phosphorylation O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
upstream O
kinase O
activators O
, O
LKB1 O
and O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinase O
- O
II O
( O
CaMKII O
) O
. O

DPEP B
induced O
dose O
- O
dependent O
reduction O
of O
the O
protein O
levels O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
and O
concomitant O
reduction O
in O
the O
production O
of O
NO B
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
. O

In O
~ O
50 O
% O
of O
the O
visits O
, O
stimulant O
drugs O
like O
cocaine B
and O
amphetamine B
- O
like O
substances O
( O
e O
. O
g O
. O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
, O
the O
main O
active O
ingredient O
of O
ecstasy B
) O
) O
are O
involved O
, O
whereas O
in O
~ O
60 O
% O
multiple O
drugs O
are O
involved O
. O

We O
therefore O
investigated O
the O
effects O
of O
combinations O
of O
commonly O
abused O
stimulant O
drugs O
( O
cocaine B
, O
MDMA B
, O
3 B
, I
4 I
- I
methylenedioxyamphet I
( O
MDA B
) O
and O
meta B
- I
chlorophenylpiperazi I
( O
mCPP B
) O
) O
on O
the O
function O
of O
the O
human O
alpha O
1 O
beta O
2 O
gamma O
2 O
GABAA O
receptor O
( O
hGABAA O
- O
R O
) O
, O
expressed O
in O
Xenopus O
oocytes O
, O
using O
the O
two O
- O
electrode O
voltage O
- O
clamp O
technique O
. O

Some O
evidence O
has O
been O
built O
for O
the O
neuro O
- O
cognitive O
benefits O
of O
supplementation O
with O
long B
chain I
polyunsaturated I
fatty I
acids I
( O
LCPUFA B
) O
such O
as O
DHA B
during O
pregnancy O
; O
however O
, O
recent O
data O
indicate O
that O
the O
anti O
- O
inflammatory O
properties O
may O
be O
of O
at O
least O
equal O
significance O
. O

Left O
unrepaired O
the O
syn B
- I
8 I
- I
oxoG I
/ O
dAMP B
base O
pair O
results O
in O
a O
G O
- O
C O
to O
T O
- O
A O
transversion O
. O

Ternary O
complexes O
with O
incoming O
dCTP B
resemble O
the O
wild O
- O
type O
enzyme O
, O
with O
templating O
anti B
- I
8 I
- I
oxoG I
base O
pairing O
with O
incoming O
cytosine B
. O

These O
results O
demonstrate O
that O
the O
incoming O
nucleotide B
is O
unable O
to O
induce O
a O
syn B
- I
8 I
- I
oxoG I
conformation O
without O
minor O
groove O
DNA O
polymerase O
interactions O
that O
influence O
templating O
( O
anti O
- O
/ O
syn O
- O
equilibrium O
) O
of O
8 B
- I
oxoG I
while O
modulating O
fidelity O
. O

In O
this O
study O
we O
report O
the O
isolation O
of O
three O
endophytic O
fungi O
from O
fruit O
and O
seed O
regions O
of O
Miquelia O
dentata O
( O
Icacinaceae O
) O
, O
that O
produce O
CPT B
, O
9 B
- I
methoxy I
CPT I
( O
9 B
- I
MeO I
- I
CPT I
) O
and O
10 B
- I
hydroxy I
CPT I
( O
10 B
- I
OH I
- I
CPT I
) O
. O

In O
this O
study O
we O
report O
the O
isolation O
of O
three O
endophytic O
fungi O
from O
fruit O
and O
seed O
regions O
of O
Miquelia O
dentata O
( O
Icacinaceae O
) O
, O
that O
produce O
CPT B
, O
9 B
- I
methoxy I
CPT I
( O
9 B
- I
MeO I
- I
CPT I
) O
and O
10 B
- I
hydroxy I
CPT I
( O
10 B
- I
OH I
- I
CPT I
) O
. O

( O
Sacc O
. O
) O
produced O
CPT B
, O
9 B
- I
MeO I
- I
CPT I
and O
10 B
- I
OH I
- I
CPT I
in O
mycelial O
mats O
in O
shake O
flasks O
containing O
potato O
dextrose O
broth O
. O

( O
Sacc O
. O
) O
produced O
CPT B
, O
9 B
- I
MeO I
- I
CPT I
and O
10 B
- I
OH I
- I
CPT I
in O
mycelial O
mats O
in O
shake O
flasks O
containing O
potato O
dextrose O
broth O
. O

These O
data O
suggest O
that O
G6pc2 O
represents O
a O
novel O
, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose B
- I
6 I
- I
phosphate I
, O
thereby O
reducing O
glycolytic O
flux O
. O

Thiosemicarbazone B
chelators O
, O
including O
the O
2 B
' I
- I
benzoylpyridine I
thiosemicarbazones I
( O
BpT B
) O
class O
, O
show O
marked O
potential O
as O
anticancer O
agents O
. O

In O
this O
work O
, O
we O
fabricated O
a O
series O
of O
mixed O
shell O
micelles O
( O
MSMs O
) O
with O
approximately O
the O
same O
size O
, O
charge O
and O
core O
composition O
but O
with O
varied O
hydrophilic O
/ O
hydrophobic O
ratios O
in O
the O
shell O
through O
spontaneously O
self O
- O
assembly O
of O
block O
copolymers O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
l I
- I
lysine I
) I
( O
PEG B
- I
b I
- I
PLys I
) O
and O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- I
block I
- I
poly I
( I
aspartic I
acid I
) I
( O
PNIPAM B
- I
b I
- I
PAsp I
) O
in O

In O
this O
work O
, O
we O
fabricated O
a O
series O
of O
mixed O
shell O
micelles O
( O
MSMs O
) O
with O
approximately O
the O
same O
size O
, O
charge O
and O
core O
composition O
but O
with O
varied O
hydrophilic O
/ O
hydrophobic O
ratios O
in O
the O
shell O
through O
spontaneously O
self O
- O
assembly O
of O
block O
copolymers O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
l I
- I
lysine I
) I
( O
PEG B
- I
b I
- I
PLys I
) O
and O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- I
block I
- I
poly I
( I
aspartic I
acid I
) I
( O
PNIPAM B
- I
b I
- I
PAsp I
) O
in O

Mis O
- O
incorporation O
causes O
the O
transcription O
elongation O
complex O
to O
backtrack O
, O
releasing O
a O
single O
strand O
3 O
' O
- O
RNA O
segment O
bearing O
a O
noncognate O
residue O
, O
which O
is O
hydrolyzed O
by O
the O
active O
center O
that O
carries O
two O
Mg B
( I
2 I
+ I
) I
ions O
. O

However O
, O
in O
most O
x O
- O
ray O
structures O
only O
one O
Mg B
( I
2 I
+ I
) I
is O
present O
. O

This O
Mg B
( I
2 I
+ I
) I
is O
tightly O
bound O
to O
the O
active O
center O
aspartates B
, O
creating O
an O
inactive O
stable O
state O
. O

The O
first O
residue O
of O
the O
single O
strand O
RNA O
segment O
in O
the O
backtracked O
transcription O
elongation O
complex O
strongly O
promotes O
transcript O
hydrolytic O
cleavage O
by O
establishing O
a O
network O
of O
interactions O
that O
force O
a O
shift O
of O
stably O
bound O
Mg B
( I
2 I
+ I
) I
to O
release O
some O
of O
its O
aspartate B
coordination O
valences O
for O
binding O
to O
the O
second O
Mg B
( I
2 I
+ I
) I
thus O
enabling O
catalysis O
. O

The O
first O
residue O
of O
the O
single O
strand O
RNA O
segment O
in O
the O
backtracked O
transcription O
elongation O
complex O
strongly O
promotes O
transcript O
hydrolytic O
cleavage O
by O
establishing O
a O
network O
of O
interactions O
that O
force O
a O
shift O
of O
stably O
bound O
Mg B
( I
2 I
+ I
) I
to O
release O
some O
of O
its O
aspartate B
coordination O
valences O
for O
binding O
to O
the O
second O
Mg B
( I
2 I
+ I
) I
thus O
enabling O
catalysis O
. O

Transcription O
factor O
Gre O
builds O
on O
the O
ACT O
mechanism O
in O
the O
same O
reaction O
by O
increasing O
the O
retention O
of O
the O
second O
Mg B
( I
2 I
+ I
) I
and O
by O
activating O
the O
attacking O
water O
, O
causing O
3000 O
- O
4000 O
- O
fold O
reaction O
acceleration O
and O
strongly O
reinforcing O
proofreading O
. O

The O
model O
was O
fabricated O
using O
a O
dual O
photochemical O
approach O
, O
where O
poly B
( I
methyl I
methacrylate I
) I
( O
PMMA B
) O
thin O
films O
were O
cross O
- O
linked O
by O
a O
photoactive O
benzophenone B
monolayer O
and O
blended O
cross O
- O
linking O
agent O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
( O
SAR O
) O
studies O
around O
the O
3 B
, I
5 I
- I
dimethylphenyl I
and O
4 B
- I
methoxyphenyl I
regions O
resulted O
in O
the O
identification O
of O
a O
novel O
series O
of O
non O
- O
peptidic O
submicromolar O
NPBWR1 O
antagonists O
based O
on O
a O
5 B
- I
chloro I
- I
4 I
- I
( I
4 I
- I
alkoxyphenoxy I
) I
- I
2 I
- I
( I
benzyl I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
chemotype O
. O

Cyclic B
di I
- I
GMP I
( O
c B
- I
di I
- I
GMP I
) O
has O
emerged O
as O
a O
prominent O
intracellular O
messenger O
that O
coordinates O
biofilm O
formation O
and O
pathogenicity O
in O
many O
bacterial O
species O
. O

Developing O
genetically O
encoded O
biosensors O
for O
c B
- I
di I
- I
GMP I
will O
help O
us O
understand O
how O
bacterial O
cells O
respond O
to O
environmental O
changes O
via O
the O
modulation O
of O
cellular O
c B
- I
di I
- I
GMP I
levels O
. O

Developing O
genetically O
encoded O
biosensors O
for O
c B
- I
di I
- I
GMP I
will O
help O
us O
understand O
how O
bacterial O
cells O
respond O
to O
environmental O
changes O
via O
the O
modulation O
of O
cellular O
c B
- I
di I
- I
GMP I
levels O
. O

Here O
we O
report O
the O
design O
of O
two O
genetically O
encoded O
c B
- I
di I
- I
GMP I
fluorescent O
biosensors O
with O
complementary O
dynamic O
ranges O
. O

By O
using O
the O
biosensors O
, O
we O
found O
that O
several O
compounds O
known O
to O
promote O
biofilm O
dispersal O
trigger O
a O
decline O
in O
c B
- I
di I
- I
GMP I
levels O
in O
Escherichia O
coli O
cells O
. O

In O
contrast O
, O
cellular O
c B
- I
di I
- I
GMP I
levels O
were O
elevated O
when O
the O
bacterial O
cells O
were O
treated O
with O
subinhibitory O
concentrations O
of O
biofilm O
- O
promoting O
antibiotics O
. O

The O
biosensors O
also O
revealed O
that O
E O
. O
coli O
cells O
engulfed O
by O
macrophages O
exhibit O
lower O
c B
- I
di I
- I
GMP I
levels O
, O
most O
likely O
as O
a O
response O
to O
the O
enormous O
pressures O
of O
survival O
during O
phagocytosis O
. O

Using O
the O
phosphonate B
moiety O
as O
an O
efficient O
trans O
- O
directing O
group O
, O
the O
first O
catalytic O
asymmetric O
route O
to O
diacceptor O
cycloprop B
( I
en I
) I
ylphosphonates I
was O
developed O
by O
employing O
an O
alpha B
- I
cyano I
diazophosphonate I
and O
Rh B
( I
2 I
) I
( I
S I
- I
IBAZ I
) I
( I
4 I
) I
as O
chiral O
catalyst O
. O

The O
isosteric O
character O
of O
phosphonic B
and I
carboxylic I
acid I
derivatives O
allowed O
the O
alternative O
use O
of O
an O
alpha B
- I
cyano I
diazo I
ester I
in O
the O
process O
, O
leading O
to O
alpha B
- I
cyano I
cycloprop I
( I
en I
) I
ylcarboxylates I
in O
high O
yields O
and O
stereoselectivities O
. O

Synthesis O
of O
selenolate B
- O
protected O
Au18 B
( I
SeC6H5 I
) I
14 I
nanoclusters O
. O

Theoretical O
investigation O
into O
optical O
and O
electronic O
properties O
of O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
. O

A O
series O
of O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
has O
been O
designed O
to O
explore O
their O
optical O
, O
electronic O
, O
and O
charge O
transport O
properties O
as O
charge O
transport O
and O
/ O
or O
luminescent O
materials O
for O
organic O
light O
- O
emitting O
diodes O
( O
OLEDs O
) O
. O

The O
calculated O
results O
show O
that O
their O
optical O
and O
electronic O
properties O
are O
affected O
by O
the O
substituent O
groups O
in O
4 O
- O
position O
of O
1 B
, I
8 I
- I
naphthalimide I
. O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

The O
cOATPs O
were O
stably O
transfected O
in O
human O
embryonic O
kidney O
cells O
and O
were O
functionally O
similar O
to O
the O
corresponding O
human O
OATPs O
( O
hOATPs O
) O
, O
as O
evident O
from O
the O
similar O
uptake O
rate O
of O
typical O
substrates O
( O
estradiol B
- I
17 I
beta I
- I
d I
- I
glucuronide I
, O
cholecystokinin O
octapeptide O
, O
and O
estrone B
- I
3 I
- I
sulfate I
) O
. O

All B
- I
trans I
retinoic I
acid I
protects O
hepatocellular O
carcinoma O
cells O
against O
serum O
- O
starvation O
- O
induced O
cell O
death O
by O
upregulating O
collagen O
8A2 O
. O

As O
a O
therapeutic O
or O
chemopreventative O
agent O
for O
various O
cancers O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
has O
been O
reported O
to O
inhibit O
growth O
, O
induce O
apoptosis O
or O
cause O
differentiation O
. O

The O
fluorescent O
dyes O
methylene B
blue I
, O
MB O
( O
+ O
) O
, O
and O
thionine B
, O
Th O
( O
+ O
) O
, O
can O
be O
trapped O
in O
the O
pores O
of O
mesoporous O
silica B
, O
MP O
- O
SiO B
( I
2 I
) I
, O
by O
means O
of O
functional O
nanostructures O
consisting O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
. O

The O
fluorescent O
dyes O
methylene B
blue I
, O
MB O
( O
+ O
) O
, O
and O
thionine B
, O
Th O
( O
+ O
) O
, O
can O
be O
trapped O
in O
the O
pores O
of O
mesoporous O
silica B
, O
MP O
- O
SiO B
( I
2 I
) I
, O
by O
means O
of O
functional O
nanostructures O
consisting O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
. O

In O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
or O
Zn B
( I
2 I
+ I
) I
ions O
the O
respective O
DNAzymes O
are O
activated O
, O
leading O
to O
the O
specific O
cleavage O
of O
the O
respective O
caps O
, O
and O
the O
selective O
release O
of O
MB O
( O
+ O
) O
or O
Th O
( O
+ O
) O
. O

In O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
or O
Zn B
( I
2 I
+ I
) I
ions O
the O
respective O
DNAzymes O
are O
activated O
, O
leading O
to O
the O
specific O
cleavage O
of O
the O
respective O
caps O
, O
and O
the O
selective O
release O
of O
MB O
( O
+ O
) O
or O
Th O
( O
+ O
) O
. O

The O
enlargement O
of O
the O
conserved O
loop O
domains O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
with O
foreign O
nucleotides B
prohibits O
the O
formation O
of O
active O
DNAzymes O
and O
eliminates O
the O
release O
of O
the O
respective O
dyes O
. O

The O
enlargement O
of O
the O
conserved O
loop O
domains O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
with O
foreign O
nucleotides B
prohibits O
the O
formation O
of O
active O
DNAzymes O
and O
eliminates O
the O
release O
of O
the O
respective O
dyes O
. O

The O
insertion O
of O
aptamer O
sequences O
( O
e O
. O
g O
. O
, O
the O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
aptamer O
) O
or O
ion O
- O
binding O
sequences O
( O
e O
. O
g O
. O
, O
T O
- O
rich O
Hg B
( I
2 I
+ I
) I
ion O
- O
binding O
domains O
) O
as O
foreign O
components O
to O
the O
loop O
regions O
allows O
the O
formation O
of O
active O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
structures O
through O
the O
cooperative O
formation O
of O
aptamer O
- O
ATP B
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
. O

The O
insertion O
of O
aptamer O
sequences O
( O
e O
. O
g O
. O
, O
the O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
aptamer O
) O
or O
ion O
- O
binding O
sequences O
( O
e O
. O
g O
. O
, O
T O
- O
rich O
Hg B
( I
2 I
+ I
) I
ion O
- O
binding O
domains O
) O
as O
foreign O
components O
to O
the O
loop O
regions O
allows O
the O
formation O
of O
active O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
structures O
through O
the O
cooperative O
formation O
of O
aptamer O
- O
ATP B
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
. O

The O
insertion O
of O
aptamer O
sequences O
( O
e O
. O
g O
. O
, O
the O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
aptamer O
) O
or O
ion O
- O
binding O
sequences O
( O
e O
. O
g O
. O
, O
T O
- O
rich O
Hg B
( I
2 I
+ I
) I
ion O
- O
binding O
domains O
) O
as O
foreign O
components O
to O
the O
loop O
regions O
allows O
the O
formation O
of O
active O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
structures O
through O
the O
cooperative O
formation O
of O
aptamer O
- O
ATP B
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
. O

The O
insertion O
of O
aptamer O
sequences O
( O
e O
. O
g O
. O
, O
the O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
aptamer O
) O
or O
ion O
- O
binding O
sequences O
( O
e O
. O
g O
. O
, O
T O
- O
rich O
Hg B
( I
2 I
+ I
) I
ion O
- O
binding O
domains O
) O
as O
foreign O
components O
to O
the O
loop O
regions O
allows O
the O
formation O
of O
active O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
structures O
through O
the O
cooperative O
formation O
of O
aptamer O
- O
ATP B
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
. O

These O
aptamer O
- O
substrate O
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
allosterically O
stabilize O
and O
activate O
the O
DNAzymes O
, O
thus O
allowing O
the O
selective O
release O
of O
the O
fluorescent O
substrates O
MB O
( O
+ O
) O
or O
Th O
( O
+ O
) O
. O

This O
is O
demonstrated O
with O
the O
triggered O
release O
of O
the O
anticancer O
drug O
, O
doxorubicin B
, O
by O
the O
Mg B
( I
2 I
+ I
) I
- O
DNAzyme O
- O
locked O
pores O
or O
by O
the O
aptamer O
- O
ATP B
complex O
- O
triggered O
activation O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
. O

This O
is O
demonstrated O
with O
the O
triggered O
release O
of O
the O
anticancer O
drug O
, O
doxorubicin B
, O
by O
the O
Mg B
( I
2 I
+ I
) I
- O
DNAzyme O
- O
locked O
pores O
or O
by O
the O
aptamer O
- O
ATP B
complex O
- O
triggered O
activation O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
. O

A O
novel O
polymer O
coating O
consisting O
of O
poly B
( I
lactic I
- I
co I
- I
glycolic I
) I
acid I
( O
PLGA B
) O
microsphere O
dispersed O
in O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
hydrogels O
was O
evaluated O
in O
combination O
with O
dummy O
sensors O
as O
a O
" O
smart O
" O
drug O
eluting O
biocompatible O
coating O
for O
implantable O
biosensors O
to O
prevent O
the O
foreign O
body O
response O
, O
and O
thus O
enhance O
sensor O
performance O
in O
vivo O
. O

Conclusion O
: O
A O
patch O
containing O
( B
S I
) I
- I
PR I
was O
prepared O
and O
the O
( B
S I
) I
- I
PR I
flux O
( O
13 O
. O
3 O
mu O
g O
/ O
cm O
( O
2 O
) O
/ O
h O
) O
permitted O
to O
confirm O
the O
suitability O
of O
a O
transdermal O
administration O
of O
PR O
. O

Conclusion O
: O
A O
patch O
containing O
( B
S I
) I
- I
PR I
was O
prepared O
and O
the O
( B
S I
) I
- I
PR I
flux O
( O
13 O
. O
3 O
mu O
g O
/ O
cm O
( O
2 O
) O
/ O
h O
) O
permitted O
to O
confirm O
the O
suitability O
of O
a O
transdermal O
administration O
of O
PR O
. O

In O
particular O
, O
the O
use O
of O
a O
50 O
mu O
m O
thick O
methacrylic B
matrix O
containing O
8 O
% O
( B
S I
) I
- I
PR I
and O
15 O
% O
NMP B
can O
allow O
to O
develop O
a O
patch O
non O
- O
irritating O
to O
the O
skin O
, O
in O
order O
to O
ensure O
a O
constant O
permeation O
flux O
of O
PR O
over O
48 O
h O
. O

Surface O
coating O
with O
methoxypoly B
( I
ethylene I
glycol I
) I
- O
based O
amphiphiles O
, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O
CNTs O
, O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O

CNTs O
with O
linear O
poly B
( I
ethylene I
glycol I
) I
amphiphiles O
trigger O
the O
lectin O
pathway O
of O
the O
complement O
through O
both O
L O
- O
ficolin O
and O
mannan O
- O
binding O
lectin O
recognition O
. O

An O
amphiphile O
with O
branched O
poly B
( I
ethylene I
glycol I
) I
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L O
- O
ficolin O
recognition O
. O

Based O
on O
the O
reported O
anticancer O
activity O
of O
quinolines B
, O
a O
new O
series O
of O
7 B
- I
chloroquinoline I
derivatives O
bearing O
the O
biologically O
active O
benzenesulfonamide B
moiety O
2 O
- O
17 O
and O
19 O
- O
25 O
were O
synthesized O
starting O
with O
4 B
, I
7 I
- I
dichloroquinolne I
1 O
. O

We O
previously O
reported O
that O
caffeoyl B
- I
amino I
acidyl I
- I
hydroxamic I
acid I
( O
CA B
- I
Xaa I
- I
NHOH I
) O
acted O
as O
both O
a O
good O
antioxidant O
and O
tyrosinase O
inhibitor O
, O
in O
particular O
when O
caffeic B
acid I
was O
conjugated O
with O
proline B
or O
amino B
acids I
having O
aromatic O
ring O
like O
phenylalanine B
. O

Here O
, O
various O
hydroxycinnamic B
acid I
( O
HCA B
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl B
hydroxamic I
acid I
and O
prolyl B
hydroxamic I
acid I
( O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

Here O
, O
various O
hydroxycinnamic B
acid I
( O
HCA B
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl B
hydroxamic I
acid I
and O
prolyl B
hydroxamic I
acid I
( O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

When O
their O
biological O
activities O
were O
evaluated O
, O
all O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
exhibited O
enhanced O
antioxidant O
activity O
compared O
to O
HCA B
alone O
. O

When O
their O
biological O
activities O
were O
evaluated O
, O
all O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
exhibited O
enhanced O
antioxidant O
activity O
compared O
to O
HCA B
alone O
. O

Over O
the O
last O
60 O
years O
, O
many O
members O
of O
the O
parent O
compound O
, O
canthin B
- I
6 I
- I
one I
( O
1 O
) O
, O
have O
been O
isolated O
from O
various O
plant O
sources O
, O
principally O
the O
Rutaceae O
and O
Simaroubaceae O
families O
, O
and O
recently O
from O
fungi O
. O

Diels O
- O
Alder O
mediated O
controlled O
release O
from O
a O
poly B
( I
ethylene I
glycol I
) I
based O
hydrogel O
. O

Peptides O
expressing O
the O
furan B
moiety O
were O
attached O
to O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
hydrogels O
through O
a O
thermally O
reversible O
covalent O
bond O
formed O
by O
a O
Diels O
- O
Alder O
reaction O
. O

Poly B
( I
ferrocenyl I
( I
3 I
- I
bromopropyl I
) I
methylsilane I
) I
and O
poly B
( I
ethylene I
imine I
) I
are O
employed O
in O
a O
layer O
- O
by O
- O
layer O
deposition O
process O
to O
form O
covalently O
connected O
, O
redox O
- O
active O
multilayer O
thin O
films O
by O
means O
of O
an O
amine B
alkylation O
reaction O
. O

Thio O
derivatives O
of O
hydroxytyrosol B
containing O
thiol B
, O
thioacetate B
and O
disulfide B
functionalities O
were O
synthesized O
from O
natural O
hydroxytyrosol B
( O
3 B
, I
4 I
- I
DHPEA I
) O
via O
3 B
, I
4 I
- I
dihydroxyphenethyl I
halides I
. O

It O
was O
found O
that O
all O
synthesized O
compounds O
were O
more O
effective O
than O
3 B
, I
4 I
- I
DHPEA I
in O
inducing O
apoptosis O
on O
HL60R O
cells O
, O
and O
that O
the O
hydroxytyrosol B
disulfide B
was O
the O
most O
active O
pro O
- O
apoptotic O
and O
anti O
- O
proliferative O
compound O
on O
both O
HL60 O
and O
HL60R O
cells O
. O

Different O
from O
3 B
, I
4 I
- I
DHPEA I
, O
all O
thio O
derivatives O
of O
hydroxytyrosol B
induced O
apoptosis O
by O
a O
mechanism O
not O
involving O
the O
release O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
in O
the O
culture O
medium O
. O

Benzo B
[ I
alpha I
] I
pyrene I
repressed O
DNA O
mismatch O
repair O
in O
human O
breast O
cancer O
cells O
. O

Specifically O
, O
we O
quantitatively O
measured O
MMR O
activity O
in O
ZR75 O
- O
1 O
cells O
after O
they O
were O
exposed O
to O
benzo B
[ I
alpha I
] I
pyrene I
( O
BaP B
) O
, O
a O
prototypical O
PAH B
, O
at O
various O
concentrations O
. O

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids B
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 B
- I
hydroxyphloretin I
6 I
' I
- I
O I
- I
hexoside I
, O
quercetin B
- I
7 I
- I
hexoside I
, O
apigenin7 B
- I
O I
- I
glucoside I
, O
luteolin B
7 I
- I
O I
- I
glucoside I
, O
apigenin B
7 I
- I
O I
- I
galactoside I
, O
acacetin B
7 I
- I
O I
- I
( I
alpha I
- I
D I
- I
apio I
- I
furanosyl I
) I
( I
1 I
- I
- I
> I
6 I

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids B
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 B
- I
hydroxyphloretin I
6 I
' I
- I
O I
- I
hexoside I
, O
quercetin B
- I
7 I
- I
hexoside I
, O
apigenin7 B
- I
O I
- I
glucoside I
, O
luteolin B
7 I
- I
O I
- I
glucoside I
, O
apigenin B
7 I
- I
O I
- I
galactoside I
, O
acacetin B
7 I
- I
O I
- I
( I
alpha I
- I
D I
- I
apio I
- I
furanosyl I
) I
( I
1 I
- I
- I
> I
6 I

Purification O
of O
the O
extracts O
yielded O
four O
chiral O
polyphenols B
, O
suffruticosol B
A I
( O
1 O
) O
, O
suffruticosol B
B I
( O
2 O
) O
, O
trans B
- I
epsilon I
- I
viniferin I
( O
3 O
) O
, O
and O
trans B
- I
gnetin I
H I
( O
4 O
) O
. O

Trans B
- I
epsilon I
- I
viniferin I
( O
3 O
) O
underwent O
trans O
- O
cis O
isomerization O
, O
which O
led O
to O
a O
reduction O
in O
inhibition O
potency O
. O

Monocyclic B
beta I
- I
lactams I
as O
antibacterial O
agents O
: O
facing O
antioxidant O
activity O
of O
N B
- I
methylthio I
- I
azetidinones I
. O

Substituted O
4 B
- I
and I
5 I
- I
amino I
- I
1 I
- I
phenylnaphthalenes I
represent O
substructures O
within O
the O
pharmacophore O
of O
these O
benzo B
[ I
c I
] I
phenanthridines I
. O

We O
report O
a O
facile O
" O
one O
- O
pot O
" O
method O
for O
the O
synthesis O
of O
Sn B
- O
embedded O
carbon B
- O
silica B
( O
CS O
) O
mesostructured O
( O
nanostructured O
) O
composites O
through O
the O
selective O
interaction O
of O
resol O
( O
carbon B
precursor O
) O
, O
tetraethylorthosilic B
( O
TEOS B
) O
, O
and O
tributylphenyltin B
( O
Sn B
precursor O
) O
with O
an O
amphiphilic O
diblock O
copolymer O
, O
poly B
( I
ethylene I
oxide I
- I
b I
- I
styrene I
) I
, O
PEO B
- I
b I
- I
PS I
. O

Neuroprotective O
efficacy O
and O
pharmacokinetic O
behavior O
of O
novel O
anti O
- O
inflammatory O
para B
- I
phenyl I
substituted I
diindolylmethanes I
in O
a O
mouse O
model O
of O
Parkinson O
' O
s O
disease O
. O

None O
of O
the O
metabolites O
cotinine B
, O
cotinine B
- I
N I
- I
oxide I
, O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
or O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
affected O
platelet O
aggregation O
or O
P O
- O
selectin O
expression O
. O

Prototypic O
substrates O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
and O
taurocholic B
acid I
were O
transported O
by O
the O
protein O
. O

Prototypic O
substrates O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
and O
taurocholic B
acid I
were O
transported O
by O
the O
protein O
. O

The O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
polymer O
was O
well O
- O
characterized O
and O
studied O
in O
terms O
of O
its O
gene O
delivery O
properties O
in O
FR O
- O
positive O
KB O
cells O
and O
FR O
- O
negative O
A549 O
cells O
under O
various O
conditions O
, O
in O
comparison O
with O
cationic O
polymers O
such O
as O
high O
molecular O
weight O
branched O
polyethylenimine B
( O
PEI B
) O
, O
gamma B
- I
CD I
- I
OEI I
star O
- O
shaped O
cationic O
polymer O
, O
gamma B
- I
CD I
- I
OEI I
- I
FA I
polymer O
where O
FA O
was O
directed O
linked O
to O
the O
star O
polymer O
without O
disulfide B
linker O
. O

A O
new O
2 B
, I
5 I
- I
diketopiperazine I
, O
( B
R I
) I
- I
2 I
- I
( I
2 I
- I
( I
furan I
- I
2 I
- I
yl I
) I
- I
oxoethyl I
) I
- I
octahydropyrrolo I
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- I
1 I
, I
4 I
- I
dione I
, O
and O
seven O
known O
compounds O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
liquid O
fermentation O
broth O
of O
Armillaria O
mellea O
. O

An O
isomerization O
- O
roaming O
pathway O
to O
the O
CH B
( I
3 I
) I
ONO I
isomer O
and O
then O
to O
the O
CH B
( I
3 I
) I
O I
+ O
NO B
products O
is O
found O
. O

An O
isomerization O
- O
roaming O
pathway O
to O
the O
CH B
( I
3 I
) I
ONO I
isomer O
and O
then O
to O
the O
CH B
( I
3 I
) I
O I
+ O
NO B
products O
is O
found O
. O

Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol B
17 I
beta I
- I
glucuronide I
, O
estrone B
3 I
- I
sulfate I
, O
and O
dehydroepiandrostero B
sulfate I
( O
DHEAS B
) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1 O
- O
6 O
using O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O

Compound O
6 O
stimulated O
OATP1B3 O
- O
mediated O
estradiol B
17 I
beta I
- I
glucuronide I
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O

Density O
functional O
theory O
was O
applied O
to O
study O
the O
interaction O
of O
group B
IIb I
transition I
- I
metal I
cations O
( O
Zn B
( I
2 I
+ I
) I
, O
Cd B
( I
2 I
+ I
) I
, O
and O
Hg B
( I
2 I
+ I
) I
) O
with O
one O
and O
two O
fully O
or O
partially O
deprotonated O
3 B
- I
mercaptopropionic I
acid I
ligands O
. O

Density O
functional O
theory O
was O
applied O
to O
study O
the O
interaction O
of O
group B
IIb I
transition I
- I
metal I
cations O
( O
Zn B
( I
2 I
+ I
) I
, O
Cd B
( I
2 I
+ I
) I
, O
and O
Hg B
( I
2 I
+ I
) I
) O
with O
one O
and O
two O
fully O
or O
partially O
deprotonated O
3 B
- I
mercaptopropionic I
acid I
ligands O
. O

Density O
functional O
theory O
was O
applied O
to O
study O
the O
interaction O
of O
group B
IIb I
transition I
- I
metal I
cations O
( O
Zn B
( I
2 I
+ I
) I
, O
Cd B
( I
2 I
+ I
) I
, O
and O
Hg B
( I
2 I
+ I
) I
) O
with O
one O
and O
two O
fully O
or O
partially O
deprotonated O
3 B
- I
mercaptopropionic I
acid I
ligands O
. O

Density O
functional O
theory O
was O
applied O
to O
study O
the O
interaction O
of O
group B
IIb I
transition I
- I
metal I
cations O
( O
Zn B
( I
2 I
+ I
) I
, O
Cd B
( I
2 I
+ I
) I
, O
and O
Hg B
( I
2 I
+ I
) I
) O
with O
one O
and O
two O
fully O
or O
partially O
deprotonated O
3 B
- I
mercaptopropionic I
acid I
ligands O
. O

Specific O
- O
heat O
measurements O
demonstrated O
that O
a O
large O
portion O
of O
the O
magnetic O
entropy O
, O
> O
60 O
% O
, O
has O
been O
removed O
above O
T O
( O
N O
) O
as O
a O
result O
of O
strong O
spin O
correlations O
within O
the O
quasi O
- O
one O
- O
dimensional O
Mn B
( I
3 I
+ I
) I
- O
spin O
chains O
. O

Second O
, O
the O
effects O
from O
two O
typical O
airborne O
quinones B
, O
9 B
, I
10 I
- I
anthraquinone I
( O
AQ O
) O
and O
1 B
, I
4 I
- I
naphthroquinone I
( O
NQ O
) O
were O
compared O
. O

Second O
, O
the O
effects O
from O
two O
typical O
airborne O
quinones B
, O
9 B
, I
10 I
- I
anthraquinone I
( O
AQ O
) O
and O
1 B
, I
4 I
- I
naphthroquinone I
( O
NQ O
) O
were O
compared O
. O

beta B
- I
Lapachone I
( O
beta B
- I
Lap I
) O
is O
a O
1 B
, I
2 I
- I
orthonaphthoquinone I
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
- O
1 O
( O
NQO1 O
) O
. O

beta B
- I
Lapachone I
( O
beta B
- I
Lap I
) O
is O
a O
1 B
, I
2 I
- I
orthonaphthoquinone I
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
- O
1 O
( O
NQO1 O
) O
. O

We O
formulated O
beta B
- I
Lap I
in O
an O
optimal O
random O
methylated B
- I
beta I
- I
cyclodextrin I
/ O
poloxamer B
407 I
mixture O
( O
i O
. O
e O
. O
, O
beta B
- I
Lap I
ternary O
system O
) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF O
- O
7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti O
- O
tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O

We O
reported O
previously O
that O
Ca B
( I
2 I
+ I
) I
influx O
through O
N B
- I
methly I
- I
d I
- I
aspartate I
- O
gated O
channels O
evokes O
ATP B
- O
sensitive O
K B
( I
+ I
) I
( O
K B
- O
ATP B
) O
currents O
in O
rat O
subthalamic O
nucleus O
( O
STN O
) O
neurons O
. O

DHPG B
- O
evoked O
outward O
current O
was O
blocked O
by O
cyclopiazonic B
acid I
and O
thapsigargin B
and O
mimicked O
by O
caffeine B
, O
suggesting O
mediation O
by O
release O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
. O

DHPG B
outward O
current O
was O
also O
blocked O
by O
ryanodine B
and O
2 B
- I
aminoethoxydiphenylb I
, O
suggesting O
mediation O
by O
ryanodine B
- O
and O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
- O
sensitive O
Ca B
( I
2 I
+ I
) I
release O
. O

These O
results O
show O
that O
group O
I O
mGluR O
stimulation O
generates O
K B
- O
ATP B
current O
by O
a O
nitric B
oxide I
- O
and O
protein O
kinase O
G O
- O
dependent O
process O
that O
is O
mediated O
by O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
intracellular O
stores O
. O

Here O
the O
uptake O
and O
intracellular O
delivery O
of O
disc O
- O
shaped O
zeolite B
L I
nanocrystals O
as O
porous O
aminosilicates B
with O
well O
- O
defined O
crystal O
structure O
, O
uncoated O
as O
well O
as O
with O
COOH B
- I
, O
NH B
( I
2 I
) I
- I
, O
polyethyleneglycol B
( O
PEG B
) O
- O
and O
polyallylamine B
hydrochloride I
( O
PAH B
) O
surface O
coatings O
are O
reported O
. O

Structure O
analysis O
of O
the O
isolated O
OKA B
analogue O
19 B
- I
epi I
- I
OKA I
showed O
important O
conformation O
differences O
expected O
to O
result O
in O
lower O
protein O
phosphatase O
( O
PP O
) O
inhibitory O
potencies O
than O
OKA B
. O

However O
, O
19 B
- I
epi I
- I
OKA I
and O
OKA B
inhibitory O
activities O
versus O
PP2A O
were O
unexpectedly O
found O
to O
be O
virtually O
equipotent O
. O

To O
investigate O
the O
toxicological O
relevance O
of O
these O
findings O
, O
we O
tested O
the O
effects O
of O
19 B
- I
epi I
- I
OKA I
on O
cultured O
cerebellar O
cells O
and O
compared O
them O
with O
those O
of O
OKA B
and O
its O
isomer O
dinophysistoxin B
- I
2 I
. O

19 B
- I
epi I
- I
OKA I
caused O
degeneration O
of O
neurites O
and O
neuronal O
death O
with O
much O
lower O
potency O
than O
its O
congeners O
. O

The O
concentration O
of O
19 B
- I
epi I
- I
OKA I
that O
reduced O
after O
24h O
the O
maximum O
neuronal O
survival O
( O
EC5024 O
) O
by O
50 O
% O
was O
~ O
300nM O
compared O
with O
~ O
2nM O
and O
~ O
8nM O
for O
OKA B
and O
dinophysistoxin B
- I
2 I
, O
respectively O
. O

Exposure O
to O
19 B
- I
epi I
- I
OKA I
resulted O
also O
in O
less O
toxicity O
for O
cultured O
glial O
cells O
( O
EC5024 O
, O
19 B
- I
epi I
- I
OKA I
~ O
600nM O
; O
EC5024 O
, O
OKA B
~ O
20nM O
) O
. O

Exposure O
to O
19 B
- I
epi I
- I
OKA I
resulted O
also O
in O
less O
toxicity O
for O
cultured O
glial O
cells O
( O
EC5024 O
, O
19 B
- I
epi I
- I
OKA I
~ O
600nM O
; O
EC5024 O
, O
OKA B
~ O
20nM O
) O
. O

19 B
- I
epi I
- I
OKA I
induced O
apoptotic O
condensation O
and O
fragmentation O
of O
chromatin O
, O
activation O
of O
caspases O
, O
and O
activation O
of O
ERK1 O
/ O
2 O
MAP O
kinases O
, O
features O
previously O
reported O
for O
OKA B
and O
dinophysistoxin B
- I
2 I
. O

Also O
, O
differential O
sensitivity O
to O
19 B
- I
epi I
- I
OKA I
was O
observed O
between O
neuronal O
and O
glial O
cells O
, O
a O
specific O
characteristic O
shared O
by O
OKA B
and O
dinophysistoxin B
- I
2 I
but O
not O
by O
other O
toxins O
. O

Our O
results O
are O
consistent O
with O
19 B
- I
epi I
- I
OKA I
being O
included O
among O
the O
group O
of O
toxins O
of O
OKA B
and O
derivatives O
and O
support O
the O
suitability O
of O
cellular O
bioassays O
for O
the O
detection O
of O
these O
compounds O
. O

Clinical O
manifestations O
also O
vary O
from O
irritation O
of O
the O
eyes O
, O
skin O
and O
mucus O
membranes O
in O
T B
( I
2 I
) I
toxin I
to O
an O
acute O
flaccid O
paralysis O
of O
bilateral O
cranial O
nerve O
impairment O
of O
descending O
manner O
in O
botulism O
. O

OBJECTIVETo O
1 O
) O
determine O
if O
plasma O
25 B
- I
hydroxyvitamin I
D I
( O
25 B
[ I
OH I
] I
D I
) O
concentrations O
differ O
among O
obese O
youth O
with O
normal O
glucose B
tolerance O
( O
NGT O
) O
versus O
prediabetes O
versus O
type O
2 O
diabetes O
, O
and O
2 O
) O
assess O
the O
relationships O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
in O
this O
cohort O
. O
RESEARCH O
DESIGN O
AND O
METHODSPlasma O
25 B
( I
OH I
) I
D I
concentrations O
were O
examined O
in O
banked O
specimens O
in O
9 O
- O
to O
20 O
- O
year O
- O
old O
obese O
youth O
( O

OBJECTIVETo O
1 O
) O
determine O
if O
plasma O
25 B
- I
hydroxyvitamin I
D I
( O
25 B
[ I
OH I
] I
D I
) O
concentrations O
differ O
among O
obese O
youth O
with O
normal O
glucose B
tolerance O
( O
NGT O
) O
versus O
prediabetes O
versus O
type O
2 O
diabetes O
, O
and O
2 O
) O
assess O
the O
relationships O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
in O
this O
cohort O
. O
RESEARCH O
DESIGN O
AND O
METHODSPlasma O
25 B
( I
OH I
) I
D I
concentrations O
were O
examined O
in O
banked O
specimens O
in O
9 O
- O
to O
20 O
- O
year O
- O
old O
obese O
youth O
( O

OBJECTIVETo O
1 O
) O
determine O
if O
plasma O
25 B
- I
hydroxyvitamin I
D I
( O
25 B
[ I
OH I
] I
D I
) O
concentrations O
differ O
among O
obese O
youth O
with O
normal O
glucose B
tolerance O
( O
NGT O
) O
versus O
prediabetes O
versus O
type O
2 O
diabetes O
, O
and O
2 O
) O
assess O
the O
relationships O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
in O
this O
cohort O
. O
RESEARCH O
DESIGN O
AND O
METHODSPlasma O
25 B
( I
OH I
) I
D I
concentrations O
were O
examined O
in O
banked O
specimens O
in O
9 O
- O
to O
20 O
- O
year O
- O
old O
obese O
youth O
( O

BMI O
, O
plasma O
25 B
( I
OH I
) I
D I
, O
and O
the O
proportion O
of O
vitamin B
D I
- O
deficient O
and O
- O
insufficient O
children O
did O
not O
differ O
across O
the O
three O
groups O
. O

Furthermore O
, O
there O
was O
no O
association O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
or O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
( O
disposition O
index O
) O
in O
all O
groups O
combined O
or O
in O
each O
group O
separately O
. O
CONCLUSIONSOur O
data O
in O
obese O
youth O
show O
1 O
) O
no O
differences O
in O
plasma O
25 B
( I
OH I
) I
D I
concentrations O
across O
the O
glucose B
tolerance O
groups O
, O
and O
2 O
) O
no O
relationship O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
in O
any O
of O
the O
groups O
. O

Furthermore O
, O
there O
was O
no O
association O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
or O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
( O
disposition O
index O
) O
in O
all O
groups O
combined O
or O
in O
each O
group O
separately O
. O
CONCLUSIONSOur O
data O
in O
obese O
youth O
show O
1 O
) O
no O
differences O
in O
plasma O
25 B
( I
OH I
) I
D I
concentrations O
across O
the O
glucose B
tolerance O
groups O
, O
and O
2 O
) O
no O
relationship O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
in O
any O
of O
the O
groups O
. O

Furthermore O
, O
there O
was O
no O
association O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
or O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
( O
disposition O
index O
) O
in O
all O
groups O
combined O
or O
in O
each O
group O
separately O
. O
CONCLUSIONSOur O
data O
in O
obese O
youth O
show O
1 O
) O
no O
differences O
in O
plasma O
25 B
( I
OH I
) I
D I
concentrations O
across O
the O
glucose B
tolerance O
groups O
, O
and O
2 O
) O
no O
relationship O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
in O
any O
of O
the O
groups O
. O

Increasing O
evidence O
suggests O
that O
25 B
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
and O
parathyroid O
hormone O
( O
PTH O
) O
levels O
are O
associated O
with O
metabolic O
syndrome O
( O
MetS O
) O
. O

In O
2010 O
, O
we O
explored O
the O
association O
of O
serum O
25 B
( I
OH I
) I
D I
and O
PTH O
levels O
with O
MetS O
in O
1 O
, O
390 O
Chinese O
participants O
, O
aged O
20 O
- O
83 O
years O
. O

In O
addition O
, O
serum O
lipids O
, O
25 B
( I
OH I
) I
D I
, O
and O
PTH O
were O
measured O
. O

The O
median O
concentration O
of O
25 B
( I
OH I
) I
D I
and O
PTH O
were O
55 O
. O
3 O
nmol O
/ O
l O
and O
2 O
. O
8 O
pmol O
/ O
l O
, O
respectively O
. O

After O
accounting O
for O
confounding O
factors O
and O
serum O
PTH O
, O
a O
10 O
nmol O
/ O
l O
higher O
serum O
25 B
( I
OH I
) I
D I
level O
was O
associated O
with O
a O
10 O
% O
lower O
risk O
of O
MetS O
( O
OR O
= O
0 O
. O
90 O
, O
95 O
% O
CI O
0 O
. O
84 O
- O
0 O
. O
96 O
, O
P O
= O
0 O
. O
0007 O
) O
. O

An O
aqueous O
self O
- O
assembled O
micellar O
system O
( O
sodium B
dodecyl I
sulfate I
, O
SDS B
, O
decorated O
with O
various O
adhesive O
sites O
, O
cryptand B
Kryptofix B
222 I
and O
crown B
ether I
18 B
- I
Crown I
- I
6 I
molecules O
) O
has O
been O
investigated O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
and O
small O
angle O
x O
- O
ray O
scattering O
( O
SAXS O
) O
to O
have O
insights O
into O
the O
micellar O
structure O
, O
the O
micellar O
interactions O
, O
and O
the O
aggregation O
properties O
of O
the O
system O
. O

Because O
of O
the O
steric O
stabilization O
effect O
, O
surface O
poly B
( I
ethylene I
glycol I
) I
chains O
facilitate O
the O
dispersion O
and O
compatibility O
of O
nanocrystals O
, O
which O
also O
enhance O
the O
loading O
levels O
of O
nanocrystals O
in O
the O
hydrogel O
system O
. O

Meanwhile O
, O
uncovered O
poly B
( I
ethylene I
glycol I
) I
segments O
render O
the O
participating O
inclusion O
of O
alpha B
- I
cyclodextrin I
for O
the O
architecture O
of O
in O
situ O
hydrogels O
. O

Both O
silathio B
/ I
silasulfonyl I
acetic I
acids I
were O
efficiently O
condensed O
with O
benzohydrazides B
in O
the O
presence O
of O
phosphorus B
oxychloride I
to O
give O
sila B
- I
substituted I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
in O
high O
yields O
. O

It O
was O
found O
that O
4h O
and O
4q O
are O
potent O
and O
selective O
human O
11 O
beta O
- O
HSD1 O
inhibitors O
with O
better O
pharmacokinetic O
properties O
than O
those O
of O
the O
original O
piperidine B
- I
3 I
- I
carboxamide I
compound O
1 O
, O
and O
suitable O
for O
further O
in O
vivo O
preclinical O
study O
in O
primate O
model O
. O

In O
3 B
- I
methylglutaconyl I
- I
CoA I
hydratase O
deficiency O
( O
mutations O
in O
AUH O
) O
, O
it O
derives O
from O
leucine B
degradation O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

It O
had O
higher O
levels O
of O
oleocanthal B
( O
p B
- I
HPEA I
- I
EDA I
) O
, O
a O
nutraceutical O
compound O
exerting O
actions O
against O
COX1 O
and O
COX2 O
( O
cycloxygenases O
) O
. O

Among O
the O
other O
bioactives O
, O
we O
highlight O
its O
significant O
levels O
of O
trans B
- I
beta I
- I
carotene I
and O
xanthophylls B
( O
lutein B
, O
violaxanthin B
, O
neoxanthin B
and O
other O
carotenoids O
) O
. O

PC2 O
and O
PC3 O
cluster O
American O
- O
and O
Virginia O
- O
blends O
, O
revealing O
inverse O
correlations O
: O
Nitrogen B
oxides I
and O
amino B
- O
or O
nitroso B
- O
aromatic O
compounds O
inversely O
correlate O
to O
either O
formaldehyde B
and O
acrolein B
, O
or O
benzo B
( I
a I
) I
pyrene I
and O
di B
- I
hydroxybenzenes I
. O

We O
found O
that O
daily O
calcium B
intake O
, O
corrected O
for O
total O
energy O
intake O
and O
serum O
25 B
( I
OH I
) I
D I
status O
, O
was O
significantly O
lower O
in O
subjects O
with O
sarcopenia O
than O
in O
those O
without O
. O

Sodium B
selenite I
( O
Na2SeO3 B
) O
, O
selenomethionine B
( O
SeMet B
) O
, O
seleno B
- I
l I
- I
cystine I
( O
SeCySS B
) O
, O
and O
Se B
- I
methylselenocysteine I
( O
MeSeCys B
) O
did O
not O
have O
these O
effects O
on O
macrophages O
under O
the O
same O
treatment O
conditions O
. O

CrbpI O
delivers O
vitamin B
A I
to O
enzymes O
for O
metabolism O
into O
an O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
where O
atRA B
is O
essential O
to O
cell O
proliferation O
, O
apoptosis O
, O
differentiation O
, O
and O
migration O
. O

A O
conformational O
search O
was O
performed O
separately O
for O
structures O
having O
an O
R O
or O
S O
configuration O
at O
C O
- O
3 O
of O
the O
beta B
- I
hydroxy I
fatty I
acid I
subunit O
that O
completes O
the O
cyclic O
scaffold O
of O
1 O
, O
after O
which O
multiple O
minimizations O
for O
all O
generated O
conformers O
were O
carried O
out O
. O

Interestingly O
, O
L O
- O
type O
voltage O
- O
dependent O
Ca B
( I
2 I
+ I
) I
channel O
( O
L O
- O
VDCC O
) O
blocker O
significantly O
protected O
neurons O
from O
the O
sPLA2 O
- O
IA O
- O
induced O
apoptosis O
. O

The O
influence O
of O
five O
different O
solvents O
on O
Cu2I2 B
( I
MePyrPHOS I
) I
3 I
was O
probed O
. O

The O
existence O
of O
similar O
effects O
on O
aluminum B
and O
iridium B
compounds O
has O
been O
confirmed O
by O
application O
of O
different O
processing O
solvents O
on O
Alq3 B
and O
Ir B
( I
ppy I
) I
3 I
. O

These O
values O
increase O
when O
C B
alpha I
- I
deuterated I
alanine I
is O
used O
as O
the O
substrate O
. O

Human O
MSCs O
express O
the O
vitamin B
D I
receptor O
, O
25 O
- O
hydroxylases O
, O
1 O
alpha O
- O
hydroxylase O
, O
and O
24 O
- O
hydroxylase O
; O
stimulation O
of O
in O
vitro O
osteoblastogenesis O
by O
25 B
( I
OH I
) I
D I
depends O
on O
the O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

Expression O
and O
enzyme O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
are O
upregulated O
by O
substrate O
25 B
( I
OH I
) I
D I
and O
Parathyroid O
Hormone O
( O
PTH O
) O
and O
are O
downregulated O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

With O
subject O
age O
, O
there O
are O
decreases O
in O
basal O
osteoblast O
potential O
and O
in O
stimulation O
of O
osteoblastogenesis O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
, O
25 B
( I
OH I
) I
D I
, O
and O
PTH O
. O

In O
vitro O
treatment O
with O
a O
combination O
of O
25 B
( I
OH I
) I
D I
and O
PTH O
rejuvenated O
osteoblastogenesis O
with O
hMSCs O
from O
elders O
; O
this O
was O
attributable O
to O
increases O
in O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
and O
in O
receptor O
for O
each O
hormone O
by O
the O
reciprocal O
factor O
. O

Other O
clinical O
variables O
beside O
age O
, O
i O
. O
e O
. O
low O
serum O
25 B
( I
OH I
) I
D I
or O
low O
estimated O
glomerular O
filtration O
rate O
, O
are O
correlated O
with O
reduced O
osteoblastogenesis O
. O

These O
studies O
suggest O
that O
osteoblastogenesis O
may O
not O
be O
optimal O
unless O
there O
is O
sufficient O
serum O
25 B
( I
OH I
) I
D I
substrate O
for O
hMSCs O
to O
synthesize O
and O
respond O
to O
local O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

Results O
revealed O
that O
the O
electronic O
transitions O
of O
La B
@ O
C O
( O
2v O
) O
- O
C B
( I
82 I
) I
, O
La B
( I
2 I
) I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
, O
and O
Sc B
( I
3 I
) I
N I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
can O
be O
assigned O
using O
these O
techniques O
. O

Particularly O
, O
a O
difference O
in O
the O
electronic O
transitions O
between O
La B
( I
2 I
) I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
and O
Sc B
( I
3 I
) I
N I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
, O
which O
is O
invisible O
in O
absorption O
spectra O
, O
was O
observed O
clearly O
in O
MCD O
spectra O
. O

Both O
myosin O
- O
18A O
isoforms O
bound O
N B
- I
methylanthraniloyl I
- I
nucleotides I
, O
but O
the O
rate O
of O
ATP B
hydrolysis O
was O
very O
slow O
( O
< O
0 O
. O
002 O
s O
( O
- O
1 O
) O
) O
and O
not O
significantly O
enhanced O
by O
actin O
. O

The O
mixed O
- O
valence O
diiron B
hydrido B
complex O
( B
mu I
- I
H I
) I
Fe2 I
( I
pdt I
) I
( I
CO I
) I
2 I
( I
dppv I
) I
2 I
( O
[ O
H1 B
] O
( O
0 O
) O
, O
where O
pdt B
= O
1 B
, I
3 I
- I
propanedithiolate I
and O
dppv B
= O
cis B
- I
1 I
, I
2 I
- I
C2H2 I
( I
PPh2 I
) I
2 I
) O
, O
was O
generated O
by O
reduction O
of O
the O
differous O
hydride B
[ B
H1 I
] I
( I
+ I
) I
using O
decamethylcobaltocen B
. O

The O
Fe B
- I
- I
- I
Fe I
bond O
elongates O
to O
2 O
. O
80 O
from O
2 O
. O
66 O
A O
, O
but O
the O
Fe B
- I
P I
bonds O
only O
change O
subtly O
. O

The O
salicylate B
1 O
, O
2 O
- O
dioxygenase O
( O
SDO O
) O
from O
the O
bacterium O
Pseudaminobacter O
salicylatoxidans O
BN12 O
is O
a O
versatile O
gentisate B
1 O
, O
2 O
- O
dioxygenase O
( O
GDO O
) O
that O
converts O
both O
gentisate B
( O
2 B
, I
5 I
- I
dihydroxybenzoate I
) O
and O
various O
monohydroxylated O
substrates O
. O

The O
results O
revealed O
that O
the O
compound O
11c O
having O
2 B
, I
5 I
- I
dichlorothiophene I
substituent O
on O
pyrazole B
moiety O
and O
a O
triazole B
ring O
showed O
significant O
analgesic O
and O
antimicrobial O
activity O
. O

In O
this O
work O
we O
show O
by O
high O
resolution O
tandem O
mass O
spectrometry O
that O
CstR O
is O
readily O
modified O
by O
selenite B
( O
SeO3 B
( I
2 I
- I
) I
) O
or O
tellurite B
( O
TeO3 B
( I
2 I
- I
) I
) O
to O
form O
a O
mixture O
of O
intersubunit O
disulfides B
and O
selenotrisulfides B
or O
tellurotrisulfides B
, O
respectively O
, O
between O
Cys31 B
and O
Cys60 B
' O
. O

In O
this O
work O
we O
show O
by O
high O
resolution O
tandem O
mass O
spectrometry O
that O
CstR O
is O
readily O
modified O
by O
selenite B
( O
SeO3 B
( I
2 I
- I
) I
) O
or O
tellurite B
( O
TeO3 B
( I
2 I
- I
) I
) O
to O
form O
a O
mixture O
of O
intersubunit O
disulfides B
and O
selenotrisulfides B
or O
tellurotrisulfides B
, O
respectively O
, O
between O
Cys31 B
and O
Cys60 B
' O
. O

Treatment O
of O
rats O
with O
the O
major O
NVP B
metabolite O
, O
12 B
- I
OH I
- I
NVP I
, O
also O
caused O
the O
rash O
. O

Most O
idiosyncratic O
drug O
reactions O
are O
caused O
by O
reactive O
metabolites O
; O
12 B
- I
OH I
- I
NVP I
forms O
a O
benzylic B
sulfate I
, O
which O
was O
detected O
in O
the O
blood O
of O
animals O
treated O
with O
NVP B
or O
12 B
- I
OH I
- I
NVP I
. O

Most O
idiosyncratic O
drug O
reactions O
are O
caused O
by O
reactive O
metabolites O
; O
12 B
- I
OH I
- I
NVP I
forms O
a O
benzylic B
sulfate I
, O
which O
was O
detected O
in O
the O
blood O
of O
animals O
treated O
with O
NVP B
or O
12 B
- I
OH I
- I
NVP I
. O

Incubations O
of O
12 B
- I
OH I
- I
NVP I
with O
the O
soluble O
fraction O
from O
a O
9 O
, O
000g O
centrifugation O
( O
S9 O
) O
of O
rat O
or O
human O
skin O
homogenate O
in O
the O
presence O
of O
3 B
' I
- I
phosphoadenosine I
- I
5 I
' I
- I
phosphosulfate I
( O
PAPS B
) O
produced O
extensive O
covalent O
binding O
, O
but O
no O
covalent O
binding O
was O
detected O
with O
mouse O
skin O
S9 O
, O
which O
suggests O
that O
the O
reason O
mice O
do O
not O
develop O
a O
rash O
is O
that O
they O
lack O
the O
required O
sulfotransferase O
. O

Oxidative O
Stress O
and O
DNA O
Damage O
in O
Human O
Gastric O
Carcinoma O
: O
8 B
- I
Oxo I
- I
7 I
' I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dG I
) O
as O
a O
Possible O
Tumor O
Marker O
. O

We O
characterized O
the O
oxidative O
stress O
( O
OS O
) O
status O
by O
the O
levels O
of O
reduced B
/ I
oxidized I
glutathione I
( O
GSH B
/ O
GSSG B
) O
, O
malondialdehyde B
( O
MDA B
) O
and O
the O
mutagenic O
base O
8 B
- I
oxo I
- I
7 I
' I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dG I
) O
in O
human O
gastric O
carcinoma O
( O
HGC O
) O
samples O
and O
compared O
the O
results O
with O
normal O
tissue O
from O
the O
same O
patients O
. O

We O
also O
analyzed O
8 B
- I
oxo I
- I
dG I
in O
peripheral O
mononuclear O
cells O
( O
PMNC O
) O
and O
urine O
from O
healthy O
control O
subjects O
and O
in O
affected O
patients O
in O
the O
basal O
state O
and O
one O
, O
three O
, O
six O
, O
nine O
and O
twelve O
months O
after O
tumor O
resection O
. O

Tumor O
specimens O
exhibited O
increased O
levels O
of O
MDA B
and O
8 B
- I
oxo I
- I
dG I
compared O
with O
normal O
gastric O
tissue O
. O

Levels O
of O
8 B
- I
oxo I
- I
dG I
were O
significantly O
elevated O
in O
both O
urine O
and O
PMNC O
of O
gastric O
cancer O
patients O
compared O
with O
healthy O
controls O
. O

The O
high O
levels O
of O
8 B
- I
oxo I
- I
dG I
in O
urine O
may O
be O
related O
to O
the O
increased O
induction O
of O
DNA O
repair O
activity O
in O
tumor O
tissue O
, O
and O
the O
changes O
observed O
after O
tumor O
resection O
support O
its O
potential O
use O
as O
a O
tumor O
marker O
. O

Then O
, O
HX0969 B
disodium I
phosphate I
monoester I
( O
HX0969W B
) O
and O
glycine B
ester I
trifluoroacetic I
acid I
salt I
( O
HX101230 B
) O
were O
synthesized O
, O
and O
their O
pharmacological O
features O
were O
compared O
with O
those O
of O
Lusedra B
( O
R O
) O
, O
which O
has O
been O
recognized O
and O
marketed O
as O
a O
water O
- O
soluble O
prodrug O
of O
propofol B
since O
2008 O
. O

The O
A2A O
adenosine B
receptor O
agonist O
CGS21680 B
( O
C23H29N7O6 B
. I
HCl I
. I
xH2O I
) O
( O
0 O
. O
001 O
- O
0 O
. O
1 O
mu O
M O
) O
did O
not O
alter O
NE O
oxidation O
currents O
. O

, O
methimazole B
, O
3 B
- I
methylcholanthrene I
, O
aminotriazole B
, O
amiodarone B
, O
cadmium B
chloride I
, O
dimethoate B
, O
fenvalerate B
, O
octylmethoxycinnamat B
, O
iopanoic B
acid I
, O
methoxychlor B
, O
and O
4 B
- I
methylbenzylidene I
- I
camphor I
) O
. O

The O
authors O
conducted O
an O
aquatic O
mesocosm O
experiment O
to O
assess O
the O
behavior O
of O
three O
NBFRs O
: O
bis B
( I
tribromophenoxy I
) I
ethane I
( O
BTBPE B
) O
, O
tetrabromobisphenol B
A I
bis I
( I
2 I
, I
3 I
- I
dibromopropyl I
ether I
; O
TBBPA B
- O
DBPE B
) O
, O
and O
Firemaster B
BZ I
- I
54 I
, O
a O
commercial O
mixture O
containing O
bis B
( I
2 I
- I
ethylhexyl I
) I
tetrabromophthalate I
( O
BEHTBP B
) O
and O
2 B
- I
ethylhexyl I
- I
2 I
, I
3 I
, I
4 I

X O
- O
ray O
photoelectron O
spectroscopy O
characterization O
indicates O
that O
the O
Cu B
oxides I
formed O
at O
200 O
degrees O
C O
and O
300 O
degrees O
C O
are O
Cu B
( I
2 I
) I
O I
and O
CuO B
, O
respectively O
. O

By O
controlling O
the O
environment O
, O
temperature O
, O
and O
duration O
, O
joined O
Cu B
( I
2 I
) I
O I
or O
CuO B
nanotube O
stacked O
chips O
can O
be O
achieved O
, O
which O
serve O
as O
a O
platform O
for O
the O
further O
development O
of O
nanostructured O
, O
stacked O
devices O
. O

This O
article O
reports O
the O
pK O
( O
a O
) O
shift O
of O
an O
anti O
- O
cancer O
drug O
, O
20 B
( I
S I
) I
- I
camptothecin I
( O
CPT B
) O
, O
upon O
encapsulation O
into O
the O
nanocavity O
of O
a O
cucurbit B
[ I
7 I
] I
uril I
( O
CB7 B
) O
macrocycle O
. O

In O
overexpressing O
cell O
lines O
, O
OATP1B1 O
- O
and O
OATP1B3 O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
uptake O
and O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
were O
inhibited O
by O
most O
of O
the O
silymarin O
flavonolignans B
investigated O
. O

These O
chemical O
studies O
offer O
an O
alternate O
hypothesis O
for O
the O
mechanism O
of O
action O
of O
nitroaromatic B
anti O
- O
TB O
agents O
, O
in O
that O
the O
cysteine B
thiol I
( I
ate I
) I
or O
a O
hydride B
source O
at O
the O
active O
site O
of O
DprE1 O
may O
trigger O
the O
reduction O
of O
the O
nitro B
groups O
in O
a O
manner O
similar O
to O
the O
von O
Richter O
reaction O
to O
the O
nitroso B
intermediates O
, O
to O
initiate O
the O
inhibition O
of O
DprE1 O
. O

Selective O
oxidation O
of O
omega B
- I
tertiary I
amine I
self O
- O
assembled O
thiol B
monolayers O
to O
tertiary B
amine I
N I
- I
oxides I
is O
shown O
to O
transform O
the O
adhesion O
of O
model O
proteins O
lysozyme O
and O
fibrinogen O
upon O
them O
. O

Efficient O
preparation O
of O
both O
secondary B
and I
tertiary I
linker I
amides I
as O
judged O
by O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
and O
water O
droplet O
contact O
angle O
was O
achieved O
with O
an O
improved O
amide B
bond O
formation O
on O
gold O
quartz B
crystal O
microbalance O
( O
QCM O
) O
sensors O
using O
2 B
- I
( I
1H I
- I
7 I
- I
azabenzotriazol I
- I
1 I
- I
yl I
) I
- I
1 I
, I
1 I
, I
3 I
, I
3 I
- I
tetramethyl I
hexafluorophosphate I
methanaminium I
uronium I
( O
HATU B
) O
. O

Tertiary B
amine I
- O
functionalized O
sensors O
adsorbed O
multilayers O
of O
aggregated O
lysozyme O
, O
whereas O
tertiary B
amine I
N I
- I
oxides I
and O
triethylene B
glycol I
- O
terminated O
monolayers O
are O
consistent O
with O
small O
protein O
aggregates O
. O

We O
hypothesized O
that O
GA O
could O
deplete O
the O
dissolved O
oxygen B
( O
DO O
) O
at O
the O
expense O
of O
semiquinone B
and O
quinone B
formation O
, O
favoring O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
to O
induce O
RBC O
disruption O
and O
Fe B
( I
2 I
+ I
) I
ion O
release O
. O

6 B
- I
Iodouridine I
( O
15 O
) O
, O
a O
novel O
and O
potent O
inhibitor O
of O
orotidine B
5 I
' I
- I
monophosphate I
decarboxylase O
( O
ODCase O
) O
, O
exhibited O
efficacy O
in O
a O
mouse O
model O
infected O
by O
P O
. O
chabaudi O
chabaudi O
. O

CF O
had O
the O
most O
significant O
effect O
on O
the O
flavan B
- I
3 I
- I
ol I
and O
polymeric B
phenol I
( O
tannin B
) O
content O
of O
the O
wines O
compared O
to O
the O
control O
followed O
by O
G O
fining O
. O

It O
was O
demonstrated O
that O
the O
main O
components O
in O
LPOPC O
were O
( B
- I
) I
- I
epicatechin I
, O
A B
- I
type I
procyanidin I
dimers O
, O
trimers O
and O
tetramers O
. O

However O
, O
only O
( B
- I
) I
- I
epicatechin I
and O
its O
methylated O
derivatives O
were O
detected O
in O
rat O
plasma O
1h O
after O
300 O
mg O
/ O
kgbw O
of O
LPOPC O
administration O
. O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

Polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and I
dibenzofurans I
( O
PCDD B
/ I
Fs I
) O
, O
dioxin B
- I
like I
polychlorinated I
biphenyls I
( O
DL B
- I
PCBs I
) O
, O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
and O
hexachlorobenzene B
( O
HCB B
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

Spectroscopic O
characterization O
and O
constitutional O
and O
rotational O
isomerism O
of O
ClC B
( I
O I
) I
SCN I
and O
ClC B
( I
O I
) I
NCS I
. O

Spectroscopic O
characterization O
and O
constitutional O
and O
rotational O
isomerism O
of O
ClC B
( I
O I
) I
SCN I
and O
ClC B
( I
O I
) I
NCS I
. O

Chlorocarbonylthio B
- I
and I
isothiocyanate I
( O
ClC B
( I
O I
) I
SCN I
and O
ClC B
( I
O I
) I
NCS I
) O
have O
been O
isolated O
and O
characterized O
by O
IR O
( O
Ar B
matrix O
, O
gas O
) O
, O
Raman O
( O
liquid O
) O
, O
( B
13 I
) I
C I
NMR O
and O
UV O
- O
visible O
spectroscopies O
. O

Chlorocarbonylthio B
- I
and I
isothiocyanate I
( O
ClC B
( I
O I
) I
SCN I
and O
ClC B
( I
O I
) I
NCS I
) O
have O
been O
isolated O
and O
characterized O
by O
IR O
( O
Ar B
matrix O
, O
gas O
) O
, O
Raman O
( O
liquid O
) O
, O
( B
13 I
) I
C I
NMR O
and O
UV O
- O
visible O
spectroscopies O
. O

The O
solid O
- O
state O
structure O
of O
ClC B
( I
O I
) I
SCN I
has O
been O
determined O
by O
single O
crystal O
X O
- O
ray O
diffraction O
analysis O
at O
low O
temperature O
. O

On O
the O
other O
hand O
, O
the O
anti O
form O
is O
more O
stable O
for O
the O
ClC B
( I
O I
) I
NCS I
isomer O
. O

The O
structure O
of O
ClC B
( I
O I
) I
NCS I
and O
its O
conformational O
composition O
were O
determined O
by O
gas O
electron O
diffraction O
. O

An O
unusual O
low O
syn O
- O
- O
> O
anti O
interconversion O
energy O
barrier O
of O
0 O
. O
98 O
( O
0 O
. O
15 O
) O
kcal O
mol O
( O
- O
1 O
) O
was O
detected O
for O
ClC B
( I
O I
) I
NCS I
at O
cryogenic O
temperatures O
. O

Rearrangement O
of O
ClC B
( I
O I
) I
SCN I
to O
ClC B
( I
O I
) I
NCS I
was O
observed O
in O
the O
neat O
liquid O
and O
under O
UV O
- O
vis O
irradiation O
of O
ClC B
( I
O I
) I
SCN I
isolated O
in O
solid O
argon B
. O

Rearrangement O
of O
ClC B
( I
O I
) I
SCN I
to O
ClC B
( I
O I
) I
NCS I
was O
observed O
in O
the O
neat O
liquid O
and O
under O
UV O
- O
vis O
irradiation O
of O
ClC B
( I
O I
) I
SCN I
isolated O
in O
solid O
argon B
. O

Rearrangement O
of O
ClC B
( I
O I
) I
SCN I
to O
ClC B
( I
O I
) I
NCS I
was O
observed O
in O
the O
neat O
liquid O
and O
under O
UV O
- O
vis O
irradiation O
of O
ClC B
( I
O I
) I
SCN I
isolated O
in O
solid O
argon B
. O

Properties O
have O
been O
discussed O
in O
terms O
of O
the O
valence O
electronic O
structure O
, O
including O
the O
analysis O
of O
the O
He B
( I
I I
) I
photoelectron O
spectrum O
of O
ClC B
( I
O I
) I
SCN I
. O

The O
7KC B
/ O
7 B
beta I
OHC I
ratio O
was O
similarly O
increased O
when O
NADPH B
generation O
was O
restricted O
by O
disruption O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

Compared O
with O
the O
high O
- O
fat O
control O
( O
HFC O
) O
group O
GMP O
supplementation O
significantly O
decreased O
adipose O
tissue O
weight O
, O
activity O
of O
fatty B
acid I
synthase O
( O
FAS O
) O
and O
glycerol B
- I
3 I
- I
phosphate I
dehydrogenase O
( O
GPDH O
) O
. O

Well O
- O
defined O
amphiphilic O
linear O
- O
dendritic O
prodrugs O
( O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
) O
are O
synthesized O
by O
conjugating O
doxorubicin B
( O
DOX B
) O
, O
to O
MPEG B
- I
b I
- I
PAMAM I
through O
the O
acid O
- O
labile O
hydrazone B
bond O
. O

The O
molecular O
orientation O
and O
dynamics O
of O
di B
- I
t I
- I
butylnitroxide I
( O
DTBN B
) O
and O
4 B
- I
oxo I
- I
2 I
, I
2 I
, I
6 I
, I
6 I
- I
tetramethyl I
- I
1 I
- I
piperidinyl I
- I
1 I
- I
oxyl I
( O
TEMPONE B
) O
radicals O
in O
the O
organic O
1D O
nanochannels O
of O
tris B
( I
o I
- I
phenylenedioxy I
) I
cyclotriphosphazene I
( O
TPP B
) O
were O
investigated O
by O
examining O
inclusion O
compounds O
( O
ICs O
) O
diluted O
by O
the O
co O
- O
inclusion O
of O
nonradicals O
using O
electron O
spin O
resonance O
( O

The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium B
( O
V B
( I
5 I
+ I
) I
) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL O
/ O
6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O

For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V B
( I
5 I
+ I
) I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
absence O
and O
presence O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
( O
15 O
mu O
g O
/ O
kg O
) O
for O
6 O
and O
24 O
h O
. O

Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V B
( I
5 I
+ I
) I
( O
5 O
, O
10 O
, O
and O
20 O
mu O
M O
) O
in O
the O
absence O
and O
presence O
of O
TCDD B
( O
1 O
nM O
) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O

In O
vivo O
, O
V B
( I
5 I
+ I
) I
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O

Upon O
co O
- O
exposure O
to O
V B
( I
5 I
+ I
) I
and O
TCDD B
, O
V B
( I
5 I
+ I
) I
significantly O
potentiated O
the O
TCDD B
- O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O

Upon O
co O
- O
exposure O
to O
V B
( I
5 I
+ I
) I
and O
TCDD B
, O
V B
( I
5 I
+ I
) I
significantly O
potentiated O
the O
TCDD B
- O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O

In O
vitro O
, O
V B
( I
5 I
+ I
) I
decreased O
the O
TCDD B
- O
mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O

Furthermore O
, O
V B
( I
5 I
+ I
) I
significantly O
inhibited O
the O
TCDD B
- O
induced O
AhR O
- O
dependent O
luciferase O
activity O
. O

V B
( I
5 I
+ I
) I
also O
increased O
serum O
hemoglobin O
( O
Hb O
) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O

When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V B
( I
5 I
+ I
) I
in O
the O
presence O
of O
TCDD B
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD B
- O
mediated O
effect O
. O

The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V B
( I
5 I
+ I
) I
in O
C57BL O
/ O
6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

As O
a O
means O
of O
utilizing O
the O
self O
- O
assembled O
HNSs O
for O
targeting O
controlled O
drug O
delivery O
, O
folic B
acid I
( O
FA O
) O
and O
rhodamine B
6G I
( O
Rh6G B
) O
were O
grafted O
onto O
compound O
1 O
to O
yield O
the O
FA B
- I
Rh6G I
- I
1 I
complex O
. O

The O
HNSs O
fabricated O
with O
FA B
- I
Rh6G I
- I
1 I
showed O
low O
cytotoxicity O
against O
human O
embryonic O
kidney O
293T O
cells O
and O
CT26 O
colon O
carcinoma O
cells O
and O
good O
doxorubicin B
( O
DOX B
) O
loading O
capacity O
( O
9 O
. O
6 O
wt O
% O
) O
. O

The O
FA O
receptor O
- O
mediated O
endocytosis O
of O
FA B
- I
Rh6G I
- I
1 I
HNSs O
examined O
by O
using O
a O
confocal O
laser O
scanning O
microscope O
and O
a O
flow O
cytometer O
revealed O
that O
the O
uptake O
of O
FA B
- I
Rh6G I
- I
1 I
HNSs O
into O
CT26 O
cells O
was O
induced O
by O
FA O
receptor O
- O
mediated O
endocytosis O
. O

The O
FA O
receptor O
- O
mediated O
endocytosis O
of O
FA B
- I
Rh6G I
- I
1 I
HNSs O
examined O
by O
using O
a O
confocal O
laser O
scanning O
microscope O
and O
a O
flow O
cytometer O
revealed O
that O
the O
uptake O
of O
FA B
- I
Rh6G I
- I
1 I
HNSs O
into O
CT26 O
cells O
was O
induced O
by O
FA O
receptor O
- O
mediated O
endocytosis O
. O

Chemical O
synthesis O
of O
Nd2Fe14B B
nanoparticles O
is O
challenging O
due O
to O
the O
large O
reduction O
potential O
of O
Nd B
( I
3 I
+ I
) I
and O
the O
high O
tendency O
for O
Nd2Fe14B B
oxidation O
. O

The O
process O
consisted O
of O
Nd B
- I
Fe I
- I
B I
mixed O
oxide B
preparation O
by O
microwave O
assisted O
combustion O
, O
followed O
by O
the O
reduction O
of O
the O
mixed O
oxide B
by O
CaH2 B
. O

On O
the O
move O
: O
A O
novel O
PtCl2 B
- O
catalyzed O
tandem O
1 B
, I
6 I
- I
enyne I
cyclization O
/ O
1 B
, I
2 I
- I
acyloxy I
migration O
reaction O
was O
developed O
, O
which O
was O
shown O
to O
be O
controlled O
by O
substitution O
effects O
. O

On O
the O
move O
: O
A O
novel O
PtCl2 B
- O
catalyzed O
tandem O
1 B
, I
6 I
- I
enyne I
cyclization O
/ O
1 B
, I
2 I
- I
acyloxy I
migration O
reaction O
was O
developed O
, O
which O
was O
shown O
to O
be O
controlled O
by O
substitution O
effects O
. O

Further O
functions O
assigned O
for O
ORPs O
include O
regulation O
of O
extracellular O
signal O
regulated O
kinase O
( O
ERK O
) O
activity O
( O
OSBP O
) O
, O
control O
of O
ER O
- O
late O
endosome O
MCS O
and O
late O
endosome O
motility O
( O
ORP1L O
) O
, O
regulation O
of O
beta O
1 O
- O
integrin O
activity O
( O
ORP3 O
) O
, O
modulation O
of O
hepatocyte O
insulin O
signaling O
and O
macrophage O
migration O
( O
ORP8 O
) O
, O
as O
well O
as O
post O
- O
Golgi O
vesicle O
transport O
, O
phosphatidylinositol B
- I
4 I
- I
phosphate I
and O
target O
of O
rapamycin B
complex O
1 O
signaling O
and O
nitrogen B

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

Coumarin B
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 B
' I
- I
methoxy I
- I
5 I
, I
7 I
- I
dihydroxyflavone I
, O
2 B
- I
ethynylnaphthalene I
, O
2 B
' I
- I
methoxyflavone I
, O
2 B
- I
naphththalene I
propargyl I
ether I
, O
acenaphthene B
, O
acenaphthylene B
, O
naphthalene B
, O
1 B
- I
acetylpyrene I
, O
flavanone B
, O
chrysin B
, O
3 B
- I
ethynylphenanthrene I
, O

Synthesis O
and O
cytotoxicity O
of O
3 B
- I
aryl I
acrylic I
amide I
derivatives O
of O
the O
simplified O
saframycin B
- O
ecteinascidin B
skeleton O
prepared O
from O
l B
- I
dopa I
. O

Twenty O
four O
compounds O
with O
diversified O
3 B
- I
aryl I
acrylic I
amide I
side O
chains O
of O
the O
simplified O
saframycin B
- O
ecteinascidin B
pentacyclic O
skeleton O
were O
synthesized O
via O
a O
14 O
- O
step O
stereospecific O
route O
starting O
from O
l B
- I
dopa I
. O

Compound O
28 O
with O
3 B
- I
thiophenyl I
acrylic I
amide I
side O
chain O
exhibited O
selective O
cytotoxicity O
against O
MDA O
- O
MB O
- O
231 O
cell O
line O
with O
the O
IC50 O
value O
of O
50 O
nM O
. O

In O
an O
underdoped O
La1 B
. I
9Sr0 I
. I
1CuO4 I
film O
( O
Tc O
= O
26 O
K O
) O
, O
we O
observe O
collective O
excitations O
of O
CDW O
that O
persist O
up O
to O
100 O
K O
. O

In O
contrast O
, O
in O
an O
optimally O
doped O
La1 B
. I
84Sr0 I
. I
16CuO4 I
film O
( O
Tc O
= O
38 O
. O
5 O
K O
) O
, O
we O
detect O
no O
signatures O
of O
fluctuating O
CDWs O
at O
any O
temperature O
, O
favouring O
the O
competition O
scenario O
. O

A O
series O
of O
3 B
, I
4 I
- I
diarylpyrazoles I
were O
concisely O
synthesized O
, O
one O
of O
which O
, O
3 B
- I
methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
3 I
, I
4 I
, I
5 I
- I
trimethoxyphenyl I
) I
- I
1H I
- I
pyrazol I
- I
3 I
- I
yl I
] I
benzene I
- I
1 I
, I
2 I
- I
diol I
( O
27 O
) O
, O
proved O
to O
be O
a O
cytotoxic O
anti O
- O
tubulin O
agent O
with O
low O
nanomolar O
potency O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

The O
apparent O
clearances O
( O
CL O
) O
of O
doxylamine B
and O
pyridoxal B
5 I
' I
- I
phosphate I
( O
PLP B
; O
the O
active O
metabolite O
of O
vitamin B
B I
( I
6 I
) I
) O
during O
the O
first O
- O
trimester O
pregnancy O
in O
women O
who O
participated O
in O
a O
Diclectin B
randomized O
trial O
were O
compared O
with O
those O
of O
healthy O
, O
adult O
, O
nonpregnant O
women O
who O
participated O
in O
a O
voluntary O
PK O
trial O
. O

The O
apparent O
clearances O
( O
CL O
) O
of O
doxylamine B
and O
pyridoxal B
5 I
' I
- I
phosphate I
( O
PLP B
; O
the O
active O
metabolite O
of O
vitamin B
B I
( I
6 I
) I
) O
during O
the O
first O
- O
trimester O
pregnancy O
in O
women O
who O
participated O
in O
a O
Diclectin B
randomized O
trial O
were O
compared O
with O
those O
of O
healthy O
, O
adult O
, O
nonpregnant O
women O
who O
participated O
in O
a O
voluntary O
PK O
trial O
. O

Light O
energy O
collection O
in O
a O
porphyrin B
- I
imide I
- I
corrole I
ensemble O
. O

NIE B
is O
connected O
to O
C3 O
through O
a O
1 B
, I
3 I
- I
phenylene I
bridge O
and O
to O
the O
ZnP B
unit O
through O
a O
direct O
C B
< I
F8FF I
> I
C I
bond O
. O

NIE B
is O
connected O
to O
C3 O
through O
a O
1 B
, I
3 I
- I
phenylene I
bridge O
and O
to O
the O
ZnP B
unit O
through O
a O
direct O
C B
< I
F8FF I
> I
C I
bond O
. O

In O
comparison O
to O
extracts O
from O
other O
Salvia O
species O
, O
S O
. O
sclarea O
oil O
contains O
twice O
as O
much O
omega B
- I
3 I
fatty I
acids I
, O
which O
are O
involved O
in O
eicosanoid B
synthesis O
pathways O
, O
and O
has O
been O
found O
to O
contain O
significant O
levels O
of O
the O
psychoactive O
monoterpane O
linalool B
. O

pyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
3H I
) I
- I
one I
with O
different O
aldehydes B
followed O
by O
cyclization O
of O
the O
products O
. O

Computational O
docking O
analysis O
was O
conducted O
to O
model O
the O
interaction O
of O
these O
antagonists O
with O
the O
human O
ER O
alpha O
and O
showed O
that O
they O
could O
tightly O
bind O
to O
the O
ER O
alpha O
in O
a O
manner O
similar O
to O
that O
of O
ICI B
- I
182 I
, I
780 I
, O
a O
pure O
ER O
antagonist O
. O

These O
results O
provide O
an O
example O
that O
attachment O
of O
a O
bulky O
side O
chain O
to O
the O
C O
- O
7 O
alpha O
position O
of O
E2 O
can O
produce O
ER O
antagonists O
with O
ER O
affinity O
comparable O
to O
that O
of O
ICI B
- I
182 I
, I
780 I
. O

Here O
, O
we O
report O
that O
Arabidopsis O
thaliana O
Ca B
( I
2 I
+ I
) I
- O
dependent O
protein O
kinase11 O
( O
CPK11 O
) O
and O
CPK24 O
are O
involved O
in O
Ca B
( I
2 I
+ I
) I
- O
dependent O
regulation O
of O
the O
inward O
K B
( I
+ I
) I
( O
K B
( I
+ I
) I
in O
) O
channels O
in O
pollen O
tubes O
. O

Here O
, O
we O
report O
that O
Arabidopsis O
thaliana O
Ca B
( I
2 I
+ I
) I
- O
dependent O
protein O
kinase11 O
( O
CPK11 O
) O
and O
CPK24 O
are O
involved O
in O
Ca B
( I
2 I
+ I
) I
- O
dependent O
regulation O
of O
the O
inward O
K B
( I
+ I
) I
( O
K B
( I
+ I
) I
in O
) O
channels O
in O
pollen O
tubes O
. O

Using O
patch O
- O
clamp O
analysis O
, O
we O
demonstrated O
that O
K B
( I
+ I
) I
in O
currents O
of O
pollen O
tube O
protoplasts O
were O
inhibited O
by O
elevated O
[ O
Ca B
( I
2 I
+ I
) I
] O
cyt O
. O

However O
, O
disruption O
of O
CPK11 O
or O
CPK24 O
completely O
impaired O
the O
Ca B
( I
2 I
+ I
) I
- O
dependent O
inhibition O
of O
K B
( I
+ I
) I
in O
currents O
and O
enhanced O
pollen O
tube O
growth O
. O

We O
conclude O
that O
CPK11 O
and O
CPK24 O
together O
mediate O
the O
Ca B
( I
2 I
+ I
) I
- O
dependent O
inhibition O
of O
K B
( I
+ I
) I
in O
channels O
and O
participate O
in O
the O
regulation O
of O
pollen O
tube O
growth O
in O
Arabidopsis O
. O

The O
underwater O
adhesion O
of O
marine O
mussels O
relies O
on O
mussel O
foot O
proteins O
( O
mfps O
) O
rich O
in O
the O
catecholic O
amino O
acid O
3 B
, I
4 I
- I
dihydroxyphenylalani I
( O
Dopa B
) O
. O

In O
case O
of O
antioxidant O
activity O
, O
compound O
4a O
showed O
promising O
radical O
scavenging O
activity O
, O
ferric B
ions O
( O
Fe B
( I
3 I
+ I
) I
) O
reducing O
antioxidant O
power O
( O
FRAP O
) O
and O
metal O
chelating O
activity O
. O

Few O
GC O
- O
MS O
features O
were O
associated O
with O
the O
presence O
of O
the O
non O
- O
derivatizeable O
11oxo B
group O
in O
pregnane B
( I
ene I
) I
s I
. O

GO B
- I
PDEA I
did O
not O
show O
practical O
toxicity O
to O
N2a O
cancer O
cells O
but O
the O
GO B
- I
PDEA I
- I
CPT I
complex O
exhibited O
high O
potency O
in O
killing O
N2a O
cancer O
cells O
in O
vitro O
. O

The O
quantum O
yield O
( O
QY O
) O
was O
~ O
50 O
% O
when O
the O
feed O
ratio O
of O
Cd B
( I
2 I
+ I
) I
to O
Hg B
( I
2 I
+ I
) I
was O
equal O
to O
1 O
. O

The O
quantum O
yield O
( O
QY O
) O
was O
~ O
50 O
% O
when O
the O
feed O
ratio O
of O
Cd B
( I
2 I
+ I
) I
to O
Hg B
( I
2 I
+ I
) I
was O
equal O
to O
1 O
. O

The O
results O
showed O
that O
, O
for O
Cd0 B
. I
21Hg0 I
. I
79Te I
NCs O
, O
its O
quasi O
core O
/ O
shell O
structure O
was O
very O
stable O
and O
little O
cadmium B
ions O
were O
released O
. O

Ni B
( I
II I
) I
- I
NTA I
Modified O
Poly B
( I
ethylene I
imine I
) I
Glycopolymers O
: O
Physicochemical O
Properties O
and O
First O
In O
Vitro O
Study O
of O
Polyplexes O
Formed O
with O
HIV O
- O
Derived O
Peptides O
. O

In O
our O
study O
, O
biocompatible O
Ni B
( I
II I
) I
- I
nitrilo I
( I
triacetic I
acid I
) I
- O
modified O
poly B
( I
ethylene I
imine I
) I
- I
maltose I
( O
Ni B
- I
NTA I
- I
DG I
) O
is O
realized O
and O
evaluated O
as O
complexation O
agent O
against O
His B
- O
tagged O
peptides O
using O
fluorescence O
polarization O
and O
dynamic O
light O
scattering O
. O

In O
summary O
, O
Ni B
- I
NTA I
- I
DG I
represents O
a O
promising O
( O
delivery O
) O
platform O
for O
forthcoming O
in O
vitro O
applications O
. O

Supramolecular O
cl B
. O
. O
. O
h B
and O
o B
. O
. O
. O
h B
interactions O
in O
self O
- O
assembled O
1 B
, I
5 I
- I
dichloroanthraquinon I
layers O
on O
au B
( I
111 I
) I
. O

Here O
, O
we O
study O
the O
supramolecular O
interactions O
of O
1 B
, I
5 I
- I
dichloroanthraquinon I
molecules O
on O
Au B
( I
111 I
) I
, O
including O
Cl B
ligands O
, O
by O
using O
STM O
. O

Uptake O
of O
estrone B
- I
3 I
- I
sulfate I
( O
5 O
nM O
) O
by O
OATP1B1 O
was O
reduced O
by O
82 O
% O
- O
95 O
% O
. O

We O
report O
on O
the O
synthesis O
of O
tuned O
energy O
band O
gap O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
nanofibers O
( O
NFs O
) O
with O
different O
Mg B
( I
2 I
+ I
) I
content O
via O
the O
sol O
- O
gel O
electrospinning O
( O
ES O
) O
technique O
wherein O
the O
addition O
of O
the O
doping O
material O
affects O
not O
only O
the O
morphologies O
of O
as O
- O
spun O
ZnAc B
/ O
PVA B
and O
MgAc B
/ O
ZnAc B
/ O
PVA B
nanofibers O
but O
also O
the O
crystal O
microstructure O
and O
optical O
properties O
of O
calcined O
ZnO B
and O
Mg B
( I
x I
) I
Zn I
( I

Following O
an O
appropriate O
aqueous O
solution O
preparation O
of O
magnesium B
acetate I
( O
MgAc B
) O
and O
zinc B
acetate I
( O
ZnAc B
) O
with O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
, O
electrospinning O
is O
performed O
and O
then O
as O
- O
spun O
nanofibers O
are O
calcined O
in O
an O
air O
atmosphere O
at O
600 O
degrees O
C O
for O
3 O
h O
. O

Because O
Zn B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
have O
similar O
ionicity O
and O
atomic O
radii O
, O
some O
Zn B
( I
2 I
+ I
) I
atoms O
are O
replaced O
by O
Mg B
( I
2 I
+ I
) I
atoms O
in O
the O
crystals O
, O
leading O
to O
a O
change O
in O
the O
properties O
of O
crystal O
lattices O
. O

Because O
Zn B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
have O
similar O
ionicity O
and O
atomic O
radii O
, O
some O
Zn B
( I
2 I
+ I
) I
atoms O
are O
replaced O
by O
Mg B
( I
2 I
+ I
) I
atoms O
in O
the O
crystals O
, O
leading O
to O
a O
change O
in O
the O
properties O
of O
crystal O
lattices O
. O

Because O
Zn B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
have O
similar O
ionicity O
and O
atomic O
radii O
, O
some O
Zn B
( I
2 I
+ I
) I
atoms O
are O
replaced O
by O
Mg B
( I
2 I
+ I
) I
atoms O
in O
the O
crystals O
, O
leading O
to O
a O
change O
in O
the O
properties O
of O
crystal O
lattices O
. O

Because O
Zn B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
have O
similar O
ionicity O
and O
atomic O
radii O
, O
some O
Zn B
( I
2 I
+ I
) I
atoms O
are O
replaced O
by O
Mg B
( I
2 I
+ I
) I
atoms O
in O
the O
crystals O
, O
leading O
to O
a O
change O
in O
the O
properties O
of O
crystal O
lattices O
. O

The O
band O
gap O
energy O
of O
the O
calcined O
fibers O
increases O
significantly O
with O
addition O
of O
Mg B
( I
2 I
+ I
) I
along O
with O
an O
increase O
in O
the O
ultraviolet O
( O
UV O
) O
photoluminescence O
emission O
of O
the O
fibers O
. O

The O
beta B
- I
hydroxy I
fatty I
acyl I
chain O
is O
connected O
to O
the O
N B
- O
terminal O
of O
the O
decapeptide B
and O
can O
be O
saturated O
or O
unsaturated O
, O
ranging O
from O
14 O
to O
18 O
carbons B
. O

N B
- I
Acetyl I
- I
aspartate I
, O
a O
marker O
of O
neuronal O
viability O
, O
decreased O
in O
the O
three O
regions O
; O
however O
, O
myo B
- I
inositol I
, O
a O
glial O
cell O
marker O
, O
increased O
in O
hippocampus O
and O
PFC O
. O

Ciliatamide B
D I
( O
1 O
) O
is O
a O
congener O
of O
2 O
, O
in O
which O
N B
- I
Me I
- I
Phe I
is O
replaced O
by O
N B
- I
Me I
- I
Met I
( I
O I
) I
. O

Reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
was O
used O
to O
synthesize O
two O
various O
sized O
water O
- O
soluble O
block O
copolymer O
of O
oligoethylene B
glycol I
methylether I
methacylate I
and O
methyl B
acrylic I
acid I
( O
POEGMEMA35 B
- I
b I
- I
PMAA200 I
and O
POEGMEMA26 B
- I
b I
- I
PMAA90 I
) O
. O

Reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
was O
used O
to O
synthesize O
two O
various O
sized O
water O
- O
soluble O
block O
copolymer O
of O
oligoethylene B
glycol I
methylether I
methacylate I
and O
methyl B
acrylic I
acid I
( O
POEGMEMA35 B
- I
b I
- I
PMAA200 I
and O
POEGMEMA26 B
- I
b I
- I
PMAA90 I
) O
. O

The O
small O
micelles O
were O
in O
addition O
cross O
- O
linked O
using O
1 B
, I
8 I
- I
diaminooctane I
to O
further O
stabilize O
their O
structure O
. O

In O
this O
study O
, O
to O
develop O
biostable O
nanoparticles O
with O
high O
tumor O
targetability O
, O
poly B
( I
ethylene I
glycol I
) I
- O
conjugated O
hyaluronic O
acid O
nanoparticles O
( O
PEG B
- O
HANPs O
) O
were O
mineralized O
through O
controlled O
deposition O
of O
inorganic O
calcium B
and O
phosphate B
ions O
on O
the O
nanoparticular O
shell O
via O
a O
sequential O
addition O
method O
. O

Sensing O
of O
biologically O
important O
cations O
such O
as O
na B
( I
+ I
) I
, O
k B
( I
+ I
) I
, O
ca B
( I
2 I
+ I
) I
, O
cu B
( I
2 I
+ I
) I
, O
and O
fe B
( I
3 I
+ I
) I
using O
magnetic O
nanoemulsions O
. O

Sensing O
of O
biologically O
important O
cations O
such O
as O
na B
( I
+ I
) I
, O
k B
( I
+ I
) I
, O
ca B
( I
2 I
+ I
) I
, O
cu B
( I
2 I
+ I
) I
, O
and O
fe B
( I
3 I
+ I
) I
using O
magnetic O
nanoemulsions O
. O

Sensing O
of O
biologically O
important O
cations O
such O
as O
na B
( I
+ I
) I
, O
k B
( I
+ I
) I
, O
ca B
( I
2 I
+ I
) I
, O
cu B
( I
2 I
+ I
) I
, O
and O
fe B
( I
3 I
+ I
) I
using O
magnetic O
nanoemulsions O
. O

The O
sensor O
shows O
good O
selectivity O
to O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
and O
Fe B
( I
3 I
+ I
) I
ions O
and O
offers O
a O
rapid O
response O
compared O
to O
conventional O
techniques O
. O

The O
sensor O
shows O
good O
selectivity O
to O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
and O
Fe B
( I
3 I
+ I
) I
ions O
and O
offers O
a O
rapid O
response O
compared O
to O
conventional O
techniques O
. O

The O
sensor O
shows O
good O
selectivity O
to O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
and O
Fe B
( I
3 I
+ I
) I
ions O
and O
offers O
a O
rapid O
response O
compared O
to O
conventional O
techniques O
. O

Three O
new O
19 B
- I
hydroxy I
steroidal I
glycosides I
, O
namely O
, O
junceellosides B
E I
- I
G I
( O
2 O
- O
4 O
) O
, O
were O
isolated O
together O
with O
the O
known O
analogue O
junceelloside B
C I
( O
1 O
) O
from O
the O
South O
China O
Sea O
gorgonian O
Dichotella O
gemmacea O
. O

This O
is O
the O
first O
report O
of O
steroidal O
glycosides O
from O
the O
gorgonian O
D O
. O
gemmacea O
and O
the O
first O
report O
of O
glycosides O
with O
beta B
- I
l I
- I
arabinopyranose I
from O
marine O
sources O
. O

In O
contrast O
, O
protein O
release O
from O
1 B
, I
4 I
- I
butanediamine I
cross O
- O
linked O
nanogels O
( O
reduction O
- O
insensitive O
control O
) O
remained O
low O
under O
otherwise O
the O
same O
conditions O
. O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate B
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

Substituted O
1 B
, I
6 I
- I
diphenylnaphthalenes I
as O
FtsZ O
- O
targeting O
antibacterial O
agents O
. O

Based O
upon O
their O
structural O
similarity O
to O
these O
compounds O
, O
a O
distinct O
series O
of O
substituted O
1 B
, I
6 I
- I
diphenylnaphthalenes I
were O
synthesized O
and O
evaluated O
for O
antibacterial O
activity O
against O
Staphylococcus O
aureus O
and O
Enterococcus O
faecalis O
. O

In O
addition O
, O
the O
effect O
of O
select O
1 B
, I
6 I
- I
diphenylnaphthalenes I
on O
the O
polymerization O
dynamics O
of O
S O
. O
aureus O
FtsZ O
and O
mammalian O
beta O
- O
tubulin O
was O
also O
assessed O
. O

Four O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
, O
[ B
Ru I
( I
bpy I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
PAIDH B
= O
2 B
- I
pyridyl I
- I
1H I
- I
anthra I
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
, O
) O
, O
[ B
Ru I
( I
phen I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
) O
, O
[ B
Ru I
( I
dmp I
) I
2 I
( I

Adsorption O
of O
a O
series O
of O
primary O
substituted O
hydrocarbons B
( O
RX O
; O
C18H37PO B
( I
OH I
) I
2 I
( O
ODPA B
) O
, O
C17H35COOH B
, O
C18H37OH B
, O
C18H37NH2 B
, O
and O
C18H37SH B
) O
onto O
solid O
gallium B
substrates O
with O
and O
without O
UV O
/ O
ozone B
treatment O
was O
studied O
using O
contact O
angle O
goniometry O
, O
spectroscopic O
ellipsometry O
, O
and O
cyclic O
voltammetry O
( O
CV O
) O
. O

( B
+ I
) I
- I
Medioresinol I
( O
13 O
) O
showed O
inhibitory O
effects O
on O
LPS O
- O
stimulated O
production O
of O
IL O
- O
12p40 O
with O
an O
IC50 O
value O
of O
2 O
. O
00 O
+ O
/ O
- O
0 O
. O
15 O
mu O
M O
. O

The O
basic O
structural O
motif O
is O
composed O
of O
2D O
acetato B
- I
benzimidazolato I
- I
zinc I
layers O
of O
tetrahedrally O
coordinated O
zinc B
joined O
together O
by O
anionic O
acetate B
and O
benzimidazolate B
ligands O
. O

X O
- O
ray O
diffraction O
showed O
a O
d O
- O
spacing O
of O
44 O
. O
15 O
A O
( O
different O
from O
45 O
. O
2 O
A O
reported O
for O
Ca B
( I
Pal I
) I
2 I
) O
, O
and O
infrared O
spectroscopy O
confirmed O
the O
presence O
of O
a O
hydroxy B
group O
. O

Morphological O
observation O
and O
flow O
cytometry O
analysis O
showed O
that O
5 B
beta I
- I
spirostanol I
glycoside I
( O
2 O
) O
and O
a O
cholestane B
derivative O
( O
17a O
) O
induced O
apoptotic O
cell O
death O
in O
HL O
- O
60 O
cells O
through O
different O
mechanisms O
of O
action O
. O

Michaelis O
constants O
( O
Km O
) O
were O
obtained O
for O
4 B
- I
nitrobenzylglutathio I
( O
0 O
. O
075mM O
) O
, O
2 B
, I
4 I
- I
dinitrophenylglutath I
( O
0 O
. O
30mM O
) O
, O
4 B
- I
methylbiphenylylglut I
( O
0 O
. O
12mM O
) O
, O
1 B
- I
menaphthylglutathion I
( O
0 O
. O
23mM O
) O
, O
and O
9 B
- I
methylanthracenylglu I
( O
0 O
. O
22mM O
) O
, O
indicating O
a O
trend O
towards O
higher O
values O
for O
bulkier O
substrates O
. O

A O
new O
compound O
library O
that O
contained O
20 O
hinged O
benzimidazole B
- O
coumarin B
hybrids O
and O
their O
beta B
- I
d I
- I
ribofuranosides I
was O
established O
. O

Various O
oxidative O
stress O
markers O
, O
including O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
oxidation O
, O
DNA O
oxidation O
, O
and O
the O
ratio O
of O
reduced B
glutathione I
to O
oxidised B
glutathione I
( O
GSH B
/ O
GSSG B
) O
, O
and O
the O
activities O
of O
NADPH B
oxidase O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
gamma B
- I
glutamyl I
- I
cysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
were O
evaluated O
in O
the O
livers O
and O
kidneys O
of O
fish O
in O
the O
absence O
and O
presence O
of O

The O
PEMUs O
were O
built O
layer O
- O
by O
- O
layer O
with O
the O
polycation O
poly B
( I
allylamine I
hydrochloride I
) I
( O
PAH B
) O
and O
a O
polyanion O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
that O
was O
modified O
with O
photoreactive O
4 B
- I
( I
2 I
- I
hydroxyethoxy I
) I
benzophenone I
( O
PAABp O
) O
. O

The O
PEMUs O
were O
built O
layer O
- O
by O
- O
layer O
with O
the O
polycation O
poly B
( I
allylamine I
hydrochloride I
) I
( O
PAH B
) O
and O
a O
polyanion O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
that O
was O
modified O
with O
photoreactive O
4 B
- I
( I
2 I
- I
hydroxyethoxy I
) I
benzophenone I
( O
PAABp O
) O
. O

The O
thermodynamically O
more O
stable O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
2 I
( I
mu I
- I
O2H3 I
) I
( I
mu I
- I
OH I
) I
2 I
( I
H2O I
) I
2 I
] I
( O
from O
now O
on O
, O
( B
O2H3 I
) I
Sc I
- O
MOF O
; O
3 B
, I
5 I
- I
DSB I
= O
3 B
, I
5 I
- I
disulfobenzoic I
acid I
) O
was O
obtained O
as O
a O
pure O
and O
stable O
phase O
. O

Redox O
- O
and O
pH O
- O
Responsive O
Cysteamine B
- O
Modified O
Poly B
( I
aspartic I
acid I
) I
Showing O
a O
Reversible O
Sol O
- O
Gel O
Transition O
. O

Synthesis O
and O
characterization O
of O
a O
pH O
- O
and O
redox O
- O
sensitive O
hydrogel O
of O
poly B
( I
aspartic I
acid I
) I
are O
reported O
. O

The O
present O
work O
highlights O
the O
critical O
importance O
of O
an O
intracyclic O
NH B
group O
at O
the O
4 O
- O
position O
, O
as O
well O
as O
an O
exocyclic O
NH B
group O
linked O
to O
the O
3 O
- O
position O
of O
the O
benzo B
- I
and I
pyridothiadiazine I
dioxides I
, O
for O
activity O
on O
KATP O
channels O
. O

AAPH B
mediated O
lutein B
fragmented O
ions O
were O
identified O
as O
551 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
- O
H2O B
) O
, O
391 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 B
- I
C22H32O I
) O
and O
276 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 B
- I
C12H20O I
) O
and O
its O
isomers O
as O
13 B
- I
Z I
lutein I
, O
13 B
- I
Z I
zeaxanthin I
, O
13 B
' I
- I
Z I
zeaxanthin I
and O
all B
- I
E I
zeaxanthin I
. O

A O
library O
of O
promising O
enmein B
- O
type O
14 B
- I
O I
- I
diterpenoid I
derivatives O
was O
constructed O
from O
a O
commercially O
available O
kaurene B
- O
type O
oridonin B
by O
practical O
and O
efficient O
synthetic O
methods O
. O

Short O
peptide O
toxins O
isolated O
from O
scorpion O
venoms O
are O
able O
to O
block O
voltage O
- O
dependent O
or O
Ca B
( I
2 I
+ I
) I
- O
activated O
K B
( I
+ I
) I
channels O
. O

Quercetin B
and O
epigallocatechin B
- I
3 I
- I
gallate I
effect O
on O
the O
anisotropy O
of O
model O
membranes O
with O
cholesterol B
. O

We O
performed O
a O
study O
on O
the O
effect O
of O
quercetin B
and O
epigallocatechin B
- I
3 I
- I
gallate I
on O
2 B
- I
Dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
small O
unilamellar O
vesicles O
( O
SUVs O
) O
with O
different O
amounts O
of O
cholesterol B
, O
using O
Laurdan B
as O
a O
fluorescent O
probe O
, O
to O
put O
into O
evidence O
the O
perturbations O
of O
the O
phospholipid O
membrane O
fluidity O
and O
local O
lipid O
order O
in O
an O
attempt O
to O
decipher O
the O
action O
mechanism O
of O
the O
flavonoids B
at O
the O
cell O
membrane O
level O
. O

Quercetin B
has O
a O
dose O
- O
dependent O
effect O
on O
the O
fluidity O
and O
local O
order O
of O
the O
lipid O
membranes O
, O
whilst O
epigallocatechin B
- I
3 I
- I
gallate I
action O
is O
not O
dose O
- O
dependent O
, O
the O
differences O
being O
attributable O
to O
the O
hydrophobic O
/ O
hydrophilic O
character O
of O
the O
substances O
. O

One O
of O
the O
most O
studied O
components O
of O
the O
plant O
is O
the O
essential O
oil O
for O
which O
chemical O
analysis O
revealed O
( B
E I
) I
- I
nerolidol I
as O
major O
compound O
. O

To O
investigate O
the O
antioxidant O
activity O
we O
used O
Trolox B
equivalent O
antioxidant O
capacity O
, O
oxygen B
radical O
absorbance O
capacity O
, O
Fe B
( I
2 I
+ I
) I
chelation O
activity O
and O
the O
inhibition O
of O
Fe B
( I
2 I
+ I
) I
- O
induced O
lipid O
peroxidation O
in O
mouse O
brain O
homogenates O
( O
in O
vitro O
) O
. O

To O
investigate O
the O
antioxidant O
activity O
we O
used O
Trolox B
equivalent O
antioxidant O
capacity O
, O
oxygen B
radical O
absorbance O
capacity O
, O
Fe B
( I
2 I
+ I
) I
chelation O
activity O
and O
the O
inhibition O
of O
Fe B
( I
2 I
+ I
) I
- O
induced O
lipid O
peroxidation O
in O
mouse O
brain O
homogenates O
( O
in O
vitro O
) O
. O

Overall O
, O
all O
the O
extracts O
from O
both O
wild O
plants O
and O
in O
vitro O
cultures O
exhibited O
ability O
to O
scavenge O
free O
radicals O
, O
to O
chelate O
Fe B
( I
2 I
+ I
) I
and O
to O
protect O
against O
lipid O
peroxidation O
. O

Synthesis O
of O
indolyl B
- I
3 I
- I
acetonitrile I
derivatives O
and O
their O
inhibitory O
effects O
on O
nitric B
oxide I
and O
PGE2 B
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

Several O
indolyl B
- I
3 I
- I
acetonitrile I
derivatives O
were O
synthesized O
as O
arvelexin B
analogs O
and O
evaluated O
for O
their O
abilities O
to O
inhibit O
NO B
and O
PGE2 B
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

Of O
the O
indolyl B
- I
3 I
- I
acetonitriles I
synthesized O
, O
compound O
2k O
, O
which O
possesses O
a O
hydroxyl B
group O
at O
C O
- O
7 O
position O
of O
the O
indole B
ring O
and O
an O
N B
- I
methyl I
substituent O
, O
more O
potently O
inhibited O
NO B
and O
PGE2 B
productions O
and O
was O
less O
cytotoxic O
than O
arvelexin B
on O
macrophage O
cells O
. O

Two O
novel O
saponins B
of O
20 B
, I
26 I
- I
epoxy I
derivatives O
of O
pseudojujubogenin B
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

Two O
new O
saponins B
of O
20 B
, I
26 I
- I
epoxy I
derivatives O
of O
pseudojujubogenin B
, O
hoduloside B
XI I
( O
1 O
) O
and O
hoduloside B
XII I
( O
2 O
) O
were O
isolated O
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

A O
novel O
series O
of O
quinazolines B
5 O
- O
10 O
, O
triazoloquinazolines B
11 O
- O
17 O
and O
triazinoquinazoline B
19 O
bearing O
a O
biologically O
active O
sulfonamide B
moiety O
were O
synthesized O
, O
utilizing O
methyl B
2 I
- I
isothiocyanato I
benzoate I
2 O
. O

Design O
, O
Synthesis O
, O
Biological O
Evaluation O
, O
and O
Docking O
Studies O
of O
( B
S I
) I
- I
Phenylalanine I
Derivatives O
with O
a O
2 B
- I
Cyanopyrrolidine I
Moiety O
as O
Potent O
Dipeptidyl O
Peptidase O
4 O
Inhibitors O
. O

A O
novel O
series O
of O
( B
S I
) I
- I
phenylalanine I
derivatives O
with O
a O
2 B
- I
cyanopyrrolidine I
moiety O
were O
designed O
and O
synthesized O
through O
a O
rational O
drug O
design O
strategy O
. O

Antifreeze O
( O
Glyco O
) O
protein O
Mimetic O
Behavior O
of O
Poly B
( I
vinyl I
alcohol I
) I
: O
Detailed O
Structure O
Ice O
Recrystallization O
Inhibition O
Activity O
Study O
. O

This O
manuscript O
reports O
a O
detailed O
study O
on O
the O
ability O
of O
poly B
( I
vinyl I
alcohol I
) I
to O
act O
as O
a O
biomimetic O
surrogate O
for O
antifreeze O
( O
glyco O
) O
proteins O
, O
with O
a O
focus O
on O
the O
specific O
property O
of O
ice O
- O
recrystallization O
inhibition O
( O
IRI O
) O
. O

Poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
has O
been O
shown O
to O
display O
remarkable O
ice O
recrystallization O
inhibition O
activity O
despite O
its O
major O
structural O
differences O
to O
native O
antifreeze O
proteins O
. O

The O
highly O
reactive O
conjugated O
aldehydes B
( O
alpha B
, I
beta I
- I
unsaturated I
aldehydes I
and O
2 B
, I
3 I
- I
epoxyaldehydes I
) O
are O
sensitizing O
moieties O
, O
while O
nonconjugated O
aldehydes B
and O
nonterminal O
aliphatic O
epoxides B
show O
low O
reactivity O
and O
low O
sensitization O
potency O
. O

Our O
study O
indicated O
that O
treatment O
of O
HepG2 O
cells O
with O
CSA B
induces O
Nrf2 O
- O
dependent O
ARE O
activity O
and O
gene O
expression O
of O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
NAD B
( I
P I
) I
H I
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
, O
and O
glutamate B
- O
cysteine B
ligase O
modifier O
subunits O
by O
activation O
of O
PI3K O
/ O
AKT O
, O
ERK O
and O
JNK O
signaling O
pathways O
. O

A O
novel O
and O
stereoselective O
synthetic O
route O
towards O
carba B
- I
C I
- I
nucleosides I
was O
investigated O
applying O
an O
enantiodivergent O
biooxidation O
strategy O
by O
two O
different O
Baeyer O
- O
Villiger O
monooxygenases O
. O

Attenuated O
total O
reflection O
Fourier O
transform O
infrared O
( O
ATR O
- O
FTIR O
) O
spectroscopy O
was O
used O
to O
investigate O
the O
binding O
of O
Na B
( I
+ I
) I
and O
Ca B
( I
2 I
+ I
) I
cations O
to O
bovine O
cytochrome O
c O
oxidase O
in O
its O
fully O
oxidized O
and O
partially O
reduced O
, O
cyanide B
- O
ligated O
( O
a O
( O
2 O
+ O
) O
a3 O
( O
3 O
+ O
) O
- O
CN B
) O
( O
mixed O
valence O
) O
forms O
. O

Dissociation O
constants O
for O
Na B
( I
+ I
) I
and O
Ca B
( I
2 I
+ I
) I
with O
the O
oxidized O
enzyme O
were O
1 O
. O
2 O
mM O
and O
11 O
mu O
M O
, O
respectively O
and O
Na B
( I
+ I
) I
binding O
appeared O
to O
involve O
cooperative O
binding O
of O
two O
Na B
( I
+ I
) I
. O

Ca B
( I
2 I
+ I
) I
binding O
induced O
a O
large O
IR O
spectrum O
, O
with O
prominent O
amide B
I O
/ O
II O
polypeptide O
changes O
, O
bandshifts O
assigned O
to O
carboxylate B
and O
an O
arginine B
, O
and O
a O
number O
of O
bandshifts O
of O
heme B
a I
. O

This O
was O
attributed O
to O
the O
difficulty O
in O
fully O
depleting O
Ca B
( I
2 I
+ I
) I
from O
its O
binding O
site O
, O
as O
has O
been O
found O
with O
bacterial O
CcOs O
. O

The O
implications O
of O
Ca B
( I
2 I
+ I
) I
/ O
Na B
( I
+ I
) I
ion O
binding O
are O
discussed O
in O
terms O
of O
structure O
and O
possible O
modulation O
of O
core O
catalytic O
function O
. O

To O
investigate O
possible O
effects O
, O
we O
exposed O
the O
common O
mussel O
Mytilus O
galloprovincialis O
in O
seawater O
supplemented O
by O
30 O
mu O
g O
/ O
L O
Hg B
( I
2 I
+ I
) I
for O
15 O
days O
. O

We O
observed O
that O
Hg B
( I
2 I
+ I
) I
was O
significantly O
accumulated O
in O
the O
digestive O
glands O
of O
mussels O
, O
reaching O
a O
level O
around O
80 O
mu O
g O
/ O
g O
tissue O
( O
dry O
weight O
) O
at O
the O
15th O
day O
of O
exposure O
. O

Exposure O
of O
mussels O
to O
Hg B
( I
2 I
+ I
) I
resulted O
in O
failure O
of O
redox O
homeostasis O
, O
as O
reflected O
on O
lipid O
peroxidation O
levels O
and O
superoxide B
dismutase O
activity O
in O
glands O
, O
and O
micronucleus O
frequency O
in O
gills O
. O

Extracts O
from O
digestive O
glands O
after O
15 O
- O
day O
exposure O
to O
Hg B
( I
2 I
+ I
) I
exhibited O
decreased O
tRNA O
aminoacylation O
ability O
and O
, O
moreover O
, O
a O
70 O
% O
reduction O
in O
the O
ability O
of O
40S O
ribosomal O
subunits O
to O
form O
the O
48S O
initiation O
ribosomal O
complex O
. O

A O
similar O
reduction O
was O
detected O
in O
the O
ability O
of O
ribosomes O
to O
translocate O
peptidyl O
- O
tRNA O
from O
the O
A O
- O
site O
to O
the O
P O
- O
site O
, O
an O
observation O
coinciding O
with O
the O
notion O
that O
regulation O
of O
protein O
synthesis O
by O
Hg B
( I
2 I
+ I
) I
mainly O
occurs O
at O
the O
initiation O
and O
elongation O
stages O
of O
translation O
. O

In O
conclusion O
, O
Hg B
( I
2 I
+ I
) I
apart O
from O
being O
a O
genotoxic O
ion O
acts O
as O
a O
modulator O
of O
protein O
synthesis O
in O
mussels O
, O
an O
observation O
probably O
related O
with O
its O
ability O
to O
induce O
oxidative O
stress O
. O

Surface O
grafting O
of O
crystalline O
and O
ultrafine O
cellulose O
nanofibrils O
with O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
chains O
via O
ionic O
bonds O
was O
achieved O
by O
a O
simple O
ion O
- O
exchange O
treatment O
. O

Recently O
we O
demonstrated O
the O
ability O
of O
mercuric B
chloride I
( O
Hg B
( I
2 I
+ I
) I
) O
in O
human O
hepatoma O
HepG2 O
cells O
to O
significantly O
decrease O
the O
TCDD B
- O
mediated O
induction O
of O
Cytochrome O
P450 O
1A1 O
( O
CYP1A1 O
) O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O

Importantly O
, O
this O
inhibition O
was O
specific O
to O
CYP1A1and O
was O
not O
radiated O
to O
other O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
regulated O
genes O
, O
as O
MeHg B
induced O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
1 O
mRNA O
and O
protein O
levels O
. O

An O
intermediate O
GTX2 B
, I
3 I
- I
aldehyde I
was O
first O
synthesized O
by O
activating O
the O
NH2 B
group O
of O
the O
2nd O
and O
8th O
amino B
acid I
residues O
with O
three O
different O
aldehydes B
and O
two O
artificial O
complete O
antigens O
GTX2 B
, I
3 I
- I
aldehyde I
- O
bovine O
serum O
albumin O
( O
BSA O
) O
and O
GTX2 B
, I
3 I
- I
aldehyde I
- O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
were O
then O
prepared O
by O
cross O
- O
linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O

An O
intermediate O
GTX2 B
, I
3 I
- I
aldehyde I
was O
first O
synthesized O
by O
activating O
the O
NH2 B
group O
of O
the O
2nd O
and O
8th O
amino B
acid I
residues O
with O
three O
different O
aldehydes B
and O
two O
artificial O
complete O
antigens O
GTX2 B
, I
3 I
- I
aldehyde I
- O
bovine O
serum O
albumin O
( O
BSA O
) O
and O
GTX2 B
, I
3 I
- I
aldehyde I
- O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
were O
then O
prepared O
by O
cross O
- O
linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O

An O
intermediate O
GTX2 B
, I
3 I
- I
aldehyde I
was O
first O
synthesized O
by O
activating O
the O
NH2 B
group O
of O
the O
2nd O
and O
8th O
amino B
acid I
residues O
with O
three O
different O
aldehydes B
and O
two O
artificial O
complete O
antigens O
GTX2 B
, I
3 I
- I
aldehyde I
- O
bovine O
serum O
albumin O
( O
BSA O
) O
and O
GTX2 B
, I
3 I
- I
aldehyde I
- O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
were O
then O
prepared O
by O
cross O
- O
linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O

These O
effects O
were O
blocked O
by O
mecamylamine B
and O
dihydro B
- I
beta I
- I
erythroidine I
, O
but O
not O
methyllycaconitine B
. O

These O
effects O
were O
dependent O
upon O
functional O
DA O
D3 O
receptor O
( O
D3R O
) O
since O
nicotine B
was O
inactive O
both O
in O
cultures O
from O
D3R O
KO O
mice O
and O
following O
pharmacologic O
blockade O
with O
D3R O
antagonist O
SB B
- I
277011 I
- I
A I
( O
50 O
nM O
) O
. O

The O
process O
began O
with O
modification O
of O
the O
SBA B
- I
15 I
template O
with O
carbon B
polymers O
and O
Pt B
nanoparticles O
accompanied O
by O
adsorption O
of O
W B
( I
6 I
+ I
) I
, O
which O
was O
then O
converted O
into O
m B
- I
Pt I
- I
WO3 I
composites O
by O
heat O
treatment O
and O
subsequent O
template O
removal O
. O

The O
process O
began O
with O
modification O
of O
the O
SBA B
- I
15 I
template O
with O
carbon B
polymers O
and O
Pt B
nanoparticles O
accompanied O
by O
adsorption O
of O
W B
( I
6 I
+ I
) I
, O
which O
was O
then O
converted O
into O
m B
- I
Pt I
- I
WO3 I
composites O
by O
heat O
treatment O
and O
subsequent O
template O
removal O
. O

Comprehensive O
characterizations O
suggest O
that O
the O
as O
- O
developed O
m B
- I
Pt I
- I
WO3 I
nanohybrid O
exhibits O
unique O
properties O
with O
mesoporous O
structure O
, O
excellent O
crystalline O
structure O
, O
and O
high O
surface O
area O
. O

When O
the O
photocatalytic O
properties O
of O
m B
- I
Pt I
- I
WO3 I
nanohybrids O
were O
systematically O
investigated O
, O
it O
was O
revealed O
that O
the O
m B
- I
Pt I
- I
WO3 I
nanohybrids O
showed O
great O
promise O
for O
degrading O
the O
organic O
dye O
under O
visible O
light O
irradiation O
, O
which O
shows O
an O
excellent O
photocatalytic O
activity O
that O
far O
exceeded O
those O
of O
pure O
phase O
mesoporous O
WO3 B
and O
commercial O
TiO2 B
( O
P25 O
) O
, O
and O
was O
10 O
- O
fold O
more O
active O
than O
that O
of O
the O
bulk O
Pt B
- O
WO3 B
catalyst O
. O

When O
the O
photocatalytic O
properties O
of O
m B
- I
Pt I
- I
WO3 I
nanohybrids O
were O
systematically O
investigated O
, O
it O
was O
revealed O
that O
the O
m B
- I
Pt I
- I
WO3 I
nanohybrids O
showed O
great O
promise O
for O
degrading O
the O
organic O
dye O
under O
visible O
light O
irradiation O
, O
which O
shows O
an O
excellent O
photocatalytic O
activity O
that O
far O
exceeded O
those O
of O
pure O
phase O
mesoporous O
WO3 B
and O
commercial O
TiO2 B
( O
P25 O
) O
, O
and O
was O
10 O
- O
fold O
more O
active O
than O
that O
of O
the O
bulk O
Pt B
- O
WO3 B
catalyst O
. O

UVA O
photoirradiation O
of O
benzo B
[ I
a I
] I
pyrene I
metabolites O
: O
induction O
of O
cytotoxicity O
, O
reactive O
oxygen B
species O
, O
and O
lipid O
peroxidation O
. O

Benzo B
[ I
a I
] I
pyrene I
( O
BaP B
) O
is O
a O
prototype O
for O
studying O
carcinogenesis O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
. O

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP B
( I
7 I

The O
photocytotoxicity O
of O
BaP B
, O
3 B
- I
OH I
- I
BaP I
, O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
diol I
- I
anti I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
, O
and O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
in O
the O
HaCaT O
keratinocytes O
was O
examined O
. O

Rapid O
self O
- O
healable O
poly B
( I
ethylene I
glycol I
) I
hydrogels O
formed O
by O
selective O
metal O
- O
phosphate B
interactions O
. O

Rapid O
self O
- O
healable O
and O
biocompatible O
hydrogels O
were O
prepared O
using O
the O
selective O
formation O
of O
metal O
- O
ligand O
interactions O
between O
selected O
metal O
ions O
and O
phosphate B
end O
groups O
of O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe B
( I
3 I
+ I
) I
, O
V B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
3 I
+ I
) I
, O
and O
Ga B
( I
3 I
+ I
) I
have O
relatively O
small O
ionic O
radii O
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe B
( I
3 I
+ I
) I
, O
V B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
3 I
+ I
) I
, O
and O
Ga B
( I
3 I
+ I
) I
have O
relatively O
small O
ionic O
radii O
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe B
( I
3 I
+ I
) I
, O
V B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
3 I
+ I
) I
, O
and O
Ga B
( I
3 I
+ I
) I
have O
relatively O
small O
ionic O
radii O
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe B
( I
3 I
+ I
) I
, O
V B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
3 I
+ I
) I
, O
and O
Ga B
( I
3 I
+ I
) I
have O
relatively O
small O
ionic O
radii O
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe B
( I
3 I
+ I
) I
, O
V B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
3 I
+ I
) I
, O
and O
Ga B
( I
3 I
+ I
) I
have O
relatively O
small O
ionic O
radii O
. O

We O
have O
also O
demonstrated O
a O
gel O
- O
sol O
/ O
sol O
- O
gel O
transition O
by O
switching O
the O
redox O
states O
of O
Fe B
( I
3 I
+ I
) I
/ O
Fe B
( I
2 I
+ I
) I
ions O
. O

We O
have O
also O
demonstrated O
a O
gel O
- O
sol O
/ O
sol O
- O
gel O
transition O
by O
switching O
the O
redox O
states O
of O
Fe B
( I
3 I
+ I
) I
/ O
Fe B
( I
2 I
+ I
) I
ions O
. O

Amorphous O
Ni B
( I
OH I
) I
2 I
Nanoboxes O
: O
Fast O
Fabrication O
and O
Enhanced O
Sensing O
for O
Glucose B
. O

Inspired O
by O
Pearson O
' O
s O
hard O
and O
soft O
acid O
- O
base O
( O
HSAB O
) O
principle O
, O
uniform O
amorphous O
Ni B
( I
OH I
) I
2 I
nanoboxes O
with O
intact O
shell O
structures O
and O
various O
sizes O
are O
quickly O
fabricated O
by O
deliberately O
selecting O
S2 B
O3 I
( I
2 I
- I
) I
as O
the O
coordinating O
etchant O
toward O
Cu2 B
O I
templates O
and O
optimizing O
the O
reaction O
conditions O
. O

Ni B
( I
OH I
) I
2 I
nanoboxes O
, O
as O
an O
example O
, O
demonstrate O
an O
improved O
electrochemical O
sensing O
ability O
for O
glucose B
, O
which O
might O
be O
due O
to O
their O
amorphous O
and O
hollow O
structural O
features O
. O

Does O
4 B
- I
tert I
- I
octylphenol I
affect O
estrogen B
signaling O
pathways O
in O
bank O
vole O
Leydig O
cells O
and O
tumor O
mouse O
Leydig O
cells O
in O
vitro O
? O

Primary O
Leydig O
cells O
obtained O
from O
bank O
vole O
testes O
and O
the O
established O
tumor O
Leydig O
cell O
line O
( O
MA O
- O
10 O
) O
have O
been O
used O
to O
explore O
the O
effects O
of O
4 B
- I
tert I
- I
octylphenol I
( O
OP O
) O
. O

Four O
new O
cyclohexanone B
derivatives O
( O
2 O
- O
5 O
) O
and O
one O
known O
analog O
, O
( B
- I
) I
- I
Palitantin I
( O
1 O
) O
were O
isolated O
from O
the O
EtOAc B
extract O
of O
Penicillium O
commune O
, O
a O
fungal O
strain O
of O
low O
- O
temperature O
habitats O
. O

The O
difluororibonucleosi B
were O
prepared O
by O
non O
- O
stereoselective O
glycosidation O
of O
6 B
- I
chloro I
- I
7 I
- I
deazapurine I
with O
benzoyl B
- I
protected I
2 I
- I
deoxy I
- I
2 I
, I
2 I
- I
difluoro I
- I
D I
- I
erythro I
- I
pentofuranosyl I
- I
1 I
- I
mesylate I
, O
followed O
by O
amination O
and O
aqueous O
Suzuki O
cross O
- O
couplings O
with O
( B
het I
) I
arylboronic I
acids I
. O

The O
fluororibo B
derivatives O
were O
prepared O
by O
aqueous O
palladium B
- O
catalyzed O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
7 B
- I
iodo I
- I
7 I
- I
deazaadenine I
2 I
' I
- I
deoxy I
- I
2 I
' I
- I
fluororibonucleoside I
20 O
with O
( B
het I
) I
arylboronic I
acids I
. O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

Encapsulation O
of O
indole B
- I
3 I
- I
carbinol I
and O
3 B
, I
3 I
' I
- I
diindolylmethane I
in O
zein O
/ O
carboxymethyl B
chitosan O
nanoparticles O
with O
controlled O
release O
property O
and O
improved O
stability O
. O

Indole B
- I
3 I
- I
carbinol I
( O
I3C B
) O
and O
3 B
, I
3 I
' I
- I
diindolylmethane I
( O
DIM B
) O
are O
two O
bioactive O
compounds O
from O
Cruciferous O
vegetables O
. O

methyldipyrido I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
1 I
) O
and O
2 B
- I
aminodipirydo I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
2 I
) O
. O

Without O
S9 O
, O
IQ O
and O
MeIQ B
showed O
mutagenicity O
at O
10 O
( O
- O
8 O
) O
mol O
/ O
plate O
, O
MeIQx B
and O
Glu B
- I
P I
- I
1 I
at O
10 O
( O
- O
5 O
) O
mol O
/ O
plate O
, O
while O
Glu B
- I
P I
- I
2 I
was O
inactive O
. O

Without O
S9 O
, O
IQ O
and O
MeIQ B
showed O
mutagenicity O
at O
10 O
( O
- O
8 O
) O
mol O
/ O
plate O
, O
MeIQx B
and O
Glu B
- I
P I
- I
1 I
at O
10 O
( O
- O
5 O
) O
mol O
/ O
plate O
, O
while O
Glu B
- I
P I
- I
2 I
was O
inactive O
. O

No O
anti O
- O
mutagen O
capacity O
was O
noted O
for O
MeIQx B
and O
Glu B
- I
P I
- I
1 I
( O
10 O
( O
- O
5 O
) O
mol O
/ O
plate O
) O
. O

Mechanisms O
of O
saccharide B
protection O
against O
epigallocatechin B
- I
3 I
- I
gallate I
deterioration O
in O
aqueous O
solutions O
. O

We O
investigated O
the O
mechanisms O
of O
the O
protection O
conferred O
by O
sugars B
to O
epigallocatechin B
- I
3 I
- I
gallate I
( O
EGCG B
) O
against O
deterioration O
. O

Crystallization O
of O
poly B
( I
ethylene I
oxide I
) I
with O
acetaminophen B
- O
A O
study O
on O
solubility O
, O
spherulitic O
growth O
, O
and O
morphology O
. O

A O
simple O
, O
sensitive O
, O
efficient O
, O
and O
novel O
method O
analyzing O
the O
number O
of O
spherulitic O
nuclei O
was O
proposed O
to O
estimate O
the O
solubility O
of O
a O
model O
drug O
acetaminophen B
( O
APAP B
) O
in O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
) O
. O

Also O
, O
vinblastine B
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen B
species O
, O
the O
release O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal O
- O
regulating O
kinase O
1 O
, O
c O
- O
jun O
- O
N B
- O
terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaB O
alpha O
( O
I O
kappa O
B O
alpha O
) O
kinase O
, O
and O
inositol B
requiring O
enzyme O
1 O
alpha O
. O

Treating O
rats O
with O
a O
mixture O
of O
dichlorvos B
and O
deltamethrin B
caused O
an O
increase O
in O
serum O
lactate B
, O
trimethylamine B
- I
N I
- I
oxide I
( O
TMAO B
) O
, O
choline B
and O
alanine B
, O
with O
the O
highest O
levels O
of O
these O
metabolites O
observed O
in O
those O
that O
received O
the O
highest O
dose O
. O

Thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
derivatives O
analogous O
to O
rosiglitazone B
as O
potential O
antihyperglycemic O
and O
antidyslipidemic O
agents O
. O

Thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
derivatives O
analogous O
to O
rosiglitazone B
as O
potential O
antihyperglycemic O
and O
antidyslipidemic O
agents O
. O

A O
number O
of O
thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
derivatives O
were O
prepared O
by O
three O
component O
condensation O
in O
one O
pot O
reaction O
method O
. O

A O
number O
of O
thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
derivatives O
were O
prepared O
by O
three O
component O
condensation O
in O
one O
pot O
reaction O
method O
. O

The O
compounds O
with O
thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
moieties O
exhibited O
significant O
anti O
- O
hyperglycemic O
activity O
. O

The O
compounds O
with O
thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
moieties O
exhibited O
significant O
anti O
- O
hyperglycemic O
activity O
. O

Among O
them O
the O
thiazinan B
- I
4 I
- I
one I
derivative O
4a O
showed O
maximal O
( O
45 O
% O
) O
improvement O
in O
oral O
glucose B
tolerance O
test O
in O
db O
/ O
db O
mice O
at O
30 O
mg O
/ O
kg O
oral O
dose O
. O

We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf O
- O
dependent O
adaptors O
( O
AP O
- O
1 O
and O
GGAs O
) O
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo O
proteins O
( O
furin O
, O
mannose B
- I
6 I
- I
phosphate I
receptor O
( O
M6PR O
) O
and O
M6PR O
lacking O
a O
C B
- O
terminal O
domain O
M6PR O
Delta O
C O
) O
. O

Three O
metal O
complexes O
consisting O
of O
Li B
( I
+ I
) I
, O
Zn B
( I
2 I
+ I
) I
, O
and O
Al B
( I
3 I
+ I
) I
and O
quinolinol B
- I
functionalized I
l I
- I
glutamides I
( O
HQLG B
) O
, O
( O
abbreviated O
as O
LiHQLG B
, O
Zn B
( I
HQLG I
) I
2 I
, O
and O
Al B
( I
HQLG I
) I
3 I
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

Three O
metal O
complexes O
consisting O
of O
Li B
( I
+ I
) I
, O
Zn B
( I
2 I
+ I
) I
, O
and O
Al B
( I
3 I
+ I
) I
and O
quinolinol B
- I
functionalized I
l I
- I
glutamides I
( O
HQLG B
) O
, O
( O
abbreviated O
as O
LiHQLG B
, O
Zn B
( I
HQLG I
) I
2 I
, O
and O
Al B
( I
HQLG I
) I
3 I
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

Three O
metal O
complexes O
consisting O
of O
Li B
( I
+ I
) I
, O
Zn B
( I
2 I
+ I
) I
, O
and O
Al B
( I
3 I
+ I
) I
and O
quinolinol B
- I
functionalized I
l I
- I
glutamides I
( O
HQLG B
) O
, O
( O
abbreviated O
as O
LiHQLG B
, O
Zn B
( I
HQLG I
) I
2 I
, O
and O
Al B
( I
HQLG I
) I
3 I
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

Three O
metal O
complexes O
consisting O
of O
Li B
( I
+ I
) I
, O
Zn B
( I
2 I
+ I
) I
, O
and O
Al B
( I
3 I
+ I
) I
and O
quinolinol B
- I
functionalized I
l I
- I
glutamides I
( O
HQLG B
) O
, O
( O
abbreviated O
as O
LiHQLG B
, O
Zn B
( I
HQLG I
) I
2 I
, O
and O
Al B
( I
HQLG I
) I
3 I
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

Among O
them O
, O
the O
Al B
( I
HQLG I
) I
3 I
metallogels O
did O
not O
show O
any O
change O
whereas O
the O
LiHQLG B
gels O
exhibited O
the O
same O
decrease O
in O
fluorescence O
. O

Interestingly O
, O
the O
Zn B
( I
HQLG I
) I
2 I
gels O
showed O
obviously O
different O
fluorescent O
color O
with O
respect O
to O
( B
R I
, I
R I
) I
- I
and I
( I
S I
, I
S I
) I
- I
1 I
, I
2 I
- I
diaminocyclohexane I
, O
thus O
providing O
visible O
chiral O
recognition O
via O
the O
naked O
eye O
. O

It O
is O
shown O
that O
the O
MQ O
dynamics O
in O
adamantane B
is O
consistent O
with O
that O
calculated O
using O
the O
cubic O
lattice O
and O
that O
in O
Mg B
( I
OH I
) I
2 I
with O
that O
calculated O
using O
the O
honeycomb O
and O
the O
square O
lattices O
. O

A O
sub O
- O
monolayer O
distribution O
of O
isolated O
molecular O
Fe14 B
( I
bta I
) I
6 I
nanomagnets O
is O
deposited O
intact O
on O
a O
Au B
( I
111 I
) I
surface O
and O
investigated O
by O
X O
- O
ray O
magnetic O
circular O
dichroism O
spectroscopy O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca B
( I
2 I
+ I
) I
blockers O
, O
bis B
- I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetra I
- I
acetic I
acid I
acetoxymethyl I
ester I
( O
BAPTA B
- I
AM I
) O
and O
nifedipine B
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca B
( I
2 I
+ I
) I
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca B
( I
2 I
+ I
) I
blockers O
, O
bis B
- I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetra I
- I
acetic I
acid I
acetoxymethyl I
ester I
( O
BAPTA B
- I
AM I
) O
and O
nifedipine B
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca B
( I
2 I
+ I
) I
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca B
( I
2 I
+ I
) I
blockers O
, O
bis B
- I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetra I
- I
acetic I
acid I
acetoxymethyl I
ester I
( O
BAPTA B
- I
AM I
) O
and O
nifedipine B
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca B
( I
2 I
+ I
) I
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

However O
, O
Ca B
( I
2 I
+ I
) I
blockers O
also O
obviously O
attenuated O
NF O
- O
kappa O
B O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD B
. O

In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro O
- O
inflammatory O
cytokine O
and O
NF O
- O
kappa O
B O
activation O
induced O
by O
TCDD B
can O
be O
mediated O
by O
elevation O
of O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
in O
HAPI O
microglial O
cells O
. O

During O
repetitive O
stimulation O
of O
skeletal O
muscle O
, O
extracellular O
ATP B
levels O
raise O
, O
activating O
purinergic O
receptors O
, O
increasing O
Ca B
( I
2 I
+ I
) I
influx O
, O
and O
enhancing O
contractile O
force O
, O
a O
response O
called O
potentiation O
. O

Opening O
of O
Panx1 O
HCs O
during O
repetitive O
activation O
allows O
efflux O
of O
ATP B
, O
influx O
of O
glucose B
and O
possibly O
Ca B
( I
2 I
+ I
) I
too O
, O
which O
are O
required O
for O
potentiation O
of O
contraction O
. O

A O
diketopyrrolopyrrole B
( O
DPP B
) O
with O
fluorenone B
( O
FN O
) O
based O
low O
band O
gap O
alternating O
copolymer O
( O
PDPPT B
- I
alt I
- I
FN I
) O
has O
been O
synthesized O
via O
Suzuki O
coupling O
. O

PDPPT B
- I
alt I
- I
FN I
exhibits O
a O
deep O
HOMO O
level O
with O
a O
lower O
band O
gap O
. O

Fabricated O
organic O
thin O
film O
transistors O
using O
PDPPT B
- I
alt I
- I
FN I
as O
a O
channel O
semiconductor O
show O
p O
- O
channel O
behaviour O
with O
the O
highest O
hole O
mobility O
of O
0 O
. O
083 O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
measured O
in O
air O
. O

This O
study O
investigated O
the O
protective O
effect O
of O
spray O
- O
dried O
a O
c O
a O
i O
powder O
( O
AP O
) O
intake O
on O
colon O
carcinogenesis O
induced O
by O
1 B
, I
2 I
- I
dimethylhydrazine I
( O
DMH B
) O
in O
male O
Wistar O
rats O
. O

Compound O
1c O
incorporates O
a O
1 B
, I
1 I
- I
difluoroethyl I
group O
, O
which O
affords O
improved O
microsomal O
stability O
when O
compared O
to O
the O
corresponding O
ethyl B
- O
substituted O
compound O
1a O
. O

This O
paper O
reviews O
our O
current O
knowledge O
of O
the O
beneficial O
nutrient O
composition O
of O
seafood O
, O
in O
particular O
omega B
- I
3 I
fatty I
acids I
, O
selenium B
, O
taurine B
, O
vitamins B
D I
and I
B12 I
, O
in O
the O
context O
of O
the O
development O
of O
environmentally O
sustainable O
aquaculture O
. O

Synthesis O
and O
antiproliferative O
evaluation O
of O
piperazine B
- I
1 I
- I
carbothiohydrazide I
derivatives O
of O
indolin B
- I
2 I
- I
one I
. O

Synthesis O
and O
antiproliferative O
evaluation O
of O
piperazine B
- I
1 I
- I
carbothiohydrazide I
derivatives O
of O
indolin B
- I
2 I
- I
one I
. O

By O
varying O
the O
substituents O
( O
R O
( O
1 O
) O
) O
at O
the O
indolin B
- I
2 I
- I
one I
scaffold O
, O
a O
series O
of O
indolin B
- I
2 I
- I
one I
derivatives O
bearing O
4 B
- I
phenylpiperazine I
- I
1 I
- I
carbothiohydrazide I
moiety O
at O
the O
C3 O
- O
position O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
activity O
against O
three O
human O
cancer O
cell O
lines O
. O

By O
varying O
the O
substituents O
( O
R O
( O
1 O
) O
) O
at O
the O
indolin B
- I
2 I
- I
one I
scaffold O
, O
a O
series O
of O
indolin B
- I
2 I
- I
one I
derivatives O
bearing O
4 B
- I
phenylpiperazine I
- I
1 I
- I
carbothiohydrazide I
moiety O
at O
the O
C3 O
- O
position O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
activity O
against O
three O
human O
cancer O
cell O
lines O
. O

Among O
all O
the O
compounds O
synthesized O
, O
6d O
and O
6l O
were O
most O
potent O
with O
IC50 O
values O
of O
3 O
. O
59 O
and O
5 O
. O
58 O
mu O
M O
, O
respectively O
against O
A549 O
lung O
cancer O
cells O
, O
while O
5f O
and O
6l O
possessed O
IC50 O
values O
of O
3 O
. O
49 O
and O
4 O
. O
57 O
mu O
M O
, O
respectively O
against O
HCT O
- O
116 O
colon O
cancer O
cells O
which O
were O
comparable O
to O
that O
of O
Sunitinib B
, O
an O
indolin B
- I
2 I
- I
one I
derivative O
in O
cancer O
therapy O
. O

The O
strongest O
activity O
and O
cytotoxicity O
was O
observed O
for O
diimidazolinyl B
substituted I
phenylene I
- I
bisbenzothiazole I
compound O
3b O
. O

The O
highest O
tested O
selectivity O
towards O
tumour O
cells O
was O
observed O
for O
the O
imidazolyl B
substituted I
phenylene I
- I
benzothiazole I
3d O
that O
showed O
no O
cytotoxic O
effects O
on O
normal O
fibroblasts O
making O
it O
an O
excellent O
candidate O
for O
further O
chemical O
optimization O
and O
preclinical O
evaluation O
. O

Here O
we O
show O
that O
the O
QYs O
of O
Yb B
( I
3 I
+ I
) I
sensitized O
two O
- O
photon O
upconversion O
emissions O
can O
be O
well O
characterized O
by O
the O
balancing O
power O
density O
, O
at O
which O
the O
ETU O
rate O
and O
the O
linear O
decay O
rate O
have O
equal O
contributions O
, O
and O
its O
corresponding O
QY O
. O

Synaptotagmin O
1 O
is O
required O
for O
vesicular O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
. O

A O
low O
- O
affinity O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
was O
described O
in O
the O
membrane O
of O
mammalian O
brain O
synaptic O
vesicles O
. O

Synaptotagmin O
- O
1 O
, O
a O
vesicular O
protein O
interacting O
with O
membranes O
upon O
low O
- O
affinity O
Ca B
( I
2 I
+ I
) I
- O
binding O
, O
plays O
a O
major O
role O
in O
excitation O
- O
release O
coupling O
, O
by O
synchronizing O
calcium B
entry O
with O
fast O
neurotransmitter O
release O
. O

Here O
, O
we O
report O
that O
synaptotagmin O
- O
1 O
is O
necessary O
for O
expression O
of O
the O
vesicular O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
. O

We O
measured O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
in O
vesicles O
and O
granules O
of O
pheochromocytoma O
PC12 O
cells O
by O
three O
methods O
: O
( O
1 O
) O
Ca B
( I
2 I
+ I
) I
- O
induced O
dissipation O
of O
the O
vesicular O
H B
( I
+ I
) I
- O
gradient O
; O
( O
2 O
) O
bafilomycin B
- O
sensitive O
calcium B
accumulation O
and O
( O
3 O
) O
pH O
- O
jump O
- O
induced O
calcium B
accumulation O
. O

We O
measured O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
in O
vesicles O
and O
granules O
of O
pheochromocytoma O
PC12 O
cells O
by O
three O
methods O
: O
( O
1 O
) O
Ca B
( I
2 I
+ I
) I
- O
induced O
dissipation O
of O
the O
vesicular O
H B
( I
+ I
) I
- O
gradient O
; O
( O
2 O
) O
bafilomycin B
- O
sensitive O
calcium B
accumulation O
and O
( O
3 O
) O
pH O
- O
jump O
- O
induced O
calcium B
accumulation O
. O

The O
results O
were O
congruent O
and O
highly O
significant O
: O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
is O
detectable O
only O
in O
acidic O
organelles O
expressing O
functional O
synaptotagmin O
- O
1 O
. O

In O
contrast O
, O
synaptotagmin O
- O
1 O
- O
deficient O
cells O
- O
and O
cells O
where O
transgenically O
encoded O
synaptotagmin O
- O
1 O
was O
acutely O
photo O
- O
inactivated O
- O
were O
devoid O
of O
any O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
. O

Therefore O
, O
in O
addition O
to O
its O
previously O
described O
functions O
, O
synaptotagmin O
- O
1 O
is O
involved O
in O
a O
rapid O
vesicular O
Ca B
( I
2 I
+ I
) I
sequestration O
through O
a O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
antiport O
. O

Therefore O
, O
in O
addition O
to O
its O
previously O
described O
functions O
, O
synaptotagmin O
- O
1 O
is O
involved O
in O
a O
rapid O
vesicular O
Ca B
( I
2 I
+ I
) I
sequestration O
through O
a O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
antiport O
. O

Using O
reporter O
gene O
and O
electrophoretic O
gel O
mobility O
shift O
assays O
we O
demonstrated O
that O
MK2 O
catalytic O
activity O
directly O
regulated O
the O
promoters O
of O
the O
fast O
fiber O
- O
specific O
myosin O
heavy O
chain O
IId O
/ O
x O
and O
the O
slow O
fiber O
- O
specific O
sarco O
/ O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
- O
ATPase O
( O
SERCA O
) O
2 O
gene O
. O

Protein O
kinase O
inhibitor O
design O
by O
targeting O
the O
Asp B
- I
Phe I
- I
Gly I
( O
DFG O
) O
motif O
: O
the O
role O
of O
the O
DFG O
motif O
in O
the O
design O
of O
epidermal O
growth O
factor O
receptor O
inhibitors O
. O

The O
Asp B
- I
Phe I
- I
Gly I
( O
DFG O
) O
motif O
plays O
an O
important O
role O
in O
the O
regulation O
of O
kinase O
activity O
. O

Indeed O
, O
introduction O
of O
an O
N B
, I
N I
- I
dimethylamino I
tail O
resulted O
in O
4b O
, O
which O
showed O
almost O
50 O
- O
fold O
improvement O
in O
inhibition O
compared O
to O
2a O
. O

Structural O
studies O
confirmed O
this O
N B
, I
N I
- I
dimethylamino I
tail O
moved O
towards O
the O
DFG O
motif O
to O
form O
a O
salt O
bridge O
with O
the O
side O
chain O
of O
Asp831 O
. O

Recently O
, O
flaxseed O
oil O
( O
FXO O
) O
, O
a O
rich O
source O
of O
omega B
- I
3 I
fatty I
acids I
and O
lignans B
, O
has O
been O
shown O
to O
prevent O
/ O
reduce O
the O
progression O
of O
certain O
types O
of O
cardiovascular O
and O
renal O
disorders O
. O

PbAc B
increased O
the O
activities O
of O
lactate B
dehydrogenase O
and O
NADP B
- O
malic O
enzyme O
, O
whereas O
it O
decreased O
malate B
and O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
, O
glucose B
- O
6 O
- O
phosphatase O
, O
fructose B
- O
1 O
, O
6 O
- O
bisphosphatase O
, O
and O
BBM O
enzyme O
activities O
. O

Both O
nitrobenzene B
and O
1 B
, I
4 I
- I
dinitrobenzene I
decreased O
fluorescence O
intensity O
and O
molecular O
conductivity O
, O
while O
toluene B
had O
no O
effect O
. O

A O
highly O
effective O
drug O
carrier O
is O
constructed O
by O
coating O
folic B
acid I
- O
terminated O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
- O
FA O
) O
on O
single O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
in O
a O
facile O
non O
- O
covalent O
method O
. O

There O
was O
a O
marked O
increase O
in O
the O
extent O
of O
lipid O
peroxidation O
( O
33 O
. O
9 O
% O
) O
and O
enzymic O
activity O
of O
glutathione B
peroxidase O
( O
6 O
. O
7 O
% O
) O
, O
superoxide B
dismutase O
( O
35 O
. O
0 O
% O
) O
, O
catalase O
( O
43 O
. O
7 O
% O
) O
, O
glutathione B
- O
S O
- O
transferase O
( O
64 O
. O
4 O
% O
) O
, O
glutathione B
reductase O
( O
36 O
. O
7 O
% O
) O
and O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
( O
32 O
. O
1 O
% O
) O
. O

Antinociceptive O
effect O
of O
the O
synthetic O
flavonoid B
3 B
, I
3 I
- I
dibromoflavanone I
in O
mice O
. O

The O
most O
active O
compound O
, O
3 B
, I
3 I
- I
dibromoflavanone I
( O
31 O
) O
, O
a O
synthetic O
flavonoid B
, O
presented O
a O
significant O
inhibition O
of O
the O
binding O
of O
the O
selective O
mu O
opioid O
ligand O
[ B
( I
3 I
) I
H I
] I
DAMGO I
, O
with O
a O
Ki O
of O
0 O
. O
846 O
+ O
/ O
- O
0 O
. O
263 O
mu O
M O
. O

These O
findings O
demonstrated O
that O
3 B
, I
3 I
- I
dibromoflavanone I
( O
31 O
) O
, O
at O
doses O
that O
did O
not O
interfere O
with O
the O
motor O
performance O
, O
exerted O
clear O
dose O
dependent O
antinociception O
when O
assessed O
in O
the O
chemical O
and O
thermal O
models O
of O
nociception O
in O
mice O
and O
it O
seems O
that O
its O
action O
is O
related O
to O
the O
activation O
of O
the O
mu O
opioid O
receptor O
. O

Infusion O
of O
the O
alpha O
6 O
- O
selective O
antagonist O
alpha O
- O
conotoxin O
MII O
( O
alpha O
- O
ctx O
MII O
) O
produced O
a O
robust O
, O
but O
transient O
decrease O
in O
phasic O
DA O
, O
whereas O
infusion O
of O
selective O
doses O
of O
either O
the O
alpha O
4 O
beta O
2 O
- O
selective O
antagonist O
, O
dihydro B
- I
beta I
- I
erythroidine I
, O
or O
the O
alpha O
7 O
antagonist O
, O
methyllycaconitine B
, O
had O
no O
effect O
. O

We O
previously O
reported O
that O
joint O
effects O
of O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
, O
ecstasy B
) O
and O
three O
other O
often O
co O
- O
ingested O
amphetamines B
( O
methamphetamine B
, O
4 B
- I
methylthyoamphetamin I
and O
D B
- I
amphetamine I
) O
could O
be O
predicted O
by O
the O
concentration O
addition O
( O
CA O
) O
model O
in O
HepG2 O
cells O
. O

A O
prodrug O
of O
combretastatin B
A I
- I
4 I
( O
CA4 B
) O
was O
prepared O
, O
CMP B
- I
L I
- I
CA4 I
: O
CMP B
( O
dithiaporphyrin B
, O
a O
photosensitizer O
) O
and O
L O
( O
aminoacrylate B
linker O
) O
. O

Most O
significantly O
, O
CMP B
- I
L I
- I
CA4 I
had O
better O
antitumor O
efficacy O
in O
vivo O
than O
its O
non O
- O
cleavable O
( O
NC O
) O
analog O
, O
CMP B
- I
NCL I
- I
CA4 I
. O

Most O
significantly O
, O
CMP B
- I
L I
- I
CA4 I
had O
better O
antitumor O
efficacy O
in O
vivo O
than O
its O
non O
- O
cleavable O
( O
NC O
) O
analog O
, O
CMP B
- I
NCL I
- I
CA4 I
. O

This O
extract O
afforded O
six O
new O
isoflavonoids B
, O
sedonans B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
a O
new O
but B
- I
2 I
- I
enolide I
, O
4 B
' I
- I
O I
- I
methylpuerol I
A I
( O
7 O
) O
, O
and O
the O
new O
pterocarpan O
ent B
- I
sandwicensin I
( O
8 O
) O
. O

Rottlerin B
was O
found O
to O
inhibit O
IgE O
- O
induced O
PLC O
gamma O
1 O
and O
Akt O
phosphorylation O
, O
production O
of O
IP3 O
and O
rise O
in O
cytosolic O
Ca B
( I
2 I
+ I
) I
level O
in O
mast O
cells O
. O

Rats O
fed O
the O
modified O
diet O
during O
22 O
days O
showed O
decreased O
hepatic O
mitochondrial O
state O
3 O
respiration O
and O
were O
more O
susceptible O
to O
Ca B
( I
2 I
+ I
) I
- O
induced O
transition O
pore O
opening O
. O

Protective O
Role O
of O
( B
RS I
) I
- I
glucoraphanin I
Bioactivated O
with O
Myrosinase O
in O
an O
Experimental O
Model O
of O
Multiple O
Sclerosis O
. O

This O
study O
examines O
the O
potential O
neuroprotective O
and O
immunomodulatory O
effects O
of O
( B
RS I
) I
- I
glucoraphanin I
from O
Tuscan O
black O
kale O
( O
Brassica O
oleracea O
L O
. O
var O
. O
acephala O
sabellica O
) O
bioactivated O
with O
myrosinase O
( O
bioactive O
RS B
- I
GRA I
) O
( O
10 O
mg O
/ O
kg O
/ O
day O
intraperitoneally O
) O
, O
in O
an O
experimental O
autoimmune O
encephalomyelitis O
( O
EAE O
) O
, O
a O
model O
of O
multiple O
sclerosis O
. O

Their O
structures O
were O
characterised O
as O
16 B
- I
deethylindanomycin I
( O
2 O
) O
, O
iso B
- I
16 I
- I
deethylindanomycin I
( O
3 O
) O
, O
16 B
- I
deethylindanomycin I
methyl I
ester I
( O
4 O
) O
and O
iso B
- I
16 I
- I
deethylindanomycin I
methyl I
ester I
( O
5 O
) O
on O
the O
basis O
of O
NMR O
, O
HR O
- O
ESI O
- O
MS O
and O
CD O
evidences O
. O

Their O
structures O
were O
characterised O
as O
16 B
- I
deethylindanomycin I
( O
2 O
) O
, O
iso B
- I
16 I
- I
deethylindanomycin I
( O
3 O
) O
, O
16 B
- I
deethylindanomycin I
methyl I
ester I
( O
4 O
) O
and O
iso B
- I
16 I
- I
deethylindanomycin I
methyl I
ester I
( O
5 O
) O
on O
the O
basis O
of O
NMR O
, O
HR O
- O
ESI O
- O
MS O
and O
CD O
evidences O
. O

Coumarin B
( O
1 B
, I
2 I
- I
benzopyrone I
) O
was O
previously O
reported O
as O
responsible O
for O
some O
biological O
activities O
of O
this O
plant O
species O
. O

In O
mice O
, O
MPTP B
significantly O
decreased O
the O
levels O
of O
dopamine B
in O
the O
striatum O
and O
behavior O
performance O
; O
in O
contrast O
, O
both O
CRE O
and O
17 B
beta I
- I
estradiol I
benzoate I
( O
EB O
) O
recovered O
these O
parameters O
to O
normal O
levels O
. O

A O
Highly O
Crystalline O
Manganese B
- I
Doped I
Iron I
Oxide I
Nanocontainer O
with O
Predesigned O
Void O
Volume O
and O
Shape O
for O
Theranostic O
Applications O
. O

Hollow O
Mn B
- I
doped I
iron I
oxide I
nanocontainers O
, O
formed O
by O
a O
novel O
one O
- O
pot O
synthetic O
process O
, O
fulfill O
the O
dual O
requirements O
of O
delivering O
an O
effective O
dose O
of O
an O
anticancer O
drug O
to O
tumor O
tissue O
and O
enabling O
image O
- O
contrast O
monitoring O
of O
the O
nanocontainer O
fate O
through O
T2 O
- O
weighted O
magnetic O
resonance O
imaging O
, O
thereby O
determining O
the O
optimal O
balance O
between O
diagnostic O
and O
therapeutic O
moieties O
in O
an O
all O
- O
in O
- O
one O
theranostic O
nanoplatform O
. O

Synthetic O
pathway O
to O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
derivatives O
and O
their O
usefulness O
for O
obtaining O
brassinosteroid B
analogues O
. O

Recognizing O
the O
functionality O
of O
the O
pentacyclic B
steroidal I
derivative O
7a O
as O
important O
synthon O
to O
obtain O
new O
brassinosteroid B
analogs O
, O
we O
have O
accomplished O
the O
derivatization O
of O
hecogenin B
, O
a O
sapogenin O
from O
the O
25R O
serie O
containing O
a O
carbonyl B
group O
at O
C O
- O
12 O
, O
to O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
derivative O
. O

Starting O
from O
hecogenin B
acetate I
( O
5a O
) O
or O
hecogenin B
tosylate I
( O
5b O
) O
, O
we O
obtained O
two O
pentacyclic O
derivatives O
( O
7a O
and O
7b O
) O
which O
were O
subjected O
to O
an O
oxidation O
reaction O
on O
the O
double O
bond O
at O
C O
- O
12 O
( O
23 O
) O
to O
obtain O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
, O
with O
the O
regeneration O
of O
the O
carbonyl B
group O
at O
C O
- O
12 O
. O

